ID CDN2B_HUMAN Reviewed; 138 AA. AC P42772; O15125; Q6FI09; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1995, sequence version 1. DT 28-JAN-2026, entry version 206. DE RecName: Full=Cyclin-dependent kinase 4 inhibitor B; DE AltName: Full=Multiple tumor suppressor 2; DE Short=MTS-2; DE AltName: Full=p14-INK4b; DE AltName: Full=p15-INK4b; DE Short=p15INK4B; GN Name=CDKN2B; Synonyms=MTS2; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8001816; DOI=10.1101/gad.8.24.2939; RA Guan K.-L., Jenkins C.W., Li Y., Nichols M.A., Wu X., O'Keefe C.L., RA Matera G.A., Xiong Y.; RT "Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 RT inhibitor, correlates with wild-type pRb function."; RL Genes Dev. 8:2939-2952(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RX PubMed=8078588; DOI=10.1038/371257a0; RA Hannon G.J., Beach D.; RT "p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest."; RL Nature 371:257-261(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND TISSUE RP SPECIFICITY. RX PubMed=9230210; RA Tsubari M., Tiihonen E., Laiho M.; RT "Cloning and characterization of p10, an alternatively spliced form of p15 RT cyclin-dependent kinase inhibitor."; RL Cancer Res. 57:2966-2973(1997). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RG NIEHS SNPs program; RL Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 53-138. RX PubMed=8153634; DOI=10.1126/science.8153634; RA Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., RA Tavtigian S.V., Stockert E., Day R.S. III, Johnson B.E., Skolnick M.H.; RT "A cell cycle regulator potentially involved in genesis of many tumor RT types."; RL Science 264:436-440(1994). RN [9] RP STRUCTURE BY NMR. RX PubMed=10892805; DOI=10.1110/ps.9.6.1120; RA Yuan C., Selby T.L., Li J., Byeon I.J., Tsai M.D.; RT "Tumor suppressor INK4: refinement of p16INK4A structure and determination RT of p15INK4B structure by comparative modeling and NMR data."; RL Protein Sci. 9:1120-1128(2000). RN [10] RP VARIANTS LUNG ADENOCARCINOMA GLU-47 AND VAL-50. RX PubMed=7882351; RA Okamoto A., Hussain S.P., Hagiwara K., Spillare E.A., Rusin M.R., RA Demetrick D.J., Serrano M., Hannon G.J., Shiseki M., Zariwala M., Xiong Y., RA Beach D.H., Yokota J., Harris C.C.; RT "Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in RT primary and metastatic lung cancer."; RL Cancer Res. 55:1448-1451(1995). CC -!- FUNCTION: Interacts strongly with CDK4 and CDK6. Potent inhibitor. CC Potential effector of TGF-beta induced cell cycle arrest. CC -!- SUBUNIT: Heterodimer of CDKN2B with CDK4 or CDK6. Isoform 2 does not CC interact with CDK4 nor CDK6. CC -!- INTERACTION: CC P42772; Q9UI12: ATP6V1H; NbExp=3; IntAct=EBI-711280, EBI-724719; CC P42772; P15056: BRAF; NbExp=4; IntAct=EBI-711280, EBI-365980; CC P42772; P24863: CCNC; NbExp=3; IntAct=EBI-711280, EBI-395261; CC P42772; Q00537: CDK17; NbExp=3; IntAct=EBI-711280, EBI-624648; CC P42772; P11802: CDK4; NbExp=22; IntAct=EBI-711280, EBI-295644; CC P42772; Q00534: CDK6; NbExp=19; IntAct=EBI-711280, EBI-295663; CC P42772; Q6P9H4: CNKSR3; NbExp=3; IntAct=EBI-711280, EBI-10253274; CC P42772; Q0VD86: INCA1; NbExp=3; IntAct=EBI-711280, EBI-6509505; CC P42772; P43364: MAGEA11; NbExp=4; IntAct=EBI-711280, EBI-739552; CC P42772; Q9GZT8: NIF3L1; NbExp=3; IntAct=EBI-711280, EBI-740897; CC P42772; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-711280, EBI-79165; CC P42772; Q53H96: PYCR3; NbExp=3; IntAct=EBI-711280, EBI-2959680; CC P42772; A6ZKI3: RTL8C; NbExp=3; IntAct=EBI-711280, EBI-10174072; CC P42772; Q9BVN2: RUSC1; NbExp=3; IntAct=EBI-711280, EBI-6257312; CC P42772; Q9NZD8: SPG21; NbExp=6; IntAct=EBI-711280, EBI-742688; CC P42772; Q13077: TRAF1; NbExp=7; IntAct=EBI-711280, EBI-359224; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9230210}. Note=Also CC found in the nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=p15; CC IsoId=P42772-1; Sequence=Displayed; CC Name=2; Synonyms=p10; CC IsoId=P42772-2; Sequence=VSP_043898; CC -!- TISSUE SPECIFICITY: Isoform 2 is expressed in normal (keratinocytes, CC fibroblasts) and tumor cell lines. {ECO:0000269|PubMed:9230210}. CC -!- SIMILARITY: Belongs to the CDKN2 cyclin-dependent kinase inhibitor CC family. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/187/CDKN2B"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U17075; AAC50075.1; -; mRNA. DR EMBL; L36844; AAA50282.1; -; mRNA. DR EMBL; AF004819; AAB69989.1; -; mRNA. DR EMBL; CR536529; CAG38766.1; -; mRNA. DR EMBL; AF513858; AAM44859.1; -; Genomic_DNA. DR EMBL; AL449423; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC014469; AAH14469.1; -; mRNA. DR EMBL; S69805; AAD14049.1; -; Genomic_DNA. DR CCDS; CCDS6512.1; -. [P42772-1] DR CCDS; CCDS6513.1; -. [P42772-2] DR PIR; B55479; B55479. DR RefSeq; NP_004927.2; NM_004936.3. [P42772-1] DR RefSeq; NP_511042.1; NM_078487.2. [P42772-2] DR AlphaFoldDB; P42772; -. DR SMR; P42772; -. DR BioGRID; 107464; 73. DR FunCoup; P42772; 1638. DR IntAct; P42772; 28. DR MINT; P42772; -. DR STRING; 9606.ENSP00000276925; -. DR iPTMnet; P42772; -. DR PhosphoSitePlus; P42772; -. DR BioMuta; CDKN2B; -. DR DMDM; 1168869; -. DR jPOST; P42772; -. DR MassIVE; P42772; -. DR PaxDb; 9606-ENSP00000276925; -. DR PeptideAtlas; P42772; -. DR ProteomicsDB; 55555; -. [P42772-1] DR ProteomicsDB; 55556; -. [P42772-2] DR Pumba; P42772; -. DR Antibodypedia; 3605; 625 antibodies from 37 providers. DR DNASU; 1030; -. DR Ensembl; ENST00000276925.7; ENSP00000276925.6; ENSG00000147883.13. [P42772-1] DR Ensembl; ENST00000380142.5; ENSP00000369487.4; ENSG00000147883.13. [P42772-2] DR GeneID; 1030; -. DR KEGG; hsa:1030; -. DR MANE-Select; ENST00000276925.7; ENSP00000276925.6; NM_004936.4; NP_004927.2. DR UCSC; uc003zpn.4; human. [P42772-1] DR AGR; HGNC:1788; -. DR CIViC; 1030; 7 evidence items across 7 molecular profiles. DR ClinPGx; PA26321; -. DR CTD; 1030; -. DR DisGeNET; 1030; -. DR GeneCards; CDKN2B; -. DR HGNC; HGNC:1788; CDKN2B. DR HPA; ENSG00000147883; Tissue enhanced (esophagus, intestine). DR MalaCards; CDKN2B; -. DR MIM; 600431; gene. DR OpenTargets; ENSG00000147883; -. DR Orphanet; 618; Familial melanoma. DR Orphanet; 652; Multiple endocrine neoplasia type 1. DR VEuPathDB; HostDB:ENSG00000147883; -. DR eggNOG; KOG0504; Eukaryota. DR GeneTree; ENSGT00940000162423; -. DR HOGENOM; CLU_000134_37_1_1; -. DR InParanoid; P42772; -. DR OMA; SALQVMM; -. DR OrthoDB; 539213at2759; -. DR PAN-GO; P42772; 7 GO annotations based on evolutionary models. DR PhylomeDB; P42772; -. DR PathwayCommons; P42772; -. DR Reactome; R-HSA-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP). DR Reactome; R-HSA-2559585; Oncogene Induced Senescence. DR Reactome; R-HSA-69231; Cyclin D associated events in G1. DR SignaLink; P42772; -. DR SIGNOR; P42772; -. DR Agora; ENSG00000147883; -. DR BioGRID-ORCS; 1030; 23 hits in 1175 CRISPR screens. DR GeneWiki; CDKN2B; -. DR GenomeRNAi; 1030; -. DR Pharos; P42772; Tbio. DR PRO; PR:P42772; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; P42772; protein. DR Bgee; ENSG00000147883; Expressed in jejunal mucosa and 151 other cell types or tissues. DR ExpressionAtlas; P42772; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0004861; F:cyclin-dependent protein serine/threonine kinase inhibitor activity; IDA:BHF-UCL. DR GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL. DR GO; GO:0071460; P:cellular response to cell-matrix adhesion; IMP:BHF-UCL. DR GO; GO:0031670; P:cellular response to nutrient; IMP:BHF-UCL. DR GO; GO:0090398; P:cellular senescence; IMP:BHF-UCL. DR GO; GO:0030219; P:megakaryocyte differentiation; IEP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:BHF-UCL. DR GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IMP:BHF-UCL. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL. DR GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL. DR GO; GO:0070316; P:regulation of G0 to G1 transition; IMP:BHF-UCL. DR GO; GO:2000045; P:regulation of G1/S transition of mitotic cell cycle; IBA:GO_Central. DR GO; GO:0048536; P:spleen development; IEA:Ensembl. DR GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL. DR FunFam; 1.25.40.20:FF:000107; cyclin-dependent kinase 4 inhibitor B; 1. DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1. DR InterPro; IPR050776; Ank_Repeat/CDKN_Inhibitor. DR InterPro; IPR002110; Ankyrin_rpt. DR InterPro; IPR036770; Ankyrin_rpt-contain_sf. DR PANTHER; PTHR24201; ANK_REP_REGION DOMAIN-CONTAINING PROTEIN; 1. DR PANTHER; PTHR24201:SF8; CYCLIN-DEPENDENT KINASE 4 INHIBITOR B; 1. DR Pfam; PF12796; Ank_2; 1. DR SUPFAM; SSF48403; Ankyrin repeat; 1. DR PROSITE; PS50297; ANK_REP_REGION; 1. PE 1: Evidence at protein level; KW Alternative splicing; ANK repeat; Cell cycle; Cytoplasm; KW Proteomics identification; Reference proteome; Repeat; Tumor suppressor. FT CHAIN 1..138 FT /note="Cyclin-dependent kinase 4 inhibitor B" FT /id="PRO_0000144184" FT REPEAT 13..39 FT /note="ANK 1; truncated" FT REPEAT 46..74 FT /note="ANK 2" FT REPEAT 79..108 FT /note="ANK 3" FT REPEAT 112..138 FT /note="ANK 4" FT VAR_SEQ 54..138 FT /note="MMMGSARVAELLLLHGAEPNCADPATLTRPVHDAAREGFLDTLVVLHRAGAR FT LDVRDAWGRLPVDLAEERGHRDVAGYLRTATGD -> AGAPGPRRQGARERGARPRRIG FT AGT (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9230210" FT /id="VSP_043898" FT VARIANT 47 FT /note="G -> E (in lung adenocarcinoma; dbSNP:rs2131189971)" FT /evidence="ECO:0000269|PubMed:7882351" FT /id="VAR_001488" FT VARIANT 50 FT /note="A -> V (in lung adenocarcinoma; dbSNP:rs1423790481)" FT /evidence="ECO:0000269|PubMed:7882351" FT /id="VAR_001489" FT CONFLICT 20..22 FT /note="SAA -> TP (in Ref. 2; AAA50282)" FT /evidence="ECO:0000305" FT CONFLICT 32..34 FT /note="QLL -> HSW (in Ref. 2; AAA50282)" FT /evidence="ECO:0000305" SQ SEQUENCE 138 AA; 14722 MW; 0D6FFBDFA6FEAD21 CRC64; MREENKGMPS GGGSDEGLAS AAARGLVEKV RQLLEAGADP NGVNRFGRRA IQVMMMGSAR VAELLLLHGA EPNCADPATL TRPVHDAARE GFLDTLVVLH RAGARLDVRD AWGRLPVDLA EERGHRDVAG YLRTATGD // ID EPHA7_HUMAN Reviewed; 998 AA. AC Q15375; A0AUX7; B2R8W1; B7ZLJ9; B7ZLK0; Q59G40; Q5VTU0; Q8N368; Q9H124; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2007, sequence version 3. DT 28-JAN-2026, entry version 236. DE RecName: Full=Ephrin type-A receptor 7; DE EC=2.7.10.1; DE AltName: Full=EPH homology kinase 3; DE Short=EHK-3; DE AltName: Full=EPH-like kinase 11; DE Short=EK11; DE Short=hEK11; DE Flags: Precursor; GN Name=EPHA7; Synonyms=EHK3, HEK11; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=7898931; RA Fox G.M., Holst P.L., Chute H.T., Lindberg R.A., Janssen A.M., Basu R., RA Welcher A.A.; RT "cDNA cloning and tissue distribution of five human EPH-like receptor RT protein-tyrosine kinases."; RL Oncogene 10:897-905(1995). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=14574404; DOI=10.1038/nature02055; RA Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L., RA Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R., RA Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D., RA Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H., RA Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J., RA Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P., RA Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V., RA Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J., RA Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E., RA Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J., RA French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J., RA Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C., RA Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A., RA Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R., RA Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., RA Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., RA Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., RA Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M., RA Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A., RA Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L., RA Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I., RA Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y., RA Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E., RA Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A., RA Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W., RA Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., RA West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J., RA Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M., RA Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I., RA Rogers J., Beck S.; RT "The DNA sequence and analysis of human chromosome 6."; RL Nature 425:805-811(2003). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4), AND RP VARIANT VAL-138. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [8] RP FUNCTION IN MAP2K1; MAP2K2; MAPK1 AND MAPK3 PHOSPHORYLATION. RX PubMed=17726105; DOI=10.1073/pnas.0703211104; RA Nakanishi H., Nakamura T., Canaani E., Croce C.M.; RT "ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation RT in human acute leukemias."; RL Proc. Natl. Acad. Sci. U.S.A. 104:14442-14447(2007). RN [9] RP ALTERNATIVE SPLICING (ISOFORM 5). RX PubMed=20126984; RA Tsuboi M., Mori H., Bunai T., Kageyama S., Suzuki M., Okudela K., RA Takamochi K., Ogawa H., Niwa H., Shinmura K., Sugimura H.; RT "Secreted form of EphA7 in lung cancer."; RL Int. J. Oncol. 36:635-640(2010). RN [10] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 32-204. RA Walker J.R., Yermekbayeva L., Seitova A., Kania J., Bountra C., Weigelt J., RA Arrowsmith C.H., Edwards A.M., Bochkarev A., Dhe-Paganon S.; RT "Ephrin A7 ligand binding domain."; RL Submitted (JUN-2010) to the PDB data bank. RN [11] RP VARIANT [LARGE SCALE ANALYSIS] TRP-371. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-138; LYS-170; ARG-232; SER-278 AND RP SER-903. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously GPI- CC anchored ephrin-A family ligands residing on adjacent cells, leading to CC contact-dependent bidirectional signaling into neighboring cells. The CC signaling pathway downstream of the receptor is referred to as forward CC signaling while the signaling pathway downstream of the ephrin ligand CC is referred to as reverse signaling. Among GPI-anchored ephrin-A CC ligands, EFNA5 is a cognate/functional ligand for EPHA7 and their CC interaction regulates brain development modulating cell-cell adhesion CC and repulsion. Has a repellent activity on axons and is for instance CC involved in the guidance of corticothalamic axons and in the proper CC topographic mapping of retinal axons to the colliculus. May also CC regulate brain development through a caspase(CASP3)-dependent CC proapoptotic activity. Forward signaling may result in activation of CC components of the ERK signaling pathway including MAP2K1, MAP2K2, MAPK1 CC and MAPK3 which are phosphorylated upon activation of EPHA7. CC {ECO:0000269|PubMed:17726105}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses (By similarity). CC Interacts (via PDZ-binding motif) with GRIP1 and PICK1 (via PDZ domain) CC (By similarity). {ECO:0000250}. CC -!- INTERACTION: CC Q15375; P07333: CSF1R; NbExp=2; IntAct=EBI-1383428, EBI-2835440; CC Q15375; P52803: EFNA5; NbExp=4; IntAct=EBI-1383428, EBI-1753674; CC Q15375; P29317: EPHA2; NbExp=7; IntAct=EBI-1383428, EBI-702104; CC Q15375; P29320: EPHA3; NbExp=4; IntAct=EBI-1383428, EBI-1641575; CC Q15375; P29323: EPHB2; NbExp=2; IntAct=EBI-1383428, EBI-1059294; CC Q15375; P54760: EPHB4; NbExp=3; IntAct=EBI-1383428, EBI-702121; CC Q15375; Q9H8Y8: GORASP2; NbExp=2; IntAct=EBI-1383428, EBI-739467; CC Q15375; Q9NUP9: LIN7C; NbExp=2; IntAct=EBI-1383428, EBI-1171517; CC Q15375; Q16288: NTRK3; NbExp=2; IntAct=EBI-1383428, EBI-3936704; CC Q15375; Q8NI35: PATJ; NbExp=2; IntAct=EBI-1383428, EBI-724390; CC Q15375; P52793: Efna1; Xeno; NbExp=2; IntAct=EBI-1383428, EBI-5241529; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass type I CC membrane protein {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=1; Synonyms=EPHA7-FL; CC IsoId=Q15375-1; Sequence=Displayed; CC Name=2; CC IsoId=Q15375-2; Sequence=VSP_014382; CC Name=3; CC IsoId=Q15375-3; Sequence=VSP_014380, VSP_014381; CC Name=4; CC IsoId=Q15375-4; Sequence=VSP_041945; CC Name=5; Synonyms=EPHA7-S; CC IsoId=Q15375-5; Sequence=VSP_041943, VSP_041944; CC -!- TISSUE SPECIFICITY: Widely expressed. CC -!- PTM: Phosphorylated. {ECO:0000250}. CC -!- MISCELLANEOUS: [Isoform 2]: May be due to a competing donor splice CC site. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 5]: Expressed in lung cancer cells, lacks the CC kinase domain and is most probably secreted. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAD92506.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/40466/EPHA7"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L36642; AAA74243.1; -; mRNA. DR EMBL; AK313529; BAG36308.1; -; mRNA. DR EMBL; AB209269; BAD92506.1; ALT_INIT; mRNA. DR EMBL; AL121966; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL354857; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL591036; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471051; EAW48518.1; -; Genomic_DNA. DR EMBL; BC027940; AAH27940.1; -; mRNA. DR EMBL; BC126125; AAI26126.1; -; mRNA. DR EMBL; BC126151; AAI26152.1; -; mRNA. DR EMBL; BC143857; AAI43858.1; -; mRNA. DR EMBL; BC143858; AAI43859.1; -; mRNA. DR CCDS; CCDS5031.1; -. [Q15375-1] DR CCDS; CCDS75494.1; -. [Q15375-3] DR CCDS; CCDS93973.1; -. [Q15375-4] DR PIR; I58351; I58351. DR RefSeq; NP_001275558.1; NM_001288629.2. [Q15375-2] DR RefSeq; NP_001275559.1; NM_001288630.2. [Q15375-3] DR RefSeq; NP_001363394.1; NM_001376465.1. [Q15375-4] DR RefSeq; NP_004431.1; NM_004440.4. [Q15375-1] DR PDB; 2REI; X-ray; 1.60 A; A=590-899. DR PDB; 3DKO; X-ray; 2.00 A; A=590-899. DR PDB; 3H8M; X-ray; 2.10 A; A/B=919-990. DR PDB; 3NRU; X-ray; 2.30 A; A/B/C/D/E/F/G/H/I/J/K/L=32-204. DR PDB; 7EEC; X-ray; 3.10 A; A=599-899. DR PDB; 7EED; X-ray; 3.05 A; A=599-899. DR PDB; 7EEF; X-ray; 2.60 A; A=599-899. DR PDBsum; 2REI; -. DR PDBsum; 3DKO; -. DR PDBsum; 3H8M; -. DR PDBsum; 3NRU; -. DR PDBsum; 7EEC; -. DR PDBsum; 7EED; -. DR PDBsum; 7EEF; -. DR AlphaFoldDB; Q15375; -. DR SMR; Q15375; -. DR BioGRID; 108359; 316. DR FunCoup; Q15375; 1198. DR IntAct; Q15375; 282. DR MINT; Q15375; -. DR STRING; 9606.ENSP00000358309; -. DR BindingDB; Q15375; -. DR ChEMBL; CHEMBL4602; -. DR DrugBank; DB07970; 5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q15375; -. DR GuidetoPHARMACOLOGY; 1827; -. DR GlyCosmos; Q15375; 4 sites, 1 glycan. DR GlyGen; Q15375; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (2 sites). DR iPTMnet; Q15375; -. DR PhosphoSitePlus; Q15375; -. DR SwissPalm; Q15375; -. DR BioMuta; EPHA7; -. DR DMDM; 146345416; -. DR CPTAC; CPTAC-1783; -. DR CPTAC; CPTAC-2787; -. DR CPTAC; CPTAC-2830; -. DR jPOST; Q15375; -. DR MassIVE; Q15375; -. DR PaxDb; 9606-ENSP00000358309; -. DR PeptideAtlas; Q15375; -. DR ProteomicsDB; 60549; -. [Q15375-1] DR ProteomicsDB; 60550; -. [Q15375-2] DR ProteomicsDB; 60551; -. [Q15375-3] DR ProteomicsDB; 60552; -. [Q15375-4] DR ProteomicsDB; 60553; -. [Q15375-5] DR Pumba; Q15375; -. DR Antibodypedia; 642; 553 antibodies from 37 providers. DR DNASU; 2045; -. DR Ensembl; ENST00000369297.1; ENSP00000358303.1; ENSG00000135333.16. [Q15375-3] DR Ensembl; ENST00000369303.9; ENSP00000358309.4; ENSG00000135333.16. [Q15375-1] DR Ensembl; ENST00000680224.1; ENSP00000506130.1; ENSG00000135333.16. [Q15375-4] DR GeneID; 2045; -. DR KEGG; hsa:2045; -. DR MANE-Select; ENST00000369303.9; ENSP00000358309.4; NM_004440.4; NP_004431.1. DR UCSC; uc003poe.5; human. [Q15375-1] DR AGR; HGNC:3390; -. DR ClinPGx; PA27822; -. DR CTD; 2045; -. DR DisGeNET; 2045; -. DR GeneCards; EPHA7; -. DR HGNC; HGNC:3390; EPHA7. DR HPA; ENSG00000135333; Group enriched (intestine, parathyroid gland). DR MalaCards; EPHA7; -. DR MIM; 602190; gene. DR OpenTargets; ENSG00000135333; -. DR VEuPathDB; HostDB:ENSG00000135333; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000160189; -. DR HOGENOM; CLU_000288_141_0_1; -. DR InParanoid; Q15375; -. DR OMA; ETDYNTG; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; Q15375; 8 GO annotations based on evolutionary models. DR PhylomeDB; Q15375; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q15375; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; Q15375; -. DR SIGNOR; Q15375; -. DR Agora; ENSG00000135333; -. DR BioGRID-ORCS; 2045; 14 hits in 1184 CRISPR screens. DR ChiTaRS; EPHA7; human. DR EvolutionaryTrace; Q15375; -. DR GeneWiki; EPHA7; -. DR GenomeRNAi; 2045; -. DR Pharos; Q15375; Tchem. DR PRO; PR:Q15375; -. DR Proteomes; UP000005640; Chromosome 6. DR RNAct; Q15375; protein. DR Bgee; ENSG00000135333; Expressed in cortical plate and 131 other cell types or tissues. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0098686; C:hippocampal mossy fiber to CA3 synapse; IEA:Ensembl. DR GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl. DR GO; GO:0043025; C:neuronal cell body; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL. DR GO; GO:0098839; C:postsynaptic density membrane; IEA:Ensembl. DR GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008046; F:axon guidance receptor activity; ISS:UniProtKB. DR GO; GO:0045499; F:chemorepellent activity; ISS:UniProtKB. DR GO; GO:0046875; F:ephrin receptor binding; IEA:Ensembl. DR GO; GO:0005004; F:GPI-linked ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0019838; F:growth factor binding; IEA:Ensembl. DR GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central. DR GO; GO:0007411; P:axon guidance; IBA:GO_Central. DR GO; GO:0007420; P:brain development; ISS:UniProtKB. DR GO; GO:0048755; P:branching morphogenesis of a nerve; ISS:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:0050919; P:negative chemotaxis; ISS:UniProtKB. DR GO; GO:0048671; P:negative regulation of collateral sprouting; IEA:Ensembl. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:0051964; P:negative regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0072178; P:nephric duct morphogenesis; IEA:Ensembl. DR GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl. DR GO; GO:0016310; P:phosphorylation; ISS:UniProtKB. DR GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISS:UniProtKB. DR GO; GO:0022407; P:regulation of cell-cell adhesion; ISS:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB. DR GO; GO:0099175; P:regulation of postsynapse organization; IEA:Ensembl. DR GO; GO:0031952; P:regulation of protein autophosphorylation; ISS:UniProtKB. DR GO; GO:0031290; P:retinal ganglion cell axon guidance; IEA:Ensembl. DR CDD; cd10485; EphR_LBD_A7; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05066; PTKc_EphR_A; 1. DR CDD; cd09548; SAM_EPH-A7; 1. DR CDD; cd00185; TNFRSF; 1. DR FunFam; 1.10.150.50:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.10:FF:000045; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 1.10.510.10:FF:000130; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.120.260:FF:000001; Ephrin type-A receptor 7; 1. DR FunFam; 2.60.40.10:FF:000190; Ephrin type-A receptor 7; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034283; EphA7_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF9; EPHRIN TYPE-A RECEPTOR 7; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF07699; Ephrin_rec_like; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane; KW Developmental protein; Glycoprotein; Kinase; Membrane; Neurogenesis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..27 FT /evidence="ECO:0000255" FT CHAIN 28..998 FT /note="Ephrin type-A receptor 7" FT /id="PRO_0000016818" FT TOPO_DOM 28..555 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 556..576 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 577..998 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 32..210 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 331..441 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 442..537 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 633..894 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 923..987 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT MOTIF 996..998 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 758 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 639..647 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 665 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 608 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 614 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 791 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT MOD_RES 940 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000255" FT CARBOHYD 343 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 410 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 278..279 FT /note="PC -> RK (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014380" FT VAR_SEQ 280..998 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_014381" FT VAR_SEQ 442..450 FT /note="APSQVSGVM -> GMFCVYLH (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_041943" FT VAR_SEQ 451..998 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000305" FT /id="VSP_041944" FT VAR_SEQ 540..544 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|Ref.3" FT /id="VSP_014382" FT VAR_SEQ 600..604 FT /note="FKFPG -> C (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_041945" FT VARIANT 138 FT /note="I -> V (in dbSNP:rs2278107)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_022105" FT VARIANT 170 FT /note="E -> K (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042150" FT VARIANT 232 FT /note="G -> R (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs2127994473)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042151" FT VARIANT 278 FT /note="P -> S (in dbSNP:rs2278106)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_022106" FT VARIANT 371 FT /note="R -> W (in a colorectal cancer sample; somatic FT mutation; dbSNP:rs371089003)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036090" FT VARIANT 903 FT /note="P -> S (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs2127846874)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042152" FT STRAND 33..37 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 48..51 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 54..61 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 67..74 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 78..80 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 83..86 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 96..106 FT /evidence="ECO:0007829|PDB:3NRU" FT TURN 109..111 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 121..132 FT /evidence="ECO:0007829|PDB:3NRU" FT HELIX 140..142 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 144..150 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 168..174 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 178..190 FT /evidence="ECO:0007829|PDB:3NRU" FT STRAND 192..202 FT /evidence="ECO:0007829|PDB:3NRU" FT HELIX 611..613 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 614..616 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 617..624 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 630..632 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 633..641 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 643..652 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 655..657 FT /evidence="ECO:0007829|PDB:3DKO" FT STRAND 660..666 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 673..686 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 697..701 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 703..705 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 708..712 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 719..725 FT /evidence="ECO:0007829|PDB:2REI" FT TURN 726..728 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 732..751 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 761..763 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 764..766 FT /evidence="ECO:0007829|PDB:2REI" FT STRAND 772..774 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 800..802 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 805..810 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 815..830 FT /evidence="ECO:0007829|PDB:2REI" FT TURN 836..839 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 842..850 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 863..872 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 877..879 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 883..895 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 897..899 FT /evidence="ECO:0007829|PDB:2REI" FT HELIX 928..934 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 938..940 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 941..946 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 952..956 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 960..965 FT /evidence="ECO:0007829|PDB:3H8M" FT HELIX 971..988 FT /evidence="ECO:0007829|PDB:3H8M" FT CONFLICT Q15375-3:278 FT /note="R -> C (in Ref. 6; AAH27940)" FT /evidence="ECO:0000305" SQ SEQUENCE 998 AA; 112097 MW; 479B9CA0D2BB06EB CRC64; MVFQTRYPSW IILCYIWLLR FAHTGEAQAA KEVLLLDSKA QQTELEWISS PPNGWEEISG LDENYTPIRT YQVCQVMEPN QNNWLRTNWI SKGNAQRIFV ELKFTLRDCN SLPGVLGTCK ETFNLYYYET DYDTGRNIRE NLYVKIDTIA ADESFTQGDL GERKMKLNTE VREIGPLSKK GFYLAFQDVG ACIALVSVKV YYKKCWSIIE NLAIFPDTVT GSEFSSLVEV RGTCVSSAEE EAENAPRMHC SAEGEWLVPI GKCICKAGYQ QKGDTCEPCG RGFYKSSSQD LQCSRCPTHS FSDKEGSSRC ECEDGYYRAP SDPPYVACTR PPSAPQNLIF NINQTTVSLE WSPPADNGGR NDVTYRILCK RCSWEQGECV PCGSNIGYMP QQTGLEDNYV TVMDLLAHAN YTFEVEAVNG VSDLSRSQRL FAAVSITTGQ AAPSQVSGVM KERVLQRSVE LSWQEPEHPN GVITEYEIKY YEKDQRERTY STVKTKSTSA SINNLKPGTV YVFQIRAFTA AGYGNYSPRL DVATLEEATG KMFEATAVSS EQNPVIIIAV VAVAGTIILV FMVFGFIIGR RHCGYSKADQ EGDEELYFHF KFPGTKTYID PETYEDPNRA VHQFAKELDA SCIKIERVIG AGEFGEVCSG RLKLPGKRDV AVAIKTLKVG YTEKQRRDFL CEASIMGQFD HPNVVHLEGV VTRGKPVMIV IEFMENGALD AFLRKHDGQF TVIQLVGMLR GIAAGMRYLA DMGYVHRDLA ARNILVNSNL VCKVSDFGLS RVIEDDPEAV YTTTGGKIPV RWTAPEAIQY RKFTSASDVW SYGIVMWEVM SYGERPYWDM SNQDVIKAIE EGYRLPAPMD CPAGLHQLML DCWQKERAER PKFEQIVGIL DKMIRNPNSL KTPLGTCSRP ISPLLDQNTP DFTTFCSVGE WLQAIKMERY KDNFTAAGYN SLESVARMTI EDVMSLGITL VGHQKKIMSS IQTMRAQMLH LHGTGIQV // ID EPHB1_HUMAN Reviewed; 984 AA. AC P54762; A8K593; B3KTB2; B5A969; O43569; O95142; O95143; Q0VG87; DT 01-OCT-1996, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-1996, sequence version 1. DT 28-JAN-2026, entry version 236. DE RecName: Full=Ephrin type-B receptor 1; DE EC=2.7.10.1; DE AltName: Full=ELK; DE AltName: Full=EPH tyrosine kinase 2; DE AltName: Full=EPH-like kinase 6; DE Short=EK6; DE Short=hEK6; DE AltName: Full=Neuronally-expressed EPH-related tyrosine kinase; DE Short=NET; DE AltName: Full=Tyrosine-protein kinase receptor EPH-2; DE Flags: Precursor; GN Name=EPHB1; Synonyms=ELK, EPHT2, HEK6, NET; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=8666391; DOI=10.1006/geno.1995.9985; RA Tang X.X., Biegel J.A., Nycum L.M., Yoshioka A., Brodeur G.M., RA Pleasure D.E., Ikegaki N.; RT "cDNA cloning, molecular characterization, and chromosomal localization of RT NET(EPHT2), a human EPH-related receptor protein-tyrosine kinase gene RT preferentially expressed in brain."; RL Genomics 29:426-437(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN CELL ADHESION, FUNCTION RP IN JUN CASCADE ACTIVATION, INTERACTION WITH NCK1, MUTAGENESIS OF TYR-594 RP AND LYS-651, AND VARIANT TRP-973. RC TISSUE=Kidney; RX PubMed=9430661; DOI=10.1074/jbc.273.3.1303; RA Stein E., Huynh-Do U., Lane A.A., Cerretti D.P., Daniel T.O.; RT "Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to RT c-Jun kinase."; RL J. Biol. Chem. 273:1303-1308(1998). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING. RX PubMed=18593464; DOI=10.1186/ar2447; RA Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D., RA Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.; RT "Novel splice variants derived from the receptor tyrosine kinase RT superfamily are potential therapeutics for rheumatoid arthritis."; RL Arthritis Res. Ther. 10:R73-R73(2008). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2). RC TISSUE=Tongue; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16641997; DOI=10.1038/nature04728; RA Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J., RA Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P., RA Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A., RA Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L., RA Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G., RA Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W., RA Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., RA Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P., RA Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H., RA Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., RA Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., RA Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., RA Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., RA Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B., RA Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H., RA Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J., RA Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X., RA Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R., RA Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.; RT "The DNA sequence, annotation and analysis of human chromosome 3."; RL Nature 440:1194-1198(2006). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP PROTEIN SEQUENCE OF 18-32. RX PubMed=15340161; DOI=10.1110/ps.04682504; RA Zhang Z., Henzel W.J.; RT "Signal peptide prediction based on analysis of experimentally verified RT cleavage sites."; RL Protein Sci. 13:2819-2824(2004). RN [8] RP INTERACTION WITH GRB2 AND GRB10, MUTAGENESIS OF TYR-928, AND RP PHOSPHORYLATION AT TYR-928. RX PubMed=8798570; DOI=10.1074/jbc.271.38.23588; RA Stein E., Cerretti D.P., Daniel T.O.; RT "Ligand activation of ELK receptor tyrosine kinase promotes its association RT with Grb10 and Grb2 in vascular endothelial cells."; RL J. Biol. Chem. 271:23588-23593(1996). RN [9] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [10] RP FUNCTION IN ANGIOGENESIS, FUNCTION IN CELL ADHESION, INTERACTION WITH ACP1, RP AND MUTAGENESIS OF TYR-928. RX PubMed=9499402; DOI=10.1101/gad.12.5.667; RA Stein E., Lane A.A., Cerretti D.P., Schoecklmann H.O., Schroff A.D., RA Van Etten R.L., Daniel T.O.; RT "Eph receptors discriminate specific ligand oligomers to determine RT alternative signaling complexes, attachment, and assembly responses."; RL Genes Dev. 12:667-678(1998). RN [11] RP INTERACTION WITH EPHB6. RX PubMed=11713248; DOI=10.1074/jbc.m108011200; RA Freywald A., Sharfe N., Roifman C.M.; RT "The kinase-null EphB6 receptor undergoes transphosphorylation in a complex RT with EphB1."; RL J. Biol. Chem. 277:3823-3828(2002). RN [12] RP INTERACTION WITH GRB7, FUNCTION, PHOSPHORYLATION AT TYR-928, AND RP MUTAGENESIS OF TYR-928. RX PubMed=12223469; DOI=10.1074/jbc.m203165200; RA Han D.C., Shen T.L., Miao H., Wang B., Guan J.L.; RT "EphB1 associates with Grb7 and regulates cell migration."; RL J. Biol. Chem. 277:45655-45661(2002). RN [13] RP FUNCTION IN CELL MIGRATION, FUNCTION IN ERK CASCADE ACTIVATION, INTERACTION RP WITH GRB2; SHC1 AND SRC, AND MUTAGENESIS OF TYR-600 AND TYR-778. RX PubMed=12925710; DOI=10.1083/jcb.200302073; RA Vindis C., Cerretti D.P., Daniel T.O., Huynh-Do U.; RT "EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote RT chemotaxis."; RL J. Cell Biol. 162:661-671(2003). RN [14] RP FUNCTION IN ERK CASCADE ACTIVATION, UBIQUITINATION BY CBL, INTERACTION WITH RP CBL, MUTAGENESIS OF LYS-651, AUTOPHOSPHORYLATION, IDENTIFICATION OF EFNB1 RP AS LIGAND, AND SUBCELLULAR LOCATION. RX PubMed=18034775; DOI=10.1111/j.1600-0854.2007.00679.x; RA Fasen K., Cerretti D.P., Huynh-Do U.; RT "Ligand binding induces Cbl-dependent EphB1 receptor degradation through RT the lysosomal pathway."; RL Traffic 9:251-266(2008). RN [15] RP STRUCTURE BY NMR OF 899-984. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the C-terminal SAM-domain of mouse ephrin type-B RT receptor 1 precursor (EC 2.7.1.112)."; RL Submitted (JUL-2007) to the PDB data bank. RN [16] RP STRUCTURE BY NMR OF 434-528. RG RIKEN structural genomics initiative (RSGI); RT "Solution structures of the FN3 domain of human ephrin type-B receptor 1."; RL Submitted (FEB-2009) to the PDB data bank. RN [17] RP VARIANTS [LARGE SCALE ANALYSIS] VAL-18; MET-387; THR-707; VAL-719; GLN-743; RP THR-912 AND MET-981. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously CC transmembrane ephrin-B family ligands residing on adjacent cells, CC leading to contact-dependent bidirectional signaling into neighboring CC cells. The signaling pathway downstream of the receptor is referred to CC as forward signaling while the signaling pathway downstream of the CC ephrin ligand is referred to as reverse signaling. Cognate/functional CC ephrin ligands for this receptor include EFNB1, EFNB2 and EFNB3. During CC nervous system development, regulates retinal axon guidance redirecting CC ipsilaterally ventrotemporal retinal ganglion cells axons at the optic CC chiasm midline. This probably requires repulsive interaction with CC EFNB2. In the adult nervous system together with EFNB3, regulates CC chemotaxis, proliferation and polarity of the hippocampus neural CC progenitors. In addition to its role in axon guidance also plays an CC important redundant role with other ephrin-B receptors in development CC and maturation of dendritic spines and synapse formation. May also CC regulate angiogenesis. More generally, may play a role in targeted cell CC migration and adhesion. Upon activation by EFNB1 and probably other CC ephrin-B ligands activates the MAPK/ERK and the JNK signaling cascades CC to regulate cell migration and adhesion respectively. Involved in the CC maintenance of the pool of satellite cells (muscle stem cells) by CC promoting their self-renewal and reducing their activation and CC differentiation (By similarity). {ECO:0000250|UniProtKB:Q8CBF3, CC ECO:0000269|PubMed:12223469, ECO:0000269|PubMed:12925710, CC ECO:0000269|PubMed:18034775, ECO:0000269|PubMed:9430661, CC ECO:0000269|PubMed:9499402}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer CC is composed of an ephrin dimer and a receptor dimer. Oligomerization is CC probably required to induce biological responses (By similarity). CC Interacts with EPHB6; transphosphorylates EPHB6 to form an active CC signaling complex. Interacts with PICK1 (By similarity). Interacts CC (through Tyr-594) with NCK1 (via SH2 domain); activates the JUN cascade CC to regulate cell adhesion (By similarity). The ligand-activated form CC interacts (through Tyr-928) with GRB7 and GRB10 (via SH2 domains). The CC ligand-activated form interacts (residues within the catalytic domain) CC with GRB2 (via SH2 domain). Interacts with GRB2, SHC1 and SRC; CC activates the MAPK/ERK cascade to regulate cell migration. Interacts CC with CBL; regulates receptor degradation through ubiquitination. CC Interacts with ACP1. {ECO:0000250|UniProtKB:Q8CBF3, CC ECO:0000269|PubMed:11713248, ECO:0000269|PubMed:12223469, CC ECO:0000269|PubMed:12925710, ECO:0000269|PubMed:18034775, CC ECO:0000269|PubMed:8798570, ECO:0000269|PubMed:9430661, CC ECO:0000269|PubMed:9499402}. CC -!- INTERACTION: CC P54762; Q13322: GRB10; NbExp=2; IntAct=EBI-80252, EBI-80275; CC P54762; P62993: GRB2; NbExp=2; IntAct=EBI-80252, EBI-401755; CC P54762; Q14451: GRB7; NbExp=4; IntAct=EBI-80252, EBI-970191; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18034775}; CC Single-pass type I membrane protein {ECO:0000269|PubMed:18034775}. CC Early endosome membrane {ECO:0000269|PubMed:18034775}. Cell projection, CC dendrite {ECO:0000250|UniProtKB:Q8CBF3}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P54762-1; Sequence=Displayed; CC Name=2; CC IsoId=P54762-5; Sequence=VSP_056017; CC Name=3; CC IsoId=P54762-6; Sequence=VSP_056018, VSP_056019; CC -!- TISSUE SPECIFICITY: Preferentially expressed in brain. CC -!- PTM: Phosphorylated. Autophosphorylation is stimulated by the ligand CC EFNB1. Required for interaction with SH2 domain-containing interactors, CC for activation of the MAPK/ERK and JUN signaling cascades and for CC ubiquitination by CBL. {ECO:0000269|PubMed:12223469, CC ECO:0000269|PubMed:18034775, ECO:0000269|PubMed:8798570}. CC -!- PTM: Ubiquitinated; (EFNB1)ligand-induced poly- and/or multi- CC ubiquitination by CBL is regulated by SRC and leads to lysosomal CC degradation. {ECO:0000269|PubMed:18034775}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB94627.1; Type=Miscellaneous discrepancy; Note=wrong intron-exon boundaries.; Evidence={ECO:0000305}; CC Sequence=AAB94628.1; Type=Miscellaneous discrepancy; Note=wrong intron-exon boundaries.; Evidence={ECO:0000305}; CC Sequence=AAD02031.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L40636; AAB08520.1; -; mRNA. DR EMBL; AF037331; AAD02030.1; -; mRNA. DR EMBL; AF037332; AAD02031.1; ALT_SEQ; mRNA. DR EMBL; AF037333; AAB94627.1; ALT_SEQ; mRNA. DR EMBL; AF037334; AAB94628.1; ALT_SEQ; mRNA. DR EMBL; EU826607; ACF47643.1; -; mRNA. DR EMBL; AK095305; BAG53024.1; -; mRNA. DR EMBL; AK291208; BAF83897.1; -; mRNA. DR EMBL; AC016931; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC016951; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC063918; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC073244; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC092969; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC111744; AAI11745.1; -; mRNA. DR CCDS; CCDS46921.1; -. [P54762-1] DR RefSeq; NP_004432.1; NM_004441.5. [P54762-1] DR PDB; 2DJS; NMR; -; A=434-528. DR PDB; 2EAO; NMR; -; A=899-984. DR PDB; 3ZFX; X-ray; 2.50 A; A/B/C/D/E/F/G/H/I=602-896. DR PDB; 5MJA; X-ray; 2.14 A; A/B=602-896. DR PDB; 5MJB; X-ray; 2.23 A; A/B=602-896. DR PDB; 6UMW; X-ray; 1.98 A; A=602-896. DR PDB; 7KPL; X-ray; 2.71 A; A=611-889. DR PDB; 7KPM; X-ray; 1.61 A; A=611-889. DR PDBsum; 2DJS; -. DR PDBsum; 2EAO; -. DR PDBsum; 3ZFX; -. DR PDBsum; 5MJA; -. DR PDBsum; 5MJB; -. DR PDBsum; 6UMW; -. DR PDBsum; 7KPL; -. DR PDBsum; 7KPM; -. DR AlphaFoldDB; P54762; -. DR SMR; P54762; -. DR BioGRID; 108361; 30. DR FunCoup; P54762; 1441. DR IntAct; P54762; 45. DR MINT; P54762; -. DR STRING; 9606.ENSP00000381097; -. DR BindingDB; P54762; -. DR ChEMBL; CHEMBL5072; -. DR DrugBank; DB09093; Chlortetracycline. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; P54762; -. DR GuidetoPHARMACOLOGY; 1830; -. DR GlyCosmos; P54762; 3 sites, No reported glycans. DR GlyGen; P54762; 4 sites, 1 N-linked glycan (1 site). DR iPTMnet; P54762; -. DR PhosphoSitePlus; P54762; -. DR SwissPalm; P54762; -. DR BioMuta; EPHB1; -. DR DMDM; 1706663; -. DR CPTAC; CPTAC-2920; -. DR CPTAC; CPTAC-2921; -. DR jPOST; P54762; -. DR MassIVE; P54762; -. DR PaxDb; 9606-ENSP00000381097; -. DR PeptideAtlas; P54762; -. DR ProteomicsDB; 3673; -. DR ProteomicsDB; 56716; -. [P54762-1] DR Antibodypedia; 33398; 561 antibodies from 40 providers. DR DNASU; 2047; -. DR Ensembl; ENST00000398015.8; ENSP00000381097.3; ENSG00000154928.20. [P54762-1] DR Ensembl; ENST00000493838.1; ENSP00000419574.1; ENSG00000154928.20. [P54762-5] DR GeneID; 2047; -. DR KEGG; hsa:2047; -. DR MANE-Select; ENST00000398015.8; ENSP00000381097.3; NM_004441.5; NP_004432.1. DR UCSC; uc003eqt.4; human. [P54762-1] DR AGR; HGNC:3392; -. DR ClinPGx; PA27824; -. DR CTD; 2047; -. DR DisGeNET; 2047; -. DR GeneCards; EPHB1; -. DR HGNC; HGNC:3392; EPHB1. DR HPA; ENSG00000154928; Tissue enhanced (brain). DR MalaCards; EPHB1; -. DR MIM; 600600; gene. DR OpenTargets; ENSG00000154928; -. DR VEuPathDB; HostDB:ENSG00000154928; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000155297; -. DR HOGENOM; CLU_000288_141_0_1; -. DR InParanoid; P54762; -. DR OMA; AVAAMEX; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P54762; 8 GO annotations based on evolutionary models. DR PhylomeDB; P54762; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P54762; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-3928662; EPHB-mediated forward signaling. DR Reactome; R-HSA-3928664; Ephrin signaling. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P54762; -. DR SIGNOR; P54762; -. DR Agora; ENSG00000154928; -. DR BioGRID-ORCS; 2047; 6 hits in 1191 CRISPR screens. DR ChiTaRS; EPHB1; human. DR EvolutionaryTrace; P54762; -. DR GeneWiki; EPH_receptor_B1; -. DR GenomeRNAi; 2047; -. DR Pharos; P54762; Tchem. DR PRO; PR:P54762; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; P54762; protein. DR Bgee; ENSG00000154928; Expressed in cortical plate and 138 other cell types or tissues. DR ExpressionAtlas; P54762; baseline and differential. DR GO; GO:0030424; C:axon; IEA:Ensembl. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0030425; C:dendrite; IBA:GO_Central. DR GO; GO:0031901; C:early endosome membrane; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0032433; C:filopodium tip; IEA:Ensembl. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0045121; C:membrane raft; IEA:Ensembl. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008046; F:axon guidance receptor activity; IEA:Ensembl. DR GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; IDA:UniProtKB. DR GO; GO:0001525; P:angiogenesis; IDA:UniProtKB. DR GO; GO:0007411; P:axon guidance; ISS:UniProtKB. DR GO; GO:0048593; P:camera-type eye morphogenesis; IEA:Ensembl. DR GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB. DR GO; GO:0031589; P:cell-substrate adhesion; IDA:UniProtKB. DR GO; GO:0021952; P:central nervous system projection neuron axonogenesis; ISS:UniProtKB. DR GO; GO:0060996; P:dendritic spine development; ISS:UniProtKB. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:UniProtKB. DR GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; ISS:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB. DR GO; GO:0021934; P:hindbrain tangential cell migration; IEA:Ensembl. DR GO; GO:0001771; P:immunological synapse formation; IEA:Ensembl. DR GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:1902725; P:negative regulation of satellite cell differentiation; ISS:UniProtKB. DR GO; GO:1902723; P:negative regulation of skeletal muscle satellite cell proliferation; ISS:UniProtKB. DR GO; GO:0061351; P:neural precursor cell proliferation; ISS:UniProtKB. DR GO; GO:0022008; P:neurogenesis; ISS:UniProtKB. DR GO; GO:0021631; P:optic nerve morphogenesis; IEA:Ensembl. DR GO; GO:0051965; P:positive regulation of synapse assembly; ISS:UniProtKB. DR GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB. DR GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:0046328; P:regulation of JNK cascade; IDA:UniProtKB. DR GO; GO:0031290; P:retinal ganglion cell axon guidance; ISS:UniProtKB. DR GO; GO:0014719; P:skeletal muscle satellite cell activation; ISS:UniProtKB. DR CDD; cd10476; EphR_LBD_B1; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05065; PTKc_EphR_B; 1. DR CDD; cd09551; SAM_EPH-B1; 1. DR FunFam; 2.60.40.10:FF:000041; ephrin type-A receptor 3; 1. DR FunFam; 1.10.150.50:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 1.10.510.10:FF:000015; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.120.260:FF:000004; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.40.10:FF:000110; Ephrin type-B receptor 2; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034231; EphB1_rcpt_lig-bd. DR InterPro; IPR042819; EphB1_SAM. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF17; EPHRIN TYPE-B RECEPTOR 1; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS01186; EGF_2; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell adhesion; KW Cell membrane; Cell projection; Direct protein sequencing; Endosome; KW Glycoprotein; Kinase; Membrane; Neurogenesis; Nucleotide-binding; KW Phosphoprotein; Proteomics identification; Receptor; Reference proteome; KW Repeat; Signal; Transferase; Transmembrane; Transmembrane helix; KW Tyrosine-protein kinase; Ubl conjugation. FT SIGNAL 1..17 FT /evidence="ECO:0000269|PubMed:15340161" FT CHAIN 18..984 FT /note="Ephrin type-B receptor 1" FT /id="PRO_0000016824" FT TOPO_DOM 18..540 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 541..563 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 564..984 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 19..201 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 322..432 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 433..528 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 619..882 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 911..975 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT MOTIF 982..984 FT /note="PDZ-binding" FT /evidence="ECO:0000255" FT ACT_SITE 744 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 625..633 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 651 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT MOD_RES 600 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:P54753" FT MOD_RES 928 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250" FT CARBOHYD 334 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 426 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 480 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..439 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_056017" FT VAR_SEQ 158..242 FT /note="VNTEVRSFGPLTRNGFYLAFQDYGACMSLLSVRVFFKKCPSIVQNFAVFPET FT MTGAESTSLVIARGTCIPNAEEVDVPIKLYCNG -> LALQGHSRPARKLKAAPTAPPT FT AAPLQRRLPSAPVGPVITERTLTLQKWHALASHQVPAMLSPSSMRRPSFWSGTLQGRQV FT GGMM (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056018" FT VAR_SEQ 243..984 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:18593464" FT /id="VSP_056019" FT VARIANT 18 FT /note="M -> V (in dbSNP:rs55650774)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042165" FT VARIANT 87 FT /note="T -> S (in dbSNP:rs1042794)" FT /id="VAR_011801" FT VARIANT 152 FT /note="G -> R (in dbSNP:rs1042793)" FT /id="VAR_011802" FT VARIANT 367 FT /note="R -> G (in dbSNP:rs1042789)" FT /id="VAR_011803" FT VARIANT 387 FT /note="T -> M (in dbSNP:rs56396912)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042166" FT VARIANT 485 FT /note="R -> S (in dbSNP:rs1042788)" FT /id="VAR_011804" FT VARIANT 707 FT /note="S -> T (in an ovarian undifferentiated carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042167" FT VARIANT 719 FT /note="I -> V (in a gastric adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042168" FT VARIANT 743 FT /note="R -> Q (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs1338928289)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042169" FT VARIANT 847 FT /note="M -> T (in dbSNP:rs1042785)" FT /id="VAR_011805" FT VARIANT 912 FT /note="A -> T (in dbSNP:rs56345346)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042170" FT VARIANT 973 FT /note="R -> W (in dbSNP:rs1042784)" FT /evidence="ECO:0000269|PubMed:9430661" FT /id="VAR_058479" FT VARIANT 981 FT /note="T -> M (in dbSNP:rs56186270)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042171" FT MUTAGEN 594 FT /note="Y->F: Loss of interaction with NCK1." FT /evidence="ECO:0000269|PubMed:9430661" FT MUTAGEN 600 FT /note="Y->F: Loss of interaction with SHC1 and SRC." FT /evidence="ECO:0000269|PubMed:12925710" FT MUTAGEN 651 FT /note="K->R: Kinase-dead mutant. Unable to FT autophosphorylate, to interact with SH2 domain-containing FT interactors, to activate the MAPK/ERK and JUN signaling FT cascades. Not ubiquitinated by CBL." FT /evidence="ECO:0000269|PubMed:18034775, FT ECO:0000269|PubMed:9430661" FT MUTAGEN 778 FT /note="Y->F: Loss of interaction with SHC1." FT /evidence="ECO:0000269|PubMed:12925710" FT MUTAGEN 928 FT /note="Y->F: Disrupts binding with the GRB10 SH2 domain, FT providing evidence for phosphorylation. Disrupts FT interaction with GRB7 and ACP1." FT /evidence="ECO:0000269|PubMed:12223469, FT ECO:0000269|PubMed:8798570, ECO:0000269|PubMed:9499402" FT CONFLICT 12 FT /note="A -> E (in Ref. 2; AAD02030/AAB94627/AAB94628)" FT /evidence="ECO:0000305" FT CONFLICT 185 FT /note="S -> I (in Ref. 2; AAD02030/AAD02031/AAB94627/ FT AAB94628)" FT /evidence="ECO:0000305" FT CONFLICT 274 FT /note="T -> R (in Ref. 2; AAD02030/AAD02031/AAB94627/ FT AAB94628)" FT /evidence="ECO:0000305" FT CONFLICT 336 FT /note="T -> S (in Ref. 2; AAD02030/AAD02031/AAB94627/ FT AAB94628)" FT /evidence="ECO:0000305" FT CONFLICT 752 FT /note="V -> L (in Ref. 6; AAI11745)" FT /evidence="ECO:0000305" FT CONFLICT 813 FT /note="V -> H (in Ref. 2; AAD02030/AAB94627)" FT /evidence="ECO:0000305" FT CONFLICT 819 FT /note="S -> Y (in Ref. 2; AAD02030/AAB94627)" FT /evidence="ECO:0000305" FT CONFLICT 881 FT /note="M -> I (in Ref. 4; BAF83897)" FT /evidence="ECO:0000305" FT CONFLICT 903 FT /note="L -> H (in Ref. 4; BAF83897)" FT /evidence="ECO:0000305" FT STRAND 441..445 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 447..453 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 464..473 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 482..495 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 501..512 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 514..517 FT /evidence="ECO:0007829|PDB:2DJS" FT STRAND 521..524 FT /evidence="ECO:0007829|PDB:2DJS" FT HELIX 616..618 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 619..627 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 632..638 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 646..652 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 659..673 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 683..687 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 689..692 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 694..698 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 705..710 FT /evidence="ECO:0007829|PDB:7KPM" FT TURN 711..714 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 718..737 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 747..749 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 750..752 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 758..760 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 783..786 FT /evidence="ECO:0007829|PDB:5MJB" FT HELIX 788..790 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 793..798 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 803..818 FT /evidence="ECO:0007829|PDB:7KPM" FT TURN 824..827 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 830..838 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 851..860 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 865..867 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 871..883 FT /evidence="ECO:0007829|PDB:7KPM" FT HELIX 885..887 FT /evidence="ECO:0007829|PDB:7KPM" FT STRAND 889..891 FT /evidence="ECO:0007829|PDB:3ZFX" FT HELIX 916..921 FT /evidence="ECO:0007829|PDB:2EAO" FT TURN 922..924 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 926..928 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 929..935 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 940..943 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 948..954 FT /evidence="ECO:0007829|PDB:2EAO" FT HELIX 959..975 FT /evidence="ECO:0007829|PDB:2EAO" SQ SEQUENCE 984 AA; 109885 MW; 8044160E24E93A92 CRC64; MALDYLLLLL LASAVAAMEE TLMDTRTATA ELGWTANPAS GWEEVSGYDE NLNTIRTYQV CNVFEPNQNN WLLTTFINRR GAHRIYTEMR FTVRDCSSLP NVPGSCKETF NLYYYETDSV IATKKSAFWS EAPYLKVDTI AADESFSQVD FGGRLMKVNT EVRSFGPLTR NGFYLAFQDY GACMSLLSVR VFFKKCPSIV QNFAVFPETM TGAESTSLVI ARGTCIPNAE EVDVPIKLYC NGDGEWMVPI GRCTCKPGYE PENSVACKAC PAGTFKASQE AEGCSHCPSN SRSPAEASPI CTCRTGYYRA DFDPPEVACT SVPSGPRNVI SIVNETSIIL EWHPPRETGG RDDVTYNIIC KKCRADRRSC SRCDDNVEFV PRQLGLTECR VSISSLWAHT PYTFDIQAIN GVSSKSPFPP QHVSVNITTN QAAPSTVPIM HQVSATMRSI TLSWPQPEQP NGIILDYEIR YYEKEHNEFN SSMARSQTNT ARIDGLRPGM VYVVQVRART VAGYGKFSGK MCFQTLTDDD YKSELREQLP LIAGSAAAGV VFVVSLVAIS IVCSRKRAYS KEAVYSDKLQ HYSTGRGSPG MKIYIDPFTY EDPNEAVREF AKEIDVSFVK IEEVIGAGEF GEVYKGRLKL PGKREIYVAI KTLKAGYSEK QRRDFLSEAS IMGQFDHPNI IRLEGVVTKS RPVMIITEFM ENGALDSFLR QNDGQFTVIQ LVGMLRGIAA GMKYLAEMNY VHRDLAARNI LVNSNLVCKV SDFGLSRYLQ DDTSDPTYTS SLGGKIPVRW TAPEAIAYRK FTSASDVWSY GIVMWEVMSF GERPYWDMSN QDVINAIEQD YRLPPPMDCP AALHQLMLDC WQKDRNSRPR FAEIVNTLDK MIRNPASLKT VATITAVPSQ PLLDRSIPDF TAFTTVDDWL SAIKMVQYRD SFLTAGFTSL QLVTQMTSED LLRIGITLAG HQKKILNSIH SMRVQISQSP TAMA // ID EPHB2_HUMAN Reviewed; 1055 AA. AC P29323; O43477; Q5T0U6; Q5T0U7; Q5T0U8; DT 01-DEC-1992, integrated into UniProtKB/Swiss-Prot. DT 27-SEP-2005, sequence version 5. DT 28-JAN-2026, entry version 264. DE RecName: Full=Ephrin type-B receptor 2; DE EC=2.7.10.1; DE AltName: Full=Developmentally-regulated Eph-related tyrosine kinase; DE AltName: Full=ELK-related tyrosine kinase; DE AltName: Full=EPH tyrosine kinase 3; DE AltName: Full=EPH-like kinase 5; DE Short=EK5; DE Short=hEK5; DE AltName: Full=Renal carcinoma antigen NY-REN-47; DE AltName: Full=Tyrosine-protein kinase TYRO5; DE AltName: Full=Tyrosine-protein kinase receptor EPH-3; DE Contains: DE RecName: Full=EphB2/CTF1 {ECO:0000250|UniProtKB:P54763}; DE Contains: DE RecName: Full=EphB2/CTF2 {ECO:0000250|UniProtKB:P54763}; DE Flags: Precursor; GN Name=EPHB2; Synonyms=DRT, EPHT3, EPTH3, ERK, HEK5, TYRO5; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). RX PubMed=8033077; RA Kiyokawa E., Takai S., Tanaka M., Iwase T., Suzuki M., Xiang Y.Y., RA Naito Y., Yamada K., Sugimura H., Kino I.; RT "Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in RT various human tumors."; RL Cancer Res. 54:3645-3650(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RC TISSUE=Fetal brain; RX PubMed=8589679; DOI=10.1093/hmg/4.11.2033; RA Ikegaki N., Tang X.X., Liu X.-G., Biegel J.A., Allen C., Yoshioka A., RA Sulman E.P., Brodeur G.M., Pleasure D.E.; RT "Molecular characterization and chromosomal localization of DRT (EPHT3): a RT developmentally regulated human protein-tyrosine kinase gene of the EPH RT family."; RL Hum. Mol. Genet. 4:2033-2045(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=9696046; DOI=10.1038/sj.onc.1201960; RA Tang X.X., Pleasure D.E., Brodeur G.M., Ikegaki N.; RT "A variant transcript encoding an isoform of the human protein tyrosine RT kinase EPHB2 is generated by alternative splicing and alternative use of RT polyadenylation signals."; RL Oncogene 17:521-526(1998). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16710414; DOI=10.1038/nature04727; RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A., RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C., RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K., RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C., RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W., RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J., RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H., RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L., RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J., RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S., RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K., RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R., RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M., RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J., RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N., RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V., RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J., RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E., RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S., RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M., RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H., RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E., RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G., RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.; RT "The DNA sequence and biological annotation of human chromosome 1."; RL Nature 441:315-321(2006). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 15-986 (ISOFORM 2). RC TISSUE=Brain; RX PubMed=7898931; RA Fox G.M., Holst P.L., Chute H.T., Lindberg R.A., Janssen A.M., Basu R., RA Welcher A.A.; RT "cDNA cloning and tissue distribution of five human EPH-like receptor RT protein-tyrosine kinases."; RL Oncogene 10:897-905(1995). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 509-986 (ISOFORM 2). RC TISSUE=Fetal brain; RX PubMed=7601466; DOI=10.1016/0888-7543(95)80224-a; RA Saito T., Seki N., Matsuda Y., Kitahara M., Murata M., Kanda N., Nomura N., RA Yamamoto T., Hori T.-A.; RT "Identification of the human ERK gene as a putative receptor tyrosine RT kinase and its chromosomal localization to 1p36.1: a comparative mapping of RT human, mouse, and rat chromosomes."; RL Genomics 26:382-384(1995). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 640-986 (ISOFORM 2). RC TISSUE=Gastric carcinoma; RX PubMed=7688222; DOI=10.1006/bbrc.1993.1878; RA Iwase T., Tanaka M., Suzuki M., Naito Y., Sugimura H., Kino I.; RT "Identification of protein-tyrosine kinase genes preferentially expressed RT in embryo stomach and gastric cancer."; RL Biochem. Biophys. Res. Commun. 194:698-705(1993). RN [8] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 652-712. RX PubMed=1648701; RA Chan J., Watt V.M.; RT "eek and erk, new members of the eph subclass of receptor protein-tyrosine RT kinases."; RL Oncogene 6:1057-1061(1991). RN [9] RP NOMENCLATURE. RX PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0; RG Eph nomenclature committee; RT "Unified nomenclature for Eph family receptors and their ligands, the RT ephrins."; RL Cell 90:403-404(1997). RN [10] RP IDENTIFICATION AS A RENAL CANCER ANTIGEN. RC TISSUE=Renal cell carcinoma; RX PubMed=10508479; RX DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5; RA Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H., RA Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T., RA Old L.J.; RT "Antigens recognized by autologous antibody in patients with renal-cell RT carcinoma."; RL Int. J. Cancer 83:456-464(1999). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-983 (ISOFORM 2), RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-984 (ISOFORM 3), AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [13] RP POLYUBIQUITINATION, AND INTERACTION WITH SPSB1 AND SPSB4. RX PubMed=28931592; DOI=10.1091/mbc.e17-07-0450; RA Okumura F., Joo-Okumura A., Obara K., Petersen A., Nishikimi A., Fukui Y., RA Nakatsukasa K., Kamura T.; RT "Ubiquitin ligase SPSB4 diminishes cell repulsive responses mediated by RT EphB2."; RL Mol. Biol. Cell 28:3532-3541(2017). RN [14] RP UBIQUITINATION BY RNF186, AND MUTAGENESIS OF LYS-787 AND LYS-891. RX PubMed=33280498; DOI=10.1080/15548627.2020.1851496; RA Zhang H., Cui Z., Cheng D., Du Y., Guo X., Gao R., Chen J., Sun W., He R., RA Ma X., Peng Q., Martin B.N., Yan W., Rong Y., Wang C.; RT "RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic RT epithelial cells for the maintenance of intestinal homeostasis."; RL Autophagy 17:3030-3047(2021). RN [15] RP X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 910-986 (ISOFORM SHORT). RX PubMed=9933164; DOI=10.1126/science.283.5403.833; RA Thanos C.D., Goodwill K.E., Bowie J.U.; RT "Oligomeric structure of the human EphB2 receptor SAM domain."; RL Science 283:833-836(1999). RN [16] RP X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 20-195 OF HOMODIMER IN COMPLEX RP WITH ANTAGONISTIC PEPTIDE, DISULFIDE BOND, AND SUBUNIT. RX PubMed=17897949; DOI=10.1074/jbc.m706340200; RA Chrencik J.E., Brooun A., Recht M.I., Nicola G., Davis L.K., Abagyan R., RA Widmer H., Pasquale E.B., Kuhn P.; RT "Three-dimensional structure of the EphB2 receptor in complex with an RT antagonistic peptide reveals a novel mode of inhibition."; RL J. Biol. Chem. 282:36505-36513(2007). RN [17] {ECO:0007744|PDB:8EBL} RP X-RAY CRYSTALLOGRAPHY (1.37 ANGSTROMS) OF 1042-1055 IN COMPLEX WITH KLHDC2; RP ELOB AND ELOC, AND UBIQUITINATION BY CRL2(KLHDC2) E3 LIGASE COMPLEX. RX PubMed=36805027; DOI=10.1016/j.molcel.2023.01.019; RA Scott D.C., King M.T., Baek K., Gee C.T., Kalathur R., Li J., Purser N., RA Nourse A., Chai S.C., Vaithiyalingam S., Chen T., Lee R.E., Elledge S.J., RA Kleiger G., Schulman B.A.; RT "E3 ligase autoinhibition by C-degron mimicry maintains C-degron substrate RT fidelity."; RL Mol. Cell 83:770-786.e9(2023). RN [18] RP VARIANTS PROSTATE CANCER HIS-199; SER-279; ASN-679 AND MET-909, AND RP FUNCTION AS A TUMOR SUPPRESSOR. RX PubMed=15300251; DOI=10.1038/ng1408; RA Huusko P., Ponciano-Jackson D., Wolf M., Kiefer J.A., Azorsa D.O., RA Tuzmen S., Weaver D., Robbins C., Moses T., Allinen M., Hautaniemi S., RA Chen Y., Elkahloun A., Basik M., Bova G.S., Bubendorf L., Lugli A., RA Sauter G., Schleutker J., Ozcelik H., Elowe S., Pawson T., Trent J.M., RA Carpten J.D., Kallioniemi O.-P., Mousses S.; RT "Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 RT in human prostate cancer."; RL Nat. Genet. 36:979-983(2004). RN [19] RP VARIANTS PROSTATE CANCER SER-279; ALA-650 AND VAL-883. RX PubMed=16155194; DOI=10.1136/jmg.2005.035790; RA Kittles R.A., Baffoe-Bonnie A.B., Moses T.Y., Robbins C.M., Ahaghotu C., RA Huusko P., Pettaway C., Vijayakumar S., Bennett J., Hoke G., Mason T., RA Weinrich S., Trent J.M., Collins F.S., Mousses S., Bailey-Wilson J., RA Furbert-Harris P., Dunston G., Powell I.J., Carpten J.D.; RT "A common nonsense mutation in EphB2 is associated with prostate cancer RT risk in African American men with a positive family history."; RL J. Med. Genet. 43:507-511(2006). RN [20] RP VARIANTS [LARGE SCALE ANALYSIS] SER-279; GLY-289; VAL-361; ASN-678 AND RP TRP-844. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [21] RP VARIANT BDPLT22 CYS-745, INVOLVEMENT IN BDPLT22, AND FUNCTION. RX PubMed=30213874; DOI=10.1182/blood-2018-04-845644; RA Berrou E., Soukaseum C., Favier R., Adam F., Elaib Z., Kauskot A., RA Bordet J.C., Ballerini P., Loyau S., Feng M., Dias K., Muheidli A., RA Girault S., Nurden A.T., Turro E., Ouwehand W.H., Denis C.V., RA Jandrot-Perrus M., Rosa J.P., Nurden P., Bryckaert M.; RT "A mutation of the human EPHB2 gene leads to a major platelet functional RT defect."; RL Blood 132:2067-2077(2018). CC -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously CC transmembrane ephrin-B family ligands residing on adjacent cells, CC leading to contact-dependent bidirectional signaling into neighboring CC cells. The signaling pathway downstream of the receptor is referred to CC as forward signaling while the signaling pathway downstream of the CC ephrin ligand is referred to as reverse signaling. Functions in axon CC guidance during development. Involved in the guidance of commissural CC axons, that form a major interhemispheric connection between the 2 CC temporal lobes of the cerebral cortex. Also involved in guidance of CC contralateral inner ear efferent growth cones at the midline and of CC retinal ganglion cell axons to the optic disk. In addition to axon CC guidance, also regulates dendritic spines development and maturation CC and stimulates the formation of excitatory synapses. Upon activation by CC EFNB1, abolishes the ARHGEF15-mediated negative regulation on CC excitatory synapse formation. Controls other aspects of development CC including angiogenesis, palate development and in inner ear development CC through regulation of endolymph production. Forward and reverse CC signaling through the EFNB2/EPHB2 complex regulate movement and CC adhesion of cells that tubularize the urethra and septate the cloaca. CC May function as a tumor suppressor. May be involved in the regulation CC of platelet activation and blood coagulation (PubMed:30213874). CC {ECO:0000269|PubMed:15300251, ECO:0000269|PubMed:30213874}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028}; CC -!- SUBUNIT: Heterotetramer upon binding of the ligand (By similarity). The CC heterotetramer is composed of an ephrin dimer and a receptor dimer CC (PubMed:17897949). Interacts (via PDZ-binding motif) with GRIP1 and CC PICK1 (via PDZ domain) (By similarity). Interacts with ARHGEF15; CC mediates ARHGEF15 phosphorylation, ubiquitination and degradation by CC the proteasome (By similarity). Interacts with AQP1; involved in CC endolymph production in the inner ear (By similarity). Interacts with CC SPSB1 and SPSB4 (PubMed:28931592). The phosphorylated form interacts CC with RASA1 (via SH2 domain 1) (By similarity). Interacts with EFNA5 (By CC similarity). Interacts with SH2D3C (By similarity). CC {ECO:0000250|UniProtKB:P54763, ECO:0000269|PubMed:17897949, CC ECO:0000269|PubMed:28931592}. CC -!- INTERACTION: CC P29323; P07333: CSF1R; NbExp=2; IntAct=EBI-1059294, EBI-2835440; CC P29323; P98172: EFNB1; NbExp=3; IntAct=EBI-1059294, EBI-538287; CC P29323; P54764: EPHA4; NbExp=3; IntAct=EBI-1059294, EBI-5773557; CC P29323; Q15375: EPHA7; NbExp=2; IntAct=EBI-1059294, EBI-1383428; CC P29323; P49790: NUP153; NbExp=2; IntAct=EBI-1059294, EBI-286779; CC P29323-3; Q9NWW5: CLN6; NbExp=3; IntAct=EBI-25838727, EBI-6165897; CC P29323-3; P21964-2: COMT; NbExp=3; IntAct=EBI-25838727, EBI-10200977; CC P29323-3; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-25838727, EBI-1055254; CC P29323-3; O14832: PHYH; NbExp=3; IntAct=EBI-25838727, EBI-721853; CC P29323-3; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-25838727, EBI-5235340; CC P29323-3; Q13148: TARDBP; NbExp=6; IntAct=EBI-25838727, EBI-372899; CC -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane CC protein. Cell projection, axon {ECO:0000250}. Cell projection, dendrite CC {ECO:0000250}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=EPHB2v, Long; CC IsoId=P29323-1; Sequence=Displayed; CC Name=2; Synonyms=Short; CC IsoId=P29323-2; Sequence=VSP_003016, VSP_003017; CC Name=3; CC IsoId=P29323-3; Sequence=VSP_015713, VSP_003016, VSP_003017; CC -!- TISSUE SPECIFICITY: Brain, heart, lung, kidney, placenta, pancreas, CC liver and skeletal muscle. Preferentially expressed in fetal brain. CC -!- PTM: Autophosphorylated; ligand binding stimulates autophosphorylation CC on tyrosine residues. {ECO:0000250|UniProtKB:P54763}. CC -!- PTM: Polyubiquitinated; ligand binding stimulates ubiquitination CC (PubMed:28931592). Ubiquitinated by RNF186 at Lys-891, mainly through CC 'Lys-27'-linked polyubiquitin chains (PubMed:33280498). Ubiquitinated CC by CRL2(KLHDC2) E3 ligase complex (PubMed:36805027). CC {ECO:0000269|PubMed:28931592, ECO:0000269|PubMed:33280498, CC ECO:0000269|PubMed:36805027}. CC -!- PTM: Ligand binding induces cleavage by matrix metalloproteinases CC (MMPs) such as MMP7/MMP9, producing an EphB2/N-terminal fragment (NTF) CC and a C-terminal long fragment (EphB2-LF). EphB2-LF is further cleaved CC by MMPs, producing EphB2/CTF1 which is further cleaved by the CC PS1/gamma-secretase producing EphB2/CTF2. CC {ECO:0000250|UniProtKB:P54763}. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:15300251, CC ECO:0000269|PubMed:16155194}. Note=The gene represented in this entry CC may be involved in disease pathogenesis. EPHB2 mutations have been CC found in a prostate cancer cell line derived from a brain metastasis. CC -!- DISEASE: Bleeding disorder, platelet-type, 22 (BDPLT22) [MIM:618462]: CC An autosomal recessive disorder characterized by increased bleeding CC tendency due to platelet dysfunction. Clinical features include CC epistaxis, hematomas, bleeding after minor injuries, and menorrhagia. CC {ECO:0000269|PubMed:30213874}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D31661; BAA06506.1; -; mRNA. DR EMBL; L41939; AAA99310.1; -; mRNA. DR EMBL; AF025304; AAB94602.1; -; mRNA. DR EMBL; AL035704; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL158086; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL512444; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; L36643; AAA74244.1; -; mRNA. DR EMBL; D37827; BAA07073.1; -; mRNA. DR EMBL; D14717; BAA03537.1; -; mRNA. DR EMBL; X59292; CAA41981.1; -; Genomic_DNA. DR CCDS; CCDS229.2; -. [P29323-2] DR CCDS; CCDS230.1; -. [P29323-3] DR CCDS; CCDS81279.1; -. [P29323-1] DR PIR; A57174; A57174. DR PIR; I78842; I78842. DR RefSeq; NP_001296122.1; NM_001309193.2. [P29323-1] DR RefSeq; NP_004433.2; NM_004442.7. [P29323-3] DR RefSeq; NP_059145.2; NM_017449.5. [P29323-2] DR PDB; 1B4F; X-ray; 1.95 A; A/B/C/D/E/F/G/H=908-985. DR PDB; 1F0M; X-ray; 2.20 A; A=908-985. DR PDB; 2QBX; X-ray; 2.30 A; A/B=20-196. DR PDB; 3ZFM; X-ray; 2.27 A; A=604-898. DR PDB; 8EBL; X-ray; 1.37 A; C/D=1042-1055. DR PDBsum; 1B4F; -. DR PDBsum; 1F0M; -. DR PDBsum; 2QBX; -. DR PDBsum; 3ZFM; -. DR PDBsum; 8EBL; -. DR AlphaFoldDB; P29323; -. DR BMRB; P29323; -. DR SMR; P29323; -. DR BioGRID; 108362; 223. DR DIP; DIP-1162N; -. DR FunCoup; P29323; 1062. DR IntAct; P29323; 154. DR MINT; P29323; -. DR STRING; 9606.ENSP00000383053; -. DR BindingDB; P29323; -. DR ChEMBL; CHEMBL3290; -. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB12843; Oleandrin. DR DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester. DR DrugBank; DB13930; Ulixertinib. DR DrugCentral; P29323; -. DR GuidetoPHARMACOLOGY; 1831; -. DR GlyCosmos; P29323; 4 sites, No reported glycans. DR GlyGen; P29323; 5 sites, 2 N-linked glycans (2 sites), 1 O-linked glycan (1 site). DR iPTMnet; P29323; -. DR PhosphoSitePlus; P29323; -. DR SwissPalm; P29323; -. DR BioMuta; EPHB2; -. DR DMDM; 76803654; -. DR CPTAC; CPTAC-2786; -. DR CPTAC; CPTAC-3205; -. DR jPOST; P29323; -. DR MassIVE; P29323; -. DR PaxDb; 9606-ENSP00000363763; -. DR PeptideAtlas; P29323; -. DR ProteomicsDB; 54540; -. [P29323-1] DR ProteomicsDB; 54541; -. [P29323-2] DR ProteomicsDB; 54542; -. [P29323-3] DR Pumba; P29323; -. DR Antibodypedia; 30106; 653 antibodies from 41 providers. DR DNASU; 2048; -. DR Ensembl; ENST00000374630.8; ENSP00000363761.3; ENSG00000133216.17. [P29323-2] DR Ensembl; ENST00000374632.7; ENSP00000363763.3; ENSG00000133216.17. [P29323-3] DR Ensembl; ENST00000400191.7; ENSP00000383053.3; ENSG00000133216.17. [P29323-1] DR GeneID; 2048; -. DR KEGG; hsa:2048; -. DR MANE-Select; ENST00000374630.8; ENSP00000363761.3; NM_017449.5; NP_059145.2. [P29323-2] DR UCSC; uc001bge.4; human. [P29323-1] DR AGR; HGNC:3393; -. DR CIViC; 2048; 2 evidence items across 2 molecular profiles. DR ClinPGx; PA27825; -. DR CTD; 2048; -. DR DisGeNET; 2048; -. DR GeneCards; EPHB2; -. DR HGNC; HGNC:3393; EPHB2. DR HPA; ENSG00000133216; Tissue enhanced (intestine). DR MalaCards; EPHB2; -. DR MIM; 176807; phenotype. DR MIM; 600997; gene. DR MIM; 603688; phenotype. DR MIM; 618462; phenotype. DR OpenTargets; ENSG00000133216; -. DR Orphanet; 1331; Familial prostate cancer. DR VEuPathDB; HostDB:ENSG00000133216; -. DR eggNOG; KOG0196; Eukaryota. DR GeneTree; ENSGT00940000155503; -. DR InParanoid; P29323; -. DR OMA; GAINCIC; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P29323; 10 GO annotations based on evolutionary models. DR PhylomeDB; P29323; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P29323; -. DR Reactome; R-HSA-2682334; EPH-Ephrin signaling. DR Reactome; R-HSA-373760; L1CAM interactions. DR Reactome; R-HSA-3928662; EPHB-mediated forward signaling. DR Reactome; R-HSA-3928664; Ephrin signaling. DR Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. DR SignaLink; P29323; -. DR SIGNOR; P29323; -. DR Agora; ENSG00000133216; -. DR BioGRID-ORCS; 2048; 11 hits in 1193 CRISPR screens. DR ChiTaRS; EPHB2; human. DR EvolutionaryTrace; P29323; -. DR GeneWiki; EPH_receptor_B2; -. DR GenomeRNAi; 2048; -. DR Pharos; P29323; Tchem. DR PRO; PR:P29323; -. DR Proteomes; UP000005640; Chromosome 1. DR RNAct; P29323; protein. DR Bgee; ENSG00000133216; Expressed in ganglionic eminence and 165 other cell types or tissues. DR ExpressionAtlas; P29323; baseline and differential. DR GO; GO:0030424; C:axon; ISS:UniProtKB. DR GO; GO:0009986; C:cell surface; IEA:Ensembl. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0043197; C:dendritic spine; IEA:Ensembl. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl. DR GO; GO:0098686; C:hippocampal mossy fiber to CA3 synapse; IEA:Ensembl. DR GO; GO:0043025; C:neuronal cell body; IEA:Ensembl. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0098794; C:postsynapse; TAS:ARUK-UCL. DR GO; GO:0045211; C:postsynaptic membrane; IEA:Ensembl. DR GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl. DR GO; GO:0001540; F:amyloid-beta binding; ISS:ARUK-UCL. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0008046; F:axon guidance receptor activity; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB. DR GO; GO:0044877; F:protein-containing complex binding; ISS:ARUK-UCL. DR GO; GO:0005102; F:signaling receptor binding; IEA:Ensembl. DR GO; GO:0005005; F:transmembrane-ephrin receptor activity; ISS:UniProtKB. DR GO; GO:0001525; P:angiogenesis; ISS:UniProtKB. DR GO; GO:0007411; P:axon guidance; ISS:UniProtKB. DR GO; GO:0007413; P:axonal fasciculation; ISS:UniProtKB. DR GO; GO:0042113; P:B cell activation; IMP:ARUK-UCL. DR GO; GO:0048593; P:camera-type eye morphogenesis; IEA:Ensembl. DR GO; GO:1904646; P:cellular response to amyloid-beta; IEA:Ensembl. DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl. DR GO; GO:0021952; P:central nervous system projection neuron axonogenesis; IEA:Ensembl. DR GO; GO:0071679; P:commissural neuron axon guidance; ISS:UniProtKB. DR GO; GO:0022038; P:corpus callosum development; ISS:UniProtKB. DR GO; GO:0060996; P:dendritic spine development; ISS:UniProtKB. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:UniProtKB. DR GO; GO:0048013; P:ephrin receptor signaling pathway; ISS:UniProtKB. DR GO; GO:0021934; P:hindbrain tangential cell migration; IEA:Ensembl. DR GO; GO:0042472; P:inner ear morphogenesis; ISS:UniProtKB. DR GO; GO:0007612; P:learning; ISS:ARUK-UCL. DR GO; GO:0007611; P:learning or memory; ISS:ARUK-UCL. DR GO; GO:0050771; P:negative regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0007162; P:negative regulation of cell adhesion; IMP:ARUK-UCL. DR GO; GO:1900016; P:negative regulation of cytokine production involved in inflammatory response; IEA:Ensembl. DR GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISS:ARUK-UCL. DR GO; GO:1900450; P:negative regulation of glutamate receptor signaling pathway; ISS:ARUK-UCL. DR GO; GO:0046580; P:negative regulation of Ras protein signal transduction; ISS:ARUK-UCL. DR GO; GO:0007399; P:nervous system development; TAS:UniProtKB. DR GO; GO:1990535; P:neuron projection maintenance; ISS:ARUK-UCL. DR GO; GO:0106028; P:neuron projection retraction; ISS:ARUK-UCL. DR GO; GO:0021631; P:optic nerve morphogenesis; IEA:Ensembl. DR GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISS:UniProtKB. DR GO; GO:0016310; P:phosphorylation; ISS:UniProtKB. DR GO; GO:0030890; P:positive regulation of B cell proliferation; IMP:ARUK-UCL. DR GO; GO:0030335; P:positive regulation of cell migration; IGI:ARUK-UCL. DR GO; GO:0061003; P:positive regulation of dendritic spine morphogenesis; IEA:Ensembl. DR GO; GO:0010628; P:positive regulation of gene expression; ISS:ARUK-UCL. DR GO; GO:1900451; P:positive regulation of glutamate receptor signaling pathway; ISS:ARUK-UCL. DR GO; GO:0002639; P:positive regulation of immunoglobulin production; IMP:ARUK-UCL. DR GO; GO:0048170; P:positive regulation of long-term neuronal synaptic plasticity; IEA:Ensembl. DR GO; GO:1900273; P:positive regulation of long-term synaptic potentiation; ISS:ARUK-UCL. DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IEA:Ensembl. DR GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; ISS:ARUK-UCL. DR GO; GO:0051965; P:positive regulation of synapse assembly; ISS:UniProtKB. DR GO; GO:0031915; P:positive regulation of synaptic plasticity; ISS:ARUK-UCL. DR GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IMP:ARUK-UCL. DR GO; GO:0097104; P:postsynaptic membrane assembly; IEA:Ensembl. DR GO; GO:2000822; P:regulation of behavioral fear response; IEA:Ensembl. DR GO; GO:0030193; P:regulation of blood coagulation; IMP:UniProtKB. DR GO; GO:0050878; P:regulation of body fluid levels; ISS:UniProtKB. DR GO; GO:0051489; P:regulation of filopodium assembly; IEA:Ensembl. DR GO; GO:0048168; P:regulation of neuronal synaptic plasticity; ISS:ARUK-UCL. DR GO; GO:0046425; P:regulation of receptor signaling pathway via JAK-STAT; IEA:Ensembl. DR GO; GO:2000316; P:regulation of T-helper 17 type immune response; IEA:Ensembl. DR GO; GO:0031290; P:retinal ganglion cell axon guidance; IEA:Ensembl. DR GO; GO:0060021; P:roof of mouth development; ISS:UniProtKB. DR GO; GO:0120192; P:tight junction assembly; IEA:Ensembl. DR GO; GO:0001655; P:urogenital system development; ISS:UniProtKB. DR GO; GO:0110077; P:vesicle-mediated intercellular transport; IEA:Ensembl. DR CDD; cd10477; EphR_LBD_B2; 1. DR CDD; cd00063; FN3; 2. DR CDD; cd05065; PTKc_EphR_B; 1. DR CDD; cd09552; SAM_EPH-B2; 1. DR CDD; cd00185; TNFRSF; 1. DR FunFam; 1.10.150.50:FF:000099; EPH receptor B2; 1. DR FunFam; 2.60.40.10:FF:000041; ephrin type-A receptor 3; 1. DR FunFam; 2.10.50.10:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 2.60.40.1770:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 3.30.200.20:FF:000001; Ephrin type-A receptor 5; 1. DR FunFam; 1.10.510.10:FF:000015; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.120.260:FF:000004; Ephrin type-B receptor 2; 1. DR FunFam; 2.60.40.10:FF:000110; Ephrin type-B receptor 2; 1. DR Gene3D; 2.60.40.1770; ephrin a2 ectodomain; 1. DR Gene3D; 2.60.120.260; Galactose-binding domain-like; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.150.50; Transcription Factor, Ets-1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 1. DR InterPro; IPR027936; Eph_TM. DR InterPro; IPR034238; EphB2_rcpt_lig-bd. DR InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom. DR InterPro; IPR050449; Ephrin_rcpt_TKs. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR008979; Galactose-bd-like_sf. DR InterPro; IPR009030; Growth_fac_rcpt_cys_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR001660; SAM. DR InterPro; IPR013761; SAM/pointed_sf. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016257; Tyr_kinase_ephrin_rcpt. DR InterPro; IPR001426; Tyr_kinase_rcpt_V_CS. DR PANTHER; PTHR46877; EPH RECEPTOR A5; 1. DR PANTHER; PTHR46877:SF11; EPHRIN TYPE-B RECEPTOR 2; 1. DR Pfam; PF14575; EphA2_TM; 1. DR Pfam; PF25599; Ephrin_CRD; 1. DR Pfam; PF01404; Ephrin_lbd; 1. DR Pfam; PF07699; Ephrin_rec_like; 1. DR Pfam; PF00041; fn3; 2. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF00536; SAM_1; 1. DR PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1. DR PRINTS; PR00014; FNTYPEIII. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00615; EPH_lbd; 1. DR SMART; SM01411; Ephrin_rec_like; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00454; SAM; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF49785; Galactose-binding domain-like; 1. DR SUPFAM; SSF57184; Growth factor receptor domain; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR SUPFAM; SSF47769; SAM/Pointed domain; 1. DR PROSITE; PS51550; EPH_LBD; 1. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1. DR PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1. DR PROSITE; PS50105; SAM_DOMAIN; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Cell projection; Developmental protein; Disease variant; Disulfide bond; KW Glycoprotein; Isopeptide bond; Kinase; Membrane; Neurogenesis; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; Receptor; KW Reference proteome; Repeat; Signal; Transferase; Transmembrane; KW Transmembrane helix; Tumor suppressor; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..18 FT /evidence="ECO:0000255" FT CHAIN 19..1055 FT /note="Ephrin type-B receptor 2" FT /id="PRO_0000016827" FT CHAIN 536..986 FT /note="EphB2/CTF1" FT /evidence="ECO:0000250|UniProtKB:P54763" FT /id="PRO_0000445961" FT CHAIN 562..986 FT /note="EphB2/CTF2" FT /evidence="ECO:0000250|UniProtKB:P54763" FT /id="PRO_0000445962" FT TOPO_DOM 19..543 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 544..564 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 565..1055 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 20..202 FT /note="Eph LBD" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00883" FT DOMAIN 324..434 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 435..530 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 621..884 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 913..977 FT /note="SAM" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00184" FT REGION 990..1055 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 984..986 FT /note="PDZ-binding (in isoform 2)" FT /evidence="ECO:0000255" FT COMPBIAS 991..1002 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1025..1049 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 746 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 627..635 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 653 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 535..536 FT /note="Cleavage; by a metalloproteinase" FT /evidence="ECO:0000250|UniProtKB:P54763" FT SITE 561..562 FT /note="Cleavage; by gamma-secretase/PS1" FT /evidence="ECO:0000250|UniProtKB:P54763" FT CARBOHYD 265 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 336 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 428 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 482 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 62..184 FT /evidence="ECO:0000269|PubMed:17897949" FT DISULFID 97..107 FT /evidence="ECO:0000269|PubMed:17897949" FT CROSSLNK 891 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:33280498" FT VAR_SEQ 568 FT /note="R -> RR (in isoform 3)" FT /evidence="ECO:0000303|PubMed:8589679" FT /id="VSP_015713" FT VAR_SEQ 986 FT /note="G -> V (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:7601466, FT ECO:0000303|PubMed:7688222, ECO:0000303|PubMed:7898931, FT ECO:0000303|PubMed:8033077, ECO:0000303|PubMed:8589679" FT /id="VSP_003016" FT VAR_SEQ 987..1055 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:7601466, FT ECO:0000303|PubMed:7688222, ECO:0000303|PubMed:7898931, FT ECO:0000303|PubMed:8033077, ECO:0000303|PubMed:8589679" FT /id="VSP_003017" FT VARIANT 199 FT /note="R -> H (in prostate cancer; dbSNP:rs201754821)" FT /evidence="ECO:0000269|PubMed:15300251" FT /id="VAR_032853" FT VARIANT 279 FT /note="A -> S (in prostate cancer; dbSNP:rs35882952)" FT /evidence="ECO:0000269|PubMed:15300251, FT ECO:0000269|PubMed:16155194, ECO:0000269|PubMed:17344846" FT /id="VAR_032854" FT VARIANT 289 FT /note="C -> G" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042172" FT VARIANT 361 FT /note="I -> V (in dbSNP:rs56180036)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042173" FT VARIANT 650 FT /note="V -> A (in prostate cancer; dbSNP:rs142173175)" FT /evidence="ECO:0000269|PubMed:16155194" FT /id="VAR_032855" FT VARIANT 678 FT /note="D -> N (in dbSNP:rs28936395)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042174" FT VARIANT 679 FT /note="H -> N (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:15300251" FT /id="VAR_032856" FT VARIANT 745 FT /note="R -> C (in BDPLT22; dbSNP:rs761749948)" FT /evidence="ECO:0000269|PubMed:30213874" FT /id="VAR_082702" FT VARIANT 844 FT /note="R -> W (in dbSNP:rs55826626)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042175" FT VARIANT 883 FT /note="M -> V (in prostate cancer; dbSNP:rs372653137)" FT /evidence="ECO:0000269|PubMed:16155194" FT /id="VAR_032857" FT VARIANT 909 FT /note="I -> M (in prostate cancer)" FT /evidence="ECO:0000269|PubMed:15300251" FT /id="VAR_032858" FT MUTAGEN 787 FT /note="K->R: No loss of ubiquitination by RNF186." FT /evidence="ECO:0000269|PubMed:33280498" FT MUTAGEN 891 FT /note="K->R: Complete loss of ubiquitination by RNF186." FT /evidence="ECO:0000269|PubMed:33280498" FT CONFLICT 1..20 FT /note="MALRRLGAALLLLPLLAAVE -> MWVPVLALPVCTYA (in Ref. 1; FT BAA06506)" FT /evidence="ECO:0000305" FT CONFLICT 154 FT /note="G -> D (in Ref. 1; BAA06506)" FT /evidence="ECO:0000305" FT CONFLICT 476 FT /note="K -> KQ (in Ref. 1; BAA06506)" FT /evidence="ECO:0000305" FT CONFLICT 495..496 FT /note="Missing (in Ref. 5; AAA74244)" FT /evidence="ECO:0000305" FT CONFLICT 532 FT /note="E -> D (in Ref. 1; BAA06506)" FT /evidence="ECO:0000305" FT CONFLICT 589 FT /note="M -> I (in Ref. 5; AAA74244)" FT /evidence="ECO:0000305" FT CONFLICT 671 FT /note="A -> R (in Ref. 7; BAA03537)" FT /evidence="ECO:0000305" FT CONFLICT 788 FT /note="I -> F (in Ref. 5; AAA74244)" FT /evidence="ECO:0000305" FT CONFLICT 853 FT /note="S -> A (in Ref. 1; BAA06506, 6; BAA07073 and 7; FT BAA03537)" FT /evidence="ECO:0000305" FT CONFLICT 923 FT /note="E -> K (in Ref. 1; BAA06506, 6; BAA07073 and 7; FT BAA03537)" FT /evidence="ECO:0000305" FT CONFLICT 958 FT /note="V -> L (in Ref. 2; AAA99310)" FT /evidence="ECO:0000305" FT STRAND 21..25 FT /evidence="ECO:0007829|PDB:2QBX" FT HELIX 26..28 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 36..39 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 44..49 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 55..61 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 66..68 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 71..74 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 84..94 FT /evidence="ECO:0007829|PDB:2QBX" FT HELIX 97..99 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 111..120 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 130..132 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 135..141 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 148..152 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 155..166 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 171..183 FT /evidence="ECO:0007829|PDB:2QBX" FT STRAND 185..194 FT /evidence="ECO:0007829|PDB:2QBX" FT HELIX 618..620 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 621..626 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 635..640 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 648..655 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 661..674 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 685..689 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 691..700 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 707..712 FT /evidence="ECO:0007829|PDB:3ZFM" FT TURN 713..716 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 720..739 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 749..751 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 752..754 FT /evidence="ECO:0007829|PDB:3ZFM" FT STRAND 760..762 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 790..792 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 795..800 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 805..820 FT /evidence="ECO:0007829|PDB:3ZFM" FT TURN 826..829 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 832..840 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 853..862 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 873..885 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 887..890 FT /evidence="ECO:0007829|PDB:3ZFM" FT HELIX 918..924 FT /evidence="ECO:0007829|PDB:1B4F" FT HELIX 928..930 FT /evidence="ECO:0007829|PDB:1B4F" FT HELIX 931..936 FT /evidence="ECO:0007829|PDB:1B4F" FT HELIX 942..945 FT /evidence="ECO:0007829|PDB:1B4F" FT HELIX 950..955 FT /evidence="ECO:0007829|PDB:1B4F" FT HELIX 961..982 FT /evidence="ECO:0007829|PDB:1B4F" FT HELIX 1050..1052 FT /evidence="ECO:0007829|PDB:8EBL" FT MOD_RES P29323-2:983 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES P29323-3:984 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" SQ SEQUENCE 1055 AA; 117493 MW; 4F8BFEDC45986483 CRC64; MALRRLGAAL LLLPLLAAVE ETLMDSTTAT AELGWMVHPP SGWEEVSGYD ENMNTIRTYQ VCNVFESSQN NWLRTKFIRR RGAHRIHVEM KFSVRDCSSI PSVPGSCKET FNLYYYEADF DSATKTFPNW MENPWVKVDT IAADESFSQV DLGGRVMKIN TEVRSFGPVS RSGFYLAFQD YGGCMSLIAV RVFYRKCPRI IQNGAIFQET LSGAESTSLV AARGSCIANA EEVDVPIKLY CNGDGEWLVP IGRCMCKAGF EAVENGTVCR GCPSGTFKAN QGDEACTHCP INSRTTSEGA TNCVCRNGYY RADLDPLDMP CTTIPSAPQA VISSVNETSL MLEWTPPRDS GGREDLVYNI ICKSCGSGRG ACTRCGDNVQ YAPRQLGLTE PRIYISDLLA HTQYTFEIQA VNGVTDQSPF SPQFASVNIT TNQAAPSAVS IMHQVSRTVD SITLSWSQPD QPNGVILDYE LQYYEKELSE YNATAIKSPT NTVTVQGLKA GAIYVFQVRA RTVAGYGRYS GKMYFQTMTE AEYQTSIQEK LPLIIGSSAA GLVFLIAVVV IAIVCNRRGF ERADSEYTDK LQHYTSGHMT PGMKIYIDPF TYEDPNEAVR EFAKEIDISC VKIEQVIGAG EFGEVCSGHL KLPGKREIFV AIKTLKSGYT EKQRRDFLSE ASIMGQFDHP NVIHLEGVVT KSTPVMIITE FMENGSLDSF LRQNDGQFTV IQLVGMLRGI AAGMKYLADM NYVHRDLAAR NILVNSNLVC KVSDFGLSRF LEDDTSDPTY TSALGGKIPI RWTAPEAIQY RKFTSASDVW SYGIVMWEVM SYGERPYWDM TNQDVINAIE QDYRLPPPMD CPSALHQLML DCWQKDRNHR PKFGQIVNTL DKMIRNPNSL KAMAPLSSGI NLPLLDRTIP DYTSFNTVDE WLEAIKMGQY KESFANAGFT SFDVVSQMMM EDILRVGVTL AGHQKKILNS IQVMRAQMNQ IQSVEGQPLA RRPRATGRTK RCQPRDVTKK TCNSNDGKKK GMGKKKTDPG RGREIQGIFF KEDSHKESND CSCGG // ID KPCA_HUMAN Reviewed; 672 AA. AC P17252; B5BU22; Q15137; Q32M72; Q96RE4; DT 01-AUG-1990, integrated into UniProtKB/Swiss-Prot. DT 11-JAN-2011, sequence version 4. DT 28-JAN-2026, entry version 258. DE RecName: Full=Protein kinase C alpha type; DE Short=PKC-A; DE Short=PKC-alpha; DE EC=2.7.11.13 {ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:36040231}; GN Name=PRKCA; Synonyms=PKCA, PRKACA; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-568. RC TISSUE=Blood; RX PubMed=2336401; DOI=10.1093/nar/18.8.2183; RA Finkenzeller G., Marme D., Hug H.; RT "Sequence of human protein kinase C alpha."; RL Nucleic Acids Res. 18:2183-2183(1990). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-568. RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16625196; DOI=10.1038/nature04689; RA Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., RA Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., RA Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., RA Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., RA DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., RA Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., RA Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., RA LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., RA Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., RA Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., RA Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., RA Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., RA Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.; RT "DNA sequence of human chromosome 17 and analysis of rearrangement in the RT human lineage."; RL Nature 440:1045-1049(2006). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ILE-568. RA Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-568. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 15-445. RX PubMed=1714454; DOI=10.1016/s0021-9258(18)98596-0; RA McSwine-Kennick R.L., McKeegan E.M., Johnson M.D., Morin M.J.; RT "Phorbol diester-induced alterations in the expression of protein kinase C RT isozymes and their mRNAs. Analysis in wild-type and phorbol diester- RT resistant HL-60 cell clones."; RL J. Biol. Chem. 266:15135-15143(1991). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57. RA Haridasse V., Hackenbruck J., Glazer R.I.; RT "Homo sapiens protein kinase C alpha 5-flanking sequence."; RL Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases. RN [8] RP PROTEIN SEQUENCE OF 2-19. RC TISSUE=Platelet; RX PubMed=12665801; DOI=10.1038/nbt810; RA Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R., RA Vandekerckhove J.; RT "Exploring proteomes and analyzing protein processing by mass spectrometric RT identification of sorted N-terminal peptides."; RL Nat. Biotechnol. 21:566-569(2003). RN [9] RP FUNCTION IN APOPTOSIS, AND SUBCELLULAR LOCATION. RX PubMed=9738012; DOI=10.1074/jbc.273.39.25436; RA Ruvolo P.P., Deng X., Carr B.K., May W.S.; RT "A functional role for mitochondrial protein kinase Calpha in Bcl2 RT phosphorylation and suppression of apoptosis."; RL J. Biol. Chem. 273:25436-25442(1998). RN [10] RP FUNCTION IN INFLAMMATORY RESPONSE. RX PubMed=9830023; DOI=10.1074/jbc.273.49.32787; RA St-Denis A., Chano F., Tremblay P., St-Pierre Y., Descoteaux A.; RT "Protein kinase C-alpha modulates lipopolysaccharide-induced functions in a RT murine macrophage cell line."; RL J. Biol. Chem. 273:32787-32792(1998). RN [11] RP FUNCTION IN INFLAMMATORY RESPONSE. RX PubMed=9873035; DOI=10.1074/jbc.274.2.939; RA Han Y., Meng T., Murray N.R., Fields A.P., Brasier A.R.; RT "Interleukin-1-induced nuclear factor-kappaB-IkappaBalpha autoregulatory RT feedback loop in hepatocytes. A role for protein kinase calpha in post- RT transcriptional regulation of ikappabalpha resynthesis."; RL J. Biol. Chem. 274:939-947(1999). RN [12] RP FUNCTION IN APOPTOSIS. RX PubMed=9927633; DOI=10.1124/mol.55.2.396; RA Shen L., Dean N.M., Glazer R.I.; RT "Induction of p53-dependent, insulin-like growth factor-binding protein-3- RT mediated apoptosis in glioblastoma multiforme cells by a protein kinase RT Calpha antisense oligonucleotide."; RL Mol. Pharmacol. 55:396-402(1999). RN [13] RP FUNCTION IN CELL CYCLE PROGRESSION. RX PubMed=10848585; DOI=10.1128/mcb.20.13.4580-4590.2000; RA Besson A., Yong V.W.; RT "Involvement of p21(Waf1/Cip1) in protein kinase C alpha-induced cell cycle RT progression."; RL Mol. Cell. Biol. 20:4580-4590(2000). RN [14] RP FUNCTION IN ANGIOGENESIS. RX PubMed=11909826; DOI=10.1161/01.res.0000012503.30315.e8; RA Wang A., Nomura M., Patan S., Ware J.A.; RT "Inhibition of protein kinase Calpha prevents endothelial cell migration RT and vascular tube formation in vitro and myocardial neovascularization in RT vivo."; RL Circ. Res. 90:609-616(2002). RN [15] RP INTERACTION WITH ADAP1. RX PubMed=12893243; DOI=10.1016/s0006-291x(03)01187-2; RA Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D., RA Wakefield R.I.D., Johannes F.-J., Aitken A.; RT "Centaurin-alpha(1) associates with and is phosphorylated by isoforms of RT protein kinase C."; RL Biochem. Biophys. Res. Commun. 307:459-465(2003). RN [16] RP FUNCTION IN PLATELET AGGREGATION. RX PubMed=12724315; DOI=10.1074/jbc.m212407200; RA Tabuchi A., Yoshioka A., Higashi T., Shirakawa R., Nishioka H., Kita T., RA Horiuchi H.; RT "Direct demonstration of involvement of protein kinase Calpha in the Ca2+- RT induced platelet aggregation."; RL J. Biol. Chem. 278:26374-26379(2003). RN [17] RP FUNCTION IN PHOSPHORYLATION OF TNNT2/CTNT. RX PubMed=12832403; DOI=10.1074/jbc.m306325200; RA Sumandea M.P., Pyle W.G., Kobayashi T., de Tombe P.P., Solaro R.J.; RT "Identification of a functionally critical protein kinase C phosphorylation RT residue of cardiac troponin T."; RL J. Biol. Chem. 278:35135-35144(2003). RN [18] RP FUNCTION IN KIT SIGNALING. RX PubMed=15526160; DOI=10.1007/s00018-004-4189-6; RA Ronnstrand L.; RT "Signal transduction via the stem cell factor receptor/c-Kit."; RL Cell. Mol. Life Sci. 61:2535-2548(2004). RN [19] RP FUNCTION IN PHOSPHORYLATION OF TRPC1. RX PubMed=15016832; DOI=10.1074/jbc.m313975200; RA Ahmmed G.U., Mehta D., Vogel S., Holinstat M., Paria B.C., Tiruppathi C., RA Malik A.B.; RT "Protein kinase Calpha phosphorylates the TRPC1 channel and regulates RT store-operated Ca2+ entry in endothelial cells."; RL J. Biol. Chem. 279:20941-20949(2004). RN [20] RP INTERACTION WITH PICK1. RX PubMed=15247289; DOI=10.1074/jbc.m404499200; RA Dev K.K., Nakanishi S., Henley J.M.; RT "The PDZ domain of PICK1 differentially accepts protein kinase C-alpha and RT GluR2 as interacting ligands."; RL J. Biol. Chem. 279:41393-41397(2004). RN [21] RP FUNCTION IN PHOSPHORYLATION OF CSPG4, AND INTERACTION WITH CSPG4. RX PubMed=15504744; DOI=10.1074/jbc.m411045200; RA Makagiansar I.T., Williams S., Dahlin-Huppe K., Fukushi J., Mustelin T., RA Stallcup W.B.; RT "Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates RT polarized membrane distribution and cell motility."; RL J. Biol. Chem. 279:55262-55270(2004). RN [22] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055; RA Roskoski R. Jr.; RT "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor."; RL Biochem. Biophys. Res. Commun. 337:1-13(2005). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=17081983; DOI=10.1016/j.cell.2006.09.026; RA Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; RT "Global, in vivo, and site-specific phosphorylation dynamics in signaling RT networks."; RL Cell 127:635-648(2006). RN [24] RP INTERACTION WITH TRIM41. RX PubMed=17893151; DOI=10.1074/jbc.m703320200; RA Chen D., Gould C., Garza R., Gao T., Hampton R.Y., Newton A.C.; RT "Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin RT ligase."; RL J. Biol. Chem. 282:33776-33787(2007). RN [25] RP FUNCTION IN ANGIOGENESIS. RX PubMed=18056764; DOI=10.1093/cvr/cvm085; RA Xu H., Czerwinski P., Hortmann M., Sohn H.Y., Foerstermann U., Li H.; RT "Protein kinase C alpha promotes angiogenic activity of human endothelial RT cells via induction of vascular endothelial growth factor."; RL Cardiovasc. Res. 78:349-355(2008). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [27] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-638 AND SER-651, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [28] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [29] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [30] RP FUNCTION. RX PubMed=19176525; DOI=10.1074/jbc.m808719200; RA Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.; RT "Phosphorylation of activation transcription factor-2 at serine 121 by RT protein kinase c controls c-Jun-mediated activation of transcription."; RL J. Biol. Chem. 284:8567-8581(2009). RN [31] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [32] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-628, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226 AND THR-638, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [34] RP FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-657, AND MUTAGENESIS RP OF LYS-368. RX PubMed=21806543; DOI=10.1042/bj20110678; RA Cameron A.J., Linch M.D., Saurin A.T., Escribano C., Parker P.J.; RT "mTORC2 targets AGC kinases through Sin1-dependent recruitment."; RL Biochem. J. 439:287-297(2011). RN [35] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [36] RP FUNCTION IN PHOSPHORYLATION OF EIF4G1. RX PubMed=21576361; DOI=10.1128/mcb.05589-11; RA Dobrikov M., Dobrikova E., Shveygert M., Gromeier M.; RT "Phosphorylation of eukaryotic translation initiation factor 4G1 (eIF4G1) RT by protein kinase C{alpha} regulates eIF4G1 binding to Mnk1."; RL Mol. Cell. Biol. 31:2947-2959(2011). RN [37] RP REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION. RX PubMed=12417014; DOI=10.1093/oxfordjournals.jbchem.a003272; RA Nakashima S.; RT "Protein kinase C alpha (PKC alpha): regulation and biological function."; RL J. Biochem. 132:669-675(2002). RN [38] RP REVIEW ON FUNCTION. RX PubMed=19969380; DOI=10.1016/j.tips.2009.10.006; RA Konopatskaya O., Poole A.W.; RT "Protein kinase Calpha: disease regulator and therapeutic target."; RL Trends Pharmacol. Sci. 31:8-14(2010). RN [39] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [40] RP FUNCTION IN CELL MIGRATION, AND SUBCELLULAR LOCATION. RX PubMed=23990668; DOI=10.1093/jnci/djt224; RA Evensen N.A., Kuscu C., Nguyen H.L., Zarrabi K., Dufour A., Kadam P., RA Hu Y.J., Pulkoski-Gross A., Bahou W.F., Zucker S., Cao J.; RT "Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in RT cancer cell migration."; RL J. Natl. Cancer Inst. 105:1402-1416(2013). RN [41] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10 AND SER-226, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226; THR-638 AND SER-657, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [43] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=25313067; DOI=10.1073/pnas.1418342111; RA Shibata S., Arroyo J.P., Castaneda-Bueno M., Puthumana J., Zhang J., RA Uchida S., Stone K.L., Lam T.T., Lifton R.P.; RT "Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, RT preventing WNK4 degradation."; RL Proc. Natl. Acad. Sci. U.S.A. 111:15556-15561(2014). RN [44] RP INTERACTION WITH PARD3. RX PubMed=27925688; DOI=10.1002/humu.23153; RA Chen X., An Y., Gao Y., Guo L., Rui L., Xie H., Sun M., Lam Hung S., RA Sheng X., Zou J., Bao Y., Guan H., Niu B., Li Z., Finnell R.H., RA Gusella J.F., Wu B.L., Zhang T.; RT "Rare deleterious PARD3 variants in the aPKC-binding region are implicated RT in the pathogenesis of human cranial neural tube defects via disrupting RT apical tight junction formation."; RL Hum. Mutat. 38:378-389(2017). RN [45] RP FUNCTION. RX PubMed=28028151; DOI=10.1084/jem.20160068; RA Xu X., Han L., Zhao G., Xue S., Gao Y., Xiao J., Zhang S., Chen P., RA Wu Z.Y., Ding J., Hu R., Wei B., Wang H.; RT "LRCH1 interferes with DOCK8-Cdc42-induced T cell migration and ameliorates RT experimental autoimmune encephalomyelitis."; RL J. Exp. Med. 214:209-226(2017). RN [46] RP FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION. RX PubMed=36040231; DOI=10.1042/bcj20220308; RA Malik A.U., Karapetsas A., Nirujogi R.S., Chatterjee D., Phung T.K., RA Wightman M., Gourlay R., Morrice N., Mathea S., Knapp S., Alessi D.R.; RT "PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues RT (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain."; RL Biochem. J. 479:1941-1965(2022). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 320-672 IN COMPLEX WITH RP INHIBITOR. RX PubMed=19827831; DOI=10.1021/jm901108b; RA Wagner J., von Matt P., Sedrani R., Albert R., Cooke N., Ehrhardt C., RA Geiser M., Rummel G., Stark W., Strauss A., Cowan-Jacob S.W., Beerli C., RA Weckbecker G., Evenou J.P., Zenke G., Cottens S.; RT "Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4- RT yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein RT kinase C isotypes."; RL J. Med. Chem. 52:6193-6196(2009). RN [48] RP STRUCTURE BY NMR OF 88-169. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of the second phorbol esters/diacylglycerol binding RT domain of human protein kinase C alpha type."; RL Submitted (APR-2008) to the PDB data bank. RN [49] RP VARIANTS [LARGE SCALE ANALYSIS] SER-98; ASN-467 AND VAL-489. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol (DAG)- CC dependent serine/threonine-protein kinase that is involved in positive CC and negative regulation of cell proliferation, apoptosis, CC differentiation, migration and adhesion, tumorigenesis, cardiac CC hypertrophy, angiogenesis, platelet function and inflammation, by CC directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, CC or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. CC Involved in cell proliferation and cell growth arrest by positive and CC negative regulation of the cell cycle. Can promote cell growth by CC phosphorylating and activating RAF1, which mediates the activation of CC the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which CC facilitates active cyclin-dependent kinase (CDK) complex formation in CC glioma cells. In intestinal cells stimulated by the phorbol ester PMA, CC can trigger a cell cycle arrest program which is associated with the CC accumulation of the hyper-phosphorylated growth-suppressive form of RB1 CC and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti- CC apoptotic function in glioma cells and protects them from apoptosis by CC suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia CC cells mediates anti-apoptotic action by phosphorylating BCL2. During CC macrophage differentiation induced by macrophage colony-stimulating CC factor (CSF1), is translocated to the nucleus and is associated with CC macrophage development. After wounding, translocates from focal CC contacts to lamellipodia and participates in the modulation of CC desmosomal adhesion. Plays a role in cell motility by phosphorylating CC CSPG4, which induces association of CSPG4 with extensive lamellipodia CC at the cell periphery and polarization of the cell accompanied by CC increases in cell motility. During chemokine-induced CD4(+) T cell CC migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting CC in its dissociation from LRCH1 and the activation of GTPase CDC42 CC (PubMed:28028151). Is highly expressed in a number of cancer cells CC where it can act as a tumor promoter and is implicated in malignant CC phenotypes of several tumors such as gliomas and breast cancers. CC Negatively regulates myocardial contractility and positively regulates CC angiogenesis, platelet aggregation and thrombus formation in arteries. CC Mediates hypertrophic growth of neonatal cardiomyocytes, in part CC through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA CC treatment, is required to induce cardiomyocyte hypertrophy up to heart CC failure and death, by increasing protein synthesis, protein-DNA ratio CC and cell surface area. Regulates cardiomyocyte function by CC phosphorylating cardiac troponin T (TNNT2/CTNT), which induces CC significant reduction in actomyosin ATPase activity, myofilament CC calcium sensitivity and myocardial contractility. In angiogenesis, is CC required for full endothelial cell migration, adhesion to vitronectin CC (VTN), and vascular endothelial growth factor A (VEGFA)-dependent CC regulation of kinase activation and vascular tube formation. Involved CC in the stabilization of VEGFA mRNA at post-transcriptional level and CC mediates VEGFA-induced cell proliferation. In the regulation of CC calcium-induced platelet aggregation, mediates signals from the CC CD36/GP4 receptor for granule release, and activates the integrin CC heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. CC During response to lipopolysaccharides (LPS), may regulate selective CC LPS-induced macrophage functions involved in host defense and CC inflammation. But in some inflammatory responses, may negatively CC regulate NF-kappa-B-induced genes, through IL1A-dependent induction of CC NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O- CC tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which CC modulates EIF4G1 binding to MKNK1 and may be involved in the regulation CC of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of CC KIT activity. Phosphorylates ATF2 which promotes cooperation between CC ATF2 and JUN, activating transcription. Phosphorylates SOCS2 at 'Ser- CC 52' facilitating its ubiquitination and proteasomal degradation (By CC similarity). Phosphorylates KLHL3 in response to angiotensin II CC signaling, decreasing the interaction between KLHL3 and WNK4 CC (PubMed:25313067). Phosphorylates and activates LRRK1, which CC phosphorylates RAB proteins involved in intracellular trafficking CC (PubMed:36040231). {ECO:0000250|UniProtKB:P20444, CC ECO:0000269|PubMed:10848585, ECO:0000269|PubMed:11909826, CC ECO:0000269|PubMed:12724315, ECO:0000269|PubMed:12832403, CC ECO:0000269|PubMed:15016832, ECO:0000269|PubMed:15504744, CC ECO:0000269|PubMed:15526160, ECO:0000269|PubMed:18056764, CC ECO:0000269|PubMed:19176525, ECO:0000269|PubMed:21576361, CC ECO:0000269|PubMed:21806543, ECO:0000269|PubMed:23990668, CC ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:28028151, CC ECO:0000269|PubMed:36040231, ECO:0000269|PubMed:9738012, CC ECO:0000269|PubMed:9830023, ECO:0000269|PubMed:9873035, CC ECO:0000269|PubMed:9927633}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:36040231}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:25313067, ECO:0000269|PubMed:36040231}; CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00041}; CC Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2 CC domain. {ECO:0000250|UniProtKB:P05696}; CC -!- ACTIVITY REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB and CC PRKCG) are activated by calcium and diacylglycerol (DAG) in the CC presence of phosphatidylserine. Three specific sites; Thr-497 CC (activation loop of the kinase domain), Thr-638 (turn motif) and Ser- CC 657 (hydrophobic region), need to be phosphorylated for its full CC activation. {ECO:0000269|PubMed:21806543}. CC -!- SUBUNIT: Recruited in a circadian manner into a nuclear complex which CC also includes BMAL1 and RACK1 (By similarity). Interacts with CC ADAP1/CENTA1 (PubMed:12893243). Interacts with CSPG4 (PubMed:15504744). CC Binds to CAVIN2 in the presence of phosphatidylserine (By similarity). CC Interacts with PRKCABP/PICK1 (via PDZ domain) (PubMed:15247289). CC Interacts with TRIM41 (PubMed:17893151). Interacts with PARD3 CC (PubMed:27925688). Interacts with SOCS2 (By similarity). CC {ECO:0000250|UniProtKB:P05696, ECO:0000250|UniProtKB:P20444, CC ECO:0000269|PubMed:12893243, ECO:0000269|PubMed:15247289, CC ECO:0000269|PubMed:15504744, ECO:0000269|PubMed:17893151, CC ECO:0000269|PubMed:27925688}. CC -!- INTERACTION: CC P17252; Q15027: ACAP1; NbExp=3; IntAct=EBI-1383528, EBI-751746; CC P17252; Q06481-5: APLP2; NbExp=3; IntAct=EBI-1383528, EBI-25646567; CC P17252; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-1383528, EBI-5280499; CC P17252; Q13072: BAGE; NbExp=3; IntAct=EBI-1383528, EBI-25884811; CC P17252; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-1383528, EBI-11524452; CC P17252; Q96A33: CCDC47; NbExp=3; IntAct=EBI-1383528, EBI-720151; CC P17252; Q96LY2-2: CCDC74B; NbExp=3; IntAct=EBI-1383528, EBI-17967022; CC P17252; P15169: CPN1; NbExp=3; IntAct=EBI-1383528, EBI-2116369; CC P17252; P43234: CTSO; NbExp=3; IntAct=EBI-1383528, EBI-2874283; CC P17252; O95424: DEXI; NbExp=3; IntAct=EBI-1383528, EBI-724515; CC P17252; P78352: DLG4; NbExp=2; IntAct=EBI-1383528, EBI-80389; CC P17252; O43598: DNPH1; NbExp=3; IntAct=EBI-1383528, EBI-748674; CC P17252; P21728: DRD1; NbExp=3; IntAct=EBI-1383528, EBI-6624459; CC P17252; P00533: EGFR; NbExp=3; IntAct=EBI-1383528, EBI-297353; CC P17252; P60228: EIF3E; NbExp=3; IntAct=EBI-1383528, EBI-347740; CC P17252; Q96J88-3: EPSTI1; NbExp=3; IntAct=EBI-1383528, EBI-25885343; CC P17252; Q8IVH2-2: FOXP4; NbExp=3; IntAct=EBI-1383528, EBI-25885364; CC P17252; Q96NE9-2: FRMD6; NbExp=3; IntAct=EBI-1383528, EBI-13213391; CC P17252; O14926: FSCN2; NbExp=3; IntAct=EBI-1383528, EBI-21017948; CC P17252; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-1383528, EBI-9088619; CC P17252; P19440-3: GGT1; NbExp=3; IntAct=EBI-1383528, EBI-21558069; CC P17252; Q9UJ42: GPR160; NbExp=3; IntAct=EBI-1383528, EBI-25885139; CC P17252; P62805: H4C9; NbExp=3; IntAct=EBI-1383528, EBI-302023; CC P17252; Q9UBN7: HDAC6; NbExp=2; IntAct=EBI-1383528, EBI-301697; CC P17252; P52597: HNRNPF; NbExp=3; IntAct=EBI-1383528, EBI-352986; CC P17252; Q92826: HOXB13; NbExp=3; IntAct=EBI-1383528, EBI-11317274; CC P17252; Q02363: ID2; NbExp=3; IntAct=EBI-1383528, EBI-713450; CC P17252; Q96FT9-2: IFT43; NbExp=3; IntAct=EBI-1383528, EBI-11944538; CC P17252; P17936: IGFBP3; NbExp=3; IntAct=EBI-1383528, EBI-715709; CC P17252; P26951: IL3RA; NbExp=3; IntAct=EBI-1383528, EBI-1757512; CC P17252; Q9BYR8: KRTAP3-1; NbExp=3; IntAct=EBI-1383528, EBI-9996449; CC P17252; Q9Y234: LIPT1; NbExp=4; IntAct=EBI-1383528, EBI-727376; CC P17252; P51884: LUM; NbExp=3; IntAct=EBI-1383528, EBI-725780; CC P17252; Q9H213: MAGEH1; NbExp=3; IntAct=EBI-1383528, EBI-473834; CC P17252; P80192: MAP3K9; NbExp=3; IntAct=EBI-1383528, EBI-3951604; CC P17252; Q15759: MAPK11; NbExp=3; IntAct=EBI-1383528, EBI-298304; CC P17252; A0JLT2-2: MED19; NbExp=3; IntAct=EBI-1383528, EBI-13288755; CC P17252; Q8N983-3: MRPL43; NbExp=3; IntAct=EBI-1383528, EBI-11109389; CC P17252; P49821: NDUFV1; NbExp=3; IntAct=EBI-1383528, EBI-748312; CC P17252; Q2M1J6: OXA1L; NbExp=3; IntAct=EBI-1383528, EBI-9978021; CC P17252; Q9BRX2: PELO; NbExp=3; IntAct=EBI-1383528, EBI-1043580; CC P17252; Q9Y6X2: PIAS3; NbExp=3; IntAct=EBI-1383528, EBI-2803703; CC P17252; P11309-2: PIM1; NbExp=2; IntAct=EBI-1383528, EBI-1018633; CC P17252; Q6P1J6-2: PLB1; NbExp=3; IntAct=EBI-1383528, EBI-10694821; CC P17252; Q9UNA4: POLI; NbExp=3; IntAct=EBI-1383528, EBI-741774; CC P17252; Q02156: PRKCE; NbExp=2; IntAct=EBI-1383528, EBI-706254; CC P17252; P05129: PRKCG; NbExp=6; IntAct=EBI-1383528, EBI-949799; CC P17252; P07225: PROS1; NbExp=3; IntAct=EBI-1383528, EBI-2803380; CC P17252; Q3YEC7-3: RABL6; NbExp=3; IntAct=EBI-1383528, EBI-25885259; CC P17252; O94844: RHOBTB1; NbExp=3; IntAct=EBI-1383528, EBI-6426999; CC P17252; Q9NWS8-3: RMND1; NbExp=3; IntAct=EBI-1383528, EBI-25884400; CC P17252; Q9ULK6-3: RNF150; NbExp=3; IntAct=EBI-1383528, EBI-36513929; CC P17252; P18077: RPL35A; NbExp=3; IntAct=EBI-1383528, EBI-353383; CC P17252; Q14160: SCRIB; NbExp=3; IntAct=EBI-1383528, EBI-357345; CC P17252; P31431: SDC4; NbExp=2; IntAct=EBI-1383528, EBI-3913237; CC P17252; Q99643: SDHC; NbExp=3; IntAct=EBI-1383528, EBI-1224539; CC P17252; Q14141: SEPTIN6; NbExp=3; IntAct=EBI-1383528, EBI-745901; CC P17252; Q01105-2: SET; NbExp=3; IntAct=EBI-1383528, EBI-7481343; CC P17252; P37840: SNCA; NbExp=3; IntAct=EBI-1383528, EBI-985879; CC P17252; Q9Y5X0: SNX10; NbExp=3; IntAct=EBI-1383528, EBI-10329478; CC P17252; P56693: SOX10; NbExp=3; IntAct=EBI-1383528, EBI-1167533; CC P17252; Q9BRW5: SP2; NbExp=3; IntAct=EBI-1383528, EBI-25868254; CC P17252; O43761: SYNGR3; NbExp=3; IntAct=EBI-1383528, EBI-11321949; CC P17252; P15884: TCF4; NbExp=3; IntAct=EBI-1383528, EBI-533224; CC P17252; Q3YBM2: TMEM176B; NbExp=3; IntAct=EBI-1383528, EBI-2821479; CC P17252; Q9H8H3: TMT1A; NbExp=3; IntAct=EBI-1383528, EBI-1390168; CC P17252; P0CG48: UBC; NbExp=2; IntAct=EBI-1383528, EBI-3390054; CC P17252; P13051-2: UNG; NbExp=3; IntAct=EBI-1383528, EBI-25834258; CC P17252; Q8NB14: USP38; NbExp=3; IntAct=EBI-1383528, EBI-2512509; CC P17252; O95498: VNN2; NbExp=3; IntAct=EBI-1383528, EBI-21494555; CC P17252; Q9NZC7-5: WWOX; NbExp=3; IntAct=EBI-1383528, EBI-12040603; CC P17252; Q9BQ24: ZFYVE21; NbExp=3; IntAct=EBI-1383528, EBI-2849569; CC P17252; Q05CR2: ZNF248; NbExp=3; IntAct=EBI-1383528, EBI-25835471; CC P17252; Q8N0Y2-2: ZNF444; NbExp=3; IntAct=EBI-1383528, EBI-12010736; CC P17252; O15535: ZSCAN9; NbExp=3; IntAct=EBI-1383528, EBI-751531; CC P17252; Q24008: inaD; Xeno; NbExp=2; IntAct=EBI-1383528, EBI-195326; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:23990668}. Cell CC membrane {ECO:0000269|PubMed:23990668, ECO:0000269|PubMed:36040231}; CC Peripheral membrane protein {ECO:0000305|PubMed:23990668, CC ECO:0000305|PubMed:36040231}. Mitochondrion membrane CC {ECO:0000269|PubMed:9738012}; Peripheral membrane protein CC {ECO:0000305|PubMed:9738012}. Nucleus {ECO:0000250|UniProtKB:P20444}. CC -!- PTM: In response to growth factors, phosphorylated at Thr-631 and Ser- CC 657 by the mTORC2 complex, promoting autophosphorylation and activation CC of PRKCA. {ECO:0000269|PubMed:21806543}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X52479; CAA36718.1; -; mRNA. DR EMBL; AB451258; BAG70072.1; -; mRNA. DR EMBL; AB451383; BAG70197.1; -; mRNA. DR EMBL; AC005918; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC005988; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC006263; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC006947; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC009452; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC060796; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471099; EAW89014.1; -; Genomic_DNA. DR EMBL; BC109273; AAI09274.1; -; mRNA. DR EMBL; BC109274; AAI09275.1; -; mRNA. DR EMBL; M22199; AAA60098.1; -; mRNA. DR EMBL; AF395829; AAK84184.1; -; Genomic_DNA. DR CCDS; CCDS11664.1; -. DR PIR; S09496; KIHUCA. DR RefSeq; NP_002728.2; NM_002737.3. DR PDB; 2ELI; NMR; -; A=93-169. DR PDB; 3IW4; X-ray; 2.80 A; A/B/C=320-672. DR PDB; 4DNL; X-ray; 1.90 A; A=155-293. DR PDB; 4RA4; X-ray; 2.63 A; A=318-672. DR PDB; 8U37; X-ray; 2.48 A; A=320-672. DR PDB; 8UAK; X-ray; 2.82 A; A=320-672. DR PDBsum; 2ELI; -. DR PDBsum; 3IW4; -. DR PDBsum; 4DNL; -. DR PDBsum; 4RA4; -. DR PDBsum; 8U37; -. DR PDBsum; 8UAK; -. DR AlphaFoldDB; P17252; -. DR BMRB; P17252; -. DR SMR; P17252; -. DR BioGRID; 111564; 342. DR CORUM; P17252; -. DR DIP; DIP-531N; -. DR FunCoup; P17252; 2547. DR IntAct; P17252; 209. DR MINT; P17252; -. DR STRING; 9606.ENSP00000408695; -. DR BindingDB; P17252; -. DR ChEMBL; CHEMBL299; -. DR DrugBank; DB12996; Acteoside. DR DrugBank; DB14001; alpha-Tocopherol succinate. DR DrugBank; DB06451; Aprinocarsen. DR DrugBank; DB09096; Benzoyl peroxide. DR DrugBank; DB11752; Bryostatin 1. DR DrugBank; DB12429; CI-1040. DR DrugBank; DB14002; D-alpha-Tocopherol acetate. DR DrugBank; DB04209; Dequalinium. DR DrugBank; DB08846; Ellagic acid. DR DrugBank; DB05013; Ingenol mebutate. DR DrugBank; DB06595; Midostaurin. DR DrugBank; DB06641; Perifosine. DR DrugBank; DB06819; Phenylbutyric acid. DR DrugBank; DB00144; Phosphatidyl serine. DR DrugBank; DB12369; Sotrastaurin. DR DrugBank; DB02010; Staurosporine. DR DrugBank; DB00675; Tamoxifen. DR DrugBank; DB04462; Tetrabromo-2-Benzotriazole. DR DrugBank; DB00163; Vitamin E. DR DrugCentral; P17252; -. DR GuidetoPHARMACOLOGY; 1482; -. DR GlyGen; P17252; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P17252; -. DR MetOSite; P17252; -. DR PhosphoSitePlus; P17252; -. DR SwissPalm; P17252; -. DR BioMuta; PRKCA; -. DR DMDM; 317373571; -. DR CPTAC; CPTAC-1615; -. DR CPTAC; CPTAC-3172; -. DR CPTAC; CPTAC-3173; -. DR jPOST; P17252; -. DR MassIVE; P17252; -. DR PaxDb; 9606-ENSP00000408695; -. DR PeptideAtlas; P17252; -. DR ProteomicsDB; 53464; -. DR Pumba; P17252; -. DR Antibodypedia; 1464; 1251 antibodies from 49 providers. DR DNASU; 5578; -. DR Ensembl; ENST00000413366.8; ENSP00000408695.3; ENSG00000154229.13. DR GeneID; 5578; -. DR KEGG; hsa:5578; -. DR MANE-Select; ENST00000413366.8; ENSP00000408695.3; NM_002737.3; NP_002728.2. DR UCSC; uc002jfp.2; human. DR AGR; HGNC:9393; -. DR ClinPGx; PA33759; -. DR CTD; 5578; -. DR DisGeNET; 5578; -. DR GeneCards; PRKCA; -. DR HGNC; HGNC:9393; PRKCA. DR HPA; ENSG00000154229; Tissue enhanced (brain). DR MalaCards; PRKCA; -. DR MIM; 176960; gene. DR OpenTargets; ENSG00000154229; -. DR VEuPathDB; HostDB:ENSG00000154229; -. DR eggNOG; KOG0696; Eukaryota. DR GeneTree; ENSGT00940000156104; -. DR HOGENOM; CLU_000288_54_2_1; -. DR InParanoid; P17252; -. DR OMA; VHEIKSH; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; P17252; 3 GO annotations based on evolutionary models. DR PhylomeDB; P17252; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; P17252; -. DR Reactome; R-HSA-111933; Calmodulin induced events. DR Reactome; R-HSA-114516; Disinhibition of SNARE formation. DR Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. DR Reactome; R-HSA-1433557; Signaling by SCF-KIT. DR Reactome; R-HSA-1433559; Regulation of KIT signaling. DR Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin. DR Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade. DR Reactome; R-HSA-3000170; Syndecan interactions. DR Reactome; R-HSA-399997; Acetylcholine regulates insulin secretion. DR Reactome; R-HSA-4086398; Ca2+ pathway. DR Reactome; R-HSA-416993; Trafficking of GluR2-containing AMPA receptors. DR Reactome; R-HSA-418597; G alpha (z) signalling events. DR Reactome; R-HSA-4419969; Depolymerization of the Nuclear Lamina. DR Reactome; R-HSA-450520; HuR (ELAVL1) binds and stabilizes mRNA. DR Reactome; R-HSA-5099900; WNT5A-dependent internalization of FZD4. DR Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. DR Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases. DR Reactome; R-HSA-76005; Response to elevated platelet cytosolic Ca2+. DR Reactome; R-HSA-8853659; RET signaling. DR Reactome; R-HSA-9010642; ROBO receptors bind AKAP5. DR SABIO-RK; P17252; -. DR SignaLink; P17252; -. DR SIGNOR; P17252; -. DR Agora; ENSG00000154229; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5578; 13 hits in 1191 CRISPR screens. DR CD-CODE; DEE660B4; Stress granule. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; PRKCA; human. DR EvolutionaryTrace; P17252; -. DR GeneWiki; PKC_alpha; -. DR GenomeRNAi; 5578; -. DR Pharos; P17252; Tchem. DR PRO; PR:P17252; -. DR Proteomes; UP000005640; Chromosome 17. DR RNAct; P17252; protein. DR Bgee; ENSG00000154229; Expressed in CA1 field of hippocampus and 192 other cell types or tissues. DR ExpressionAtlas; P17252; baseline and differential. DR GO; GO:0035866; C:alphav-beta3 integrin-PKCalpha complex; ISS:BHF-UCL. DR GO; GO:0036064; C:ciliary basal body; IDA:UniProt. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0005783; C:endoplasmic reticulum; IDA:BHF-UCL. DR GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB. DR GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell. DR GO; GO:0005739; C:mitochondrion; HDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004698; F:calcium,diacylglycerol-dependent serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0019992; F:diacylglycerol binding; TAS:Reactome. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL. DR GO; GO:0035403; F:histone H3T6 kinase activity; IDA:UniProtKB. DR GO; GO:0005178; F:integrin binding; ISS:BHF-UCL. DR GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central. DR GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW. DR GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW. DR GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc. DR GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW. DR GO; GO:0021955; P:central nervous system neuron axonogenesis; IEA:Ensembl. DR GO; GO:0002159; P:desmosome assembly; IMP:BHF-UCL. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0007611; P:learning or memory; IEA:Ensembl. DR GO; GO:0007077; P:mitotic nuclear membrane disassembly; TAS:Reactome. DR GO; GO:1900016; P:negative regulation of cytokine production involved in inflammatory response; IEA:Ensembl. DR GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB. DR GO; GO:0017148; P:negative regulation of translation; IEA:Ensembl. DR GO; GO:0106071; P:positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway; ISS:BHF-UCL. DR GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB. DR GO; GO:0110063; P:positive regulation of angiotensin-activated signaling pathway; IDA:UniProt. DR GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT. DR GO; GO:0045780; P:positive regulation of bone resorption; ISS:BHF-UCL. DR GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISS:UniProtKB. DR GO; GO:0045785; P:positive regulation of cell adhesion; IMP:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB. DR GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IEA:Ensembl. DR GO; GO:2000707; P:positive regulation of dense core granule biogenesis; ISS:UniProtKB. DR GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB. DR GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB. DR GO; GO:0045921; P:positive regulation of exocytosis; IEA:Ensembl. DR GO; GO:0032024; P:positive regulation of insulin secretion; TAS:Reactome. DR GO; GO:0031666; P:positive regulation of lipopolysaccharide-mediated signaling pathway; IMP:UniProtKB. DR GO; GO:0045651; P:positive regulation of macrophage differentiation; ISS:UniProtKB. DR GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IEA:Ensembl. DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl. DR GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0070528; P:protein kinase C signaling; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome. DR GO; GO:0090330; P:regulation of platelet aggregation; IDA:UniProtKB. DR GO; GO:0051412; P:response to corticosterone; IEA:Ensembl. DR GO; GO:0032355; P:response to estradiol; IEA:Ensembl. DR GO; GO:0045471; P:response to ethanol; IEA:Ensembl. DR GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL. DR GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl. DR GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl. DR GO; GO:1904627; P:response to phorbol 13-acetate 12-myristate; IEA:Ensembl. DR GO; GO:0000302; P:response to reactive oxygen species; IEA:Ensembl. DR GO; GO:0009636; P:response to toxic substance; IEA:Ensembl. DR CDD; cd20833; C1_cPKC_rpt1; 1. DR CDD; cd20836; C1_cPKC_rpt2; 1. DR CDD; cd04026; C2_PKC_alpha_gamma; 1. DR CDD; cd05615; STKc_cPKC_alpha; 1. DR FunFam; 2.60.40.150:FF:000012; Kinase C alpha type; 1. DR FunFam; 1.10.510.10:FF:000023; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000080; Protein kinase C; 1. DR FunFam; 3.30.200.20:FF:000103; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000006; Protein kinase C; 1. DR FunFam; 3.30.60.20:FF:000031; Protein kinase C alpha; 1. DR Gene3D; 3.30.60.20; -; 2. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR046349; C1-like_sf. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR034663; cPKC_alpha. DR InterPro; IPR020454; DAG/PE-bd. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR002219; PKC_DAG/PE. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR014375; Protein_kinase_C_a/b/g. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF00130; C1_1; 2. DR Pfam; PF00168; C2; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR PIRSF; PIRSF000550; PKC_alpha; 1. DR PRINTS; PR00360; C2DOMAIN. DR PRINTS; PR00008; DAGPEDOMAIN. DR SMART; SM00109; C1; 2. DR SMART; SM00239; C2; 1. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF57889; Cysteine-rich domain; 2. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS00479; ZF_DAG_PE_1; 2. DR PROSITE; PS50081; ZF_DAG_PE_2; 2. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Angiogenesis; Apoptosis; ATP-binding; Calcium; KW Cell adhesion; Cell membrane; Cytoplasm; Direct protein sequencing; Kinase; KW Membrane; Metal-binding; Mitochondrion; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Proto-oncogene; KW Reference proteome; Repeat; Serine/threonine-protein kinase; Transferase; KW Zinc; Zinc-finger. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000269|PubMed:12665801, FT ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22814378" FT CHAIN 2..672 FT /note="Protein kinase C alpha type" FT /id="PRO_0000055679" FT DOMAIN 158..275 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 339..597 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 598..668 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT ZN_FING 36..86 FT /note="Phorbol-ester/DAG-type 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ZN_FING 101..151 FT /note="Phorbol-ester/DAG-type 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00226" FT ACT_SITE 463 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 186 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 187 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 187 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 193 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 195 FT /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- FT inositol-4,5-bisphosphate)" FT /ligand_id="ChEBI:CHEBI:58456" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 245 FT /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- FT inositol-4,5-bisphosphate)" FT /ligand_id="ChEBI:CHEBI:58456" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 246 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 246 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 247 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 248 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 252 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 254 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 254 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000250|UniProtKB:P05696" FT BINDING 345..353 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 368 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:21806543" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT MOD_RES 10 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 226 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231, FT ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569" FT MOD_RES 319 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P05696" FT MOD_RES 494 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P04409" FT MOD_RES 495 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P04409" FT MOD_RES 497 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000250|UniProtKB:P04409, ECO:0000305" FT MOD_RES 501 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P05771" FT MOD_RES 628 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 631 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:P20444" FT MOD_RES 638 FT /note="Phosphothreonine; by autocatalysis" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569" FT MOD_RES 651 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976" FT MOD_RES 657 FT /note="Phosphoserine; by MTOR" FT /evidence="ECO:0000269|PubMed:21806543, FT ECO:0007744|PubMed:24275569" FT MOD_RES 658 FT /note="Phosphotyrosine; by SYK" FT /evidence="ECO:0000250|UniProtKB:P20444" FT VARIANT 98 FT /note="P -> S (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042301" FT VARIANT 467 FT /note="D -> N (in a glioblastoma multiforme sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042302" FT VARIANT 489 FT /note="M -> V (in dbSNP:rs34406842)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042303" FT VARIANT 568 FT /note="V -> I (in dbSNP:rs6504459)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:19054851, ECO:0000269|PubMed:2336401, FT ECO:0000269|Ref.4" FT /id="VAR_050558" FT MUTAGEN 368 FT /note="K->M: Abolished protein kinase activity." FT /evidence="ECO:0000269|PubMed:21806543" FT CONFLICT 50 FT /note="C -> S (in Ref. 6; AAA60098)" FT /evidence="ECO:0000305" FT TURN 98..100 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 105..107 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 116..118 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 125..127 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 129..131 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 133..135 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 138..140 FT /evidence="ECO:0007829|PDB:2ELI" FT TURN 141..146 FT /evidence="ECO:0007829|PDB:2ELI" FT STRAND 161..169 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 172..182 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 194..202 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 222..230 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 233..237 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 239..246 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 249..251 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 254..262 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 263..268 FT /evidence="ECO:0007829|PDB:4DNL" FT STRAND 271..276 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 282..284 FT /evidence="ECO:0007829|PDB:4DNL" FT HELIX 336..338 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 339..348 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 351..358 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 364..371 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 372..378 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 381..392 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 403..408 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 410..418 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 422..424 FT /evidence="ECO:0007829|PDB:3IW4" FT HELIX 425..430 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 437..456 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 466..468 FT /evidence="ECO:0007829|PDB:4RA4" FT STRAND 469..471 FT /evidence="ECO:0007829|PDB:8U37" FT STRAND 477..479 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 502..504 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 507..510 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 518..533 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 543..552 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 563..572 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 577..579 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 587..592 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 595..597 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 602..606 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 642..645 FT /evidence="ECO:0007829|PDB:8U37" FT HELIX 650..653 FT /evidence="ECO:0007829|PDB:8U37" SQ SEQUENCE 672 AA; 76750 MW; 9EB157789A062349 CRC64; MADVFPGNDS TASQDVANRF ARKGALRQKN VHEVKDHKFI ARFFKQPTFC SHCTDFIWGF GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPDTDDPRS KHKFKIHTYG SPTFCDHCGS LLYGLIHQGM KCDTCDMNVH KQCVINVPSL CGMDHTEKRG RIYLKAEVAD EKLHVTVRDA KNLIPMDPNG LSDPYVKLKL IPDPKNESKQ KTKTIRSTLN PQWNESFTFK LKPSDKDRRL SVEIWDWDRT TRNDFMGSLS FGVSELMKMP ASGWYKLLNQ EEGEYYNVPI PEGDEEGNME LRQKFEKAKL GPAGNKVISP SEDRKQPSNN LDRVKLTDFN FLMVLGKGSF GKVMLADRKG TEELYAIKIL KKDVVIQDDD VECTMVEKRV LALLDKPPFL TQLHSCFQTV DRLYFVMEYV NGGDLMYHIQ QVGKFKEPQA VFYAAEISIG LFFLHKRGII YRDLKLDNVM LDSEGHIKIA DFGMCKEHMM DGVTTRTFCG TPDYIAPEII AYQPYGKSVD WWAYGVLLYE MLAGQPPFDG EDEDELFQSI MEHNVSYPKS LSKEAVSVCK GLMTKHPAKR LGCGPEGERD VREHAFFRRI DWEKLENREI QPPFKPKVCG KGAENFDKFF TRGQPVLTPP DQLVIANIDQ SDFEGFSYVN PQFVHPILQS AV // ID MK09_HUMAN Reviewed; 424 AA. AC P45984; A8K0S3; B5BU66; B5M0B4; D3DWQ8; D3DWQ9; Q15708; Q15710; Q15711; AC Q8N5C5; DT 01-NOV-1995, integrated into UniProtKB/Swiss-Prot. DT 24-JAN-2006, sequence version 2. DT 28-JAN-2026, entry version 240. DE RecName: Full=Mitogen-activated protein kinase 9; DE Short=MAP kinase 9; DE Short=MAPK 9; DE EC=2.7.11.24 {ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:15805466, ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:21110917, ECO:0000269|PubMed:7969172, ECO:0000269|PubMed:8001819, ECO:0000269|PubMed:8654373}; DE AltName: Full=JNK-55; DE AltName: Full=Stress-activated protein kinase 1a; DE Short=SAPK1a; DE AltName: Full=Stress-activated protein kinase JNK2; DE AltName: Full=c-Jun N-terminal kinase 2; GN Name=MAPK9; Synonyms=JNK2, PRKM9, SAPK1A; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY. RX PubMed=7969172; DOI=10.1128/mcb.14.12.8376-8384.1994; RA Sluss H.K., Barrett T., Derijard B., Davis R.J.; RT "Signal transduction by tumor necrosis factor mediated by JNK protein RT kinases."; RL Mol. Cell. Biol. 14:8376-8384(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY. RX PubMed=8001819; DOI=10.1101/gad.8.24.2996; RA Kallunki T., Su B., Tsigelny I., Sluss H.K., Derijard B., Moore G., RA Davis R., Karin M.; RT "JNK2 contains a specificity-determining region responsible for efficient RT c-Jun binding and phosphorylation."; RL Genes Dev. 8:2996-3007(1994). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA], ALTERNATIVE SPLICING, AND CATALYTIC ACTIVITY. RC TISSUE=Brain; RX PubMed=8654373; DOI=10.1002/j.1460-2075.1996.tb00636.x; RA Gupta S., Barrett T., Whitmarsh A.J., Cavanagh J., Sluss H.K., Derijard B., RA Davis R.J.; RT "Selective interaction of JNK protein kinase isoforms with transcription RT factors."; RL EMBO J. 15:2760-2770(1996). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND CATALYTIC ACTIVITY. RX PubMed=21110917; DOI=10.5483/bmbrep.2010.43.11.738; RA Wang P., Xiong Y., Ma C., Shi T., Ma D.; RT "Molecular cloning and characterization of novel human JNK2 (MAPK9) RT transcript variants that show different stimulation activities on AP-1."; RL BMB Rep. 43:738-743(2010). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RA Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P., RA Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y., RA LaBaer J.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA-2). RC TISSUE=Amygdala; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-268. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-2). RX PubMed=19054851; DOI=10.1038/nmeth.1273; RA Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R., RA Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y., RA Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B., RA Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y., RA Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A., RA Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y., RA Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T., RA Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y., RA Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S., RA Nomura N.; RT "Human protein factory for converting the transcriptome into an in vitro- RT expressed proteome."; RL Nat. Methods 5:1011-1017(2008). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15372022; DOI=10.1038/nature02919; RA Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., RA Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., RA She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., RA Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., RA Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., RA Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., RA Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., RA Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., RA Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., RA Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., RA Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., RA Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., RA Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.; RT "The DNA sequence and comparative analysis of human chromosome 5."; RL Nature 431:268-274(2004). RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Skin; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [12] RP INTERACTION WITH ATF7, AND FUNCTION. RX PubMed=10376527; DOI=10.1038/sj.onc.1202723; RA De Graeve F., Bahr A., Sabapathy K.T., Hauss C., Wagner E.F., Kedinger C., RA Chatton B.; RT "Role of the ATFa/JNK2 complex in Jun activation."; RL Oncogene 18:3491-3500(1999). RN [13] RP PHOSPHORYLATION AT THR-183 AND TYR-185, REGULATION BY MAP2K4 AND MAP2K7, RP CATALYTIC ACTIVITY, AND COFACTOR. RX PubMed=11062067; DOI=10.1042/bj3520145; RA Fleming Y., Armstrong C.G., Morrice N., Paterson A., Goedert M., Cohen P.; RT "Synergistic activation of stress-activated protein kinase 1/c-Jun N- RT terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase RT kinase 4 (MKK4) and MKK7."; RL Biochem. J. 352:145-154(2000). RN [14] RP INTERACTION WITH SPAG9. RX PubMed=15693750; DOI=10.1042/bj20041577; RA Jagadish N., Rana R., Selvi R., Mishra D., Garg M., Yadav S., Herr J.C., RA Okumura K., Hasegawa A., Koyama K., Suri A.; RT "Characterization of a novel human sperm-associated antigen 9 (SPAG9) RT having structural homology with c-Jun N-terminal kinase-interacting RT protein."; RL Biochem. J. 389:73-82(2005). RN [15] RP FUNCTION IN PHOSPHORYLATION OF RRN3, AND CATALYTIC ACTIVITY. RX PubMed=15805466; DOI=10.1101/gad.333205; RA Mayer C., Bierhoff H., Grummt I.; RT "The nucleolus as a stress sensor: JNK2 inactivates the transcription RT factor TIF-IA and down-regulates rRNA synthesis."; RL Genes Dev. 19:933-941(2005). RN [16] RP INTERACTION WITH NFATC4, AND CATALYTIC ACTIVITY. RX PubMed=17875713; DOI=10.1158/0008-5472.can-06-4788; RA Yao K., Cho Y.-Y., Bergen H.R. III, Madden B.J., Choi B.Y., Ma W.-Y., RA Bode A.M., Dong Z.; RT "Nuclear factor of activated T3 is a negative regulator of Ras-JNK1/2-AP-1 RT induced cell transformation."; RL Cancer Res. 67:8725-8735(2007). RN [17] RP INTERACTION WITH BCL10, AND CATALYTIC ACTIVITY. RX PubMed=17189706; DOI=10.1016/j.immuni.2006.11.008; RA Blonska M., Pappu B.P., Matsumoto R., Li H., Su B., Wang D., Lin X.; RT "The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in RT the T cell receptor-signaling pathway."; RL Immunity 26:55-66(2007). RN [18] RP FUNCTION IN PHOSPHORYLATION OF TP53, AND CATALYTIC ACTIVITY. RX PubMed=17525747; DOI=10.1038/sj.onc.1210526; RA Oleinik N.V., Krupenko N.I., Krupenko S.A.; RT "Cooperation between JNK1 and JNK2 in activation of p53 apoptotic RT pathway."; RL Oncogene 26:7222-7230(2007). RN [19] RP REVIEW ON FUNCTION. RX PubMed=19290929; DOI=10.1111/j.1600-065x.2008.00749.x; RA Blonska M., Lin X.; RT "CARMA1-mediated NF-kappaB and JNK activation in lymphocytes."; RL Immunol. Rev. 228:199-211(2009). RN [20] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [21] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CTNNB1. RX PubMed=19675674; DOI=10.1371/journal.pone.0006640; RA Hu D., Bi X., Fang W., Han A., Yang W.; RT "GSK3beta is involved in JNK2-mediated beta-catenin inhibition."; RL PLoS ONE 4:E6640-E6640(2009). RN [22] RP FUNCTION. RX PubMed=20595622; DOI=10.1152/ajpgi.00265.2010; RA Samak G., Suzuki T., Bhargava A., Rao R.K.; RT "c-Jun NH2-terminal kinase-2 mediates osmotic stress-induced tight junction RT disruption in the intestinal epithelium."; RL Am. J. Physiol. 299:G572-G584(2010). RN [23] RP FUNCTION IN PHOSPHORYLATION OF YAP1, AND CATALYTIC ACTIVITY. RX PubMed=21364637; DOI=10.1038/cddis.2010.7; RA Tomlinson V., Gudmundsdottir K., Luong P., Leung K.Y., Knebel A., Basu S.; RT "JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis."; RL Cell Death Dis. 1:E29-E29(2010). RN [24] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [25] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=22441692; DOI=10.1038/embor.2012.37; RA Yoshitane H., Honma S., Imamura K., Nakajima H., Nishide S.Y., Ono D., RA Kiyota H., Shinozaki N., Matsuki H., Wada N., Doi H., Hamada T., Honma K., RA Fukada Y.; RT "JNK regulates the photic response of the mammalian circadian clock."; RL EMBO Rep. 13:455-461(2012). RN [26] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=34048572; DOI=10.1093/nar/gkab415; RA Yu F., Wei J., Cui X., Yu C., Ni W., Bungert J., Wu L., He C., Qian Z.; RT "Post-translational modification of RNA m6A demethylase ALKBH5 regulates RT ROS-induced DNA damage response."; RL Nucleic Acids Res. 49:5779-5797(2021). RN [27] RP X-RAY CRYSTALLOGRAPHY (2.14 ANGSTROMS) OF 7-362. RX PubMed=18801372; DOI=10.1016/j.jmb.2008.08.086; RA Shaw D., Wang S.M., Villasenor A.G., Tsing S., Walter D., Browner M.F., RA Barnett J., Kuglstatter A.; RT "The crystal structure of JNK2 reveals conformational flexibility in the RT MAP kinase insert and indicates its involvement in the regulation of RT catalytic activity."; RL J. Mol. Biol. 383:885-893(2008). RN [28] RP VARIANTS [LARGE SCALE ANALYSIS] MET-13; ASN-56; THR-246 AND ILE-366. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [29] RP INTERACTION WITH MAPKBP1. RX PubMed=28089251; DOI=10.1016/j.ajhg.2016.12.011; RA Macia M.S., Halbritter J., Delous M., Bredrup C., Gutter A., Filhol E., RA Mellgren A.E., Leh S., Bizet A., Braun D.A., Gee H.Y., Silbermann F., RA Henry C., Krug P., Bole-Feysot C., Nitschke P., Joly D., Nicoud P., RA Paget A., Haugland H., Brackmann D., Ahmet N., Sandford R., Cengiz N., RA Knappskog P.M., Boman H., Linghu B., Yang F., Oakeley E.J., RA Saint Mezard P., Sailer A.W., Johansson S., Roedahl E., Saunier S., RA Hildebrandt F., Benmerah A.; RT "Mutations in MAPKBP1 cause juvenile or late-onset cilia-independent RT nephronophthisis."; RL Am. J. Hum. Genet. 100:323-333(2017). RN [30] RP ERRATUM OF PUBMED:28089251. RX PubMed=28157543; DOI=10.1016/j.ajhg.2017.01.025; RA Macia M.S., Halbritter J., Delous M., Bredrup C., Gutter A., Filhol E., RA Mellgren A.E., Leh S., Bizet A., Braun D.A., Gee H.Y., Silbermann F., RA Henry C., Krug P., Bole-Feysot C., Nitschke P., Joly D., Nicoud P., RA Paget A., Haugland H., Brackmann D., Ahmet N., Sandford R., Cengiz N., RA Knappskog P.M., Boman H., Linghu B., Yang F., Oakeley E.J., RA Saint Mezard P., Sailer A.W., Johansson S., Roedahl E., Saunier S., RA Hildebrandt F., Benmerah A.; RL Am. J. Hum. Genet. 100:372-372(2017). CC -!- FUNCTION: Serine/threonine-protein kinase involved in various processes CC such as cell proliferation, differentiation, migration, transformation CC and programmed cell death (PubMed:10376527, PubMed:15805466, CC PubMed:17525747, PubMed:19675674, PubMed:20595622, PubMed:21364637, CC PubMed:22441692, PubMed:34048572). Extracellular stimuli such as pro- CC inflammatory cytokines or physical stress stimulate the stress- CC activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling CC pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and CC MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2 (PubMed:10376527, CC PubMed:15805466, PubMed:17525747, PubMed:19675674, PubMed:20595622, CC PubMed:21364637, PubMed:22441692, PubMed:34048572). In turn, MAPK9/JNK2 CC phosphorylates a number of transcription factors, primarily components CC of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional CC activity (PubMed:10376527). In response to oxidative or ribotoxic CC stresses, inhibits rRNA synthesis by phosphorylating and inactivating CC the RNA polymerase 1-specific transcription initiation factor RRN3 CC (PubMed:15805466). Promotes stressed cell apoptosis by phosphorylating CC key regulatory factors including TP53 and YAP1 (PubMed:17525747, CC PubMed:21364637). In T-cells, MAPK8 and MAPK9 are required for CC polarized differentiation of T-helper cells into Th1 cells CC (PubMed:19290929). Upon T-cell receptor (TCR) stimulation, is activated CC by CARMA1, BCL10, MAP2K7 and MAP3K7/TAK1 to regulate JUN protein levels CC (PubMed:19290929). Plays an important role in the osmotic stress- CC induced epithelial tight-junctions disruption (PubMed:20595622). When CC activated, promotes beta-catenin/CTNNB1 degradation and inhibits the CC canonical Wnt signaling pathway (PubMed:19675674). Also participates in CC neurite growth in spiral ganglion neurons (By similarity). CC Phosphorylates the CLOCK-BMAL1 heterodimer and plays a role in the CC regulation of the circadian clock (PubMed:22441692). Phosphorylates CC POU5F1, which results in the inhibition of POU5F1's transcriptional CC activity and enhances its proteasomal degradation (By similarity). CC Phosphorylates ALKBH5 in response to reactive oxygen species (ROS), CC promoting ALKBH5 sumoylation and inactivation (PubMed:34048572). CC {ECO:0000250|UniProtKB:Q9WTU6, ECO:0000269|PubMed:10376527, CC ECO:0000269|PubMed:15805466, ECO:0000269|PubMed:17525747, CC ECO:0000269|PubMed:19675674, ECO:0000269|PubMed:20595622, CC ECO:0000269|PubMed:21364637, ECO:0000269|PubMed:22441692, CC ECO:0000269|PubMed:34048572, ECO:0000303|PubMed:19290929}. CC -!- FUNCTION: MAPK9 isoforms display different binding patterns: alpha-1 CC and alpha-2 preferentially bind to JUN, whereas beta-1 and beta-2 bind CC to ATF2. However, there is no correlation between binding and CC phosphorylation, which is achieved at about the same efficiency by all CC isoforms. JUNB is not a substrate for JNK2 alpha-2, and JUND binds only CC weakly to it. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24; CC Evidence={ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:15805466, CC ECO:0000269|PubMed:17189706, ECO:0000269|PubMed:17525747, CC ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:21110917, CC ECO:0000269|PubMed:21364637, ECO:0000269|PubMed:22441692, CC ECO:0000269|PubMed:34048572, ECO:0000269|PubMed:7969172, CC ECO:0000269|PubMed:8001819, ECO:0000269|PubMed:8654373}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.24; CC Evidence={ECO:0000269|PubMed:11062067, ECO:0000269|PubMed:15805466, CC ECO:0000269|PubMed:17189706, ECO:0000269|PubMed:17525747, CC ECO:0000269|PubMed:17875713, ECO:0000269|PubMed:21110917, CC ECO:0000269|PubMed:21364637, ECO:0000269|PubMed:22441692, CC ECO:0000269|PubMed:7969172, ECO:0000269|PubMed:8001819, CC ECO:0000269|PubMed:8654373}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000269|PubMed:11062067}; CC -!- ACTIVITY REGULATION: Activated by threonine and tyrosine CC phosphorylation by either of two dual specificity kinases, MAP2K4 and CC MAP2K7. MAP2K4 shows a strong preference for Tyr-185 while MAP2K7 CC phosphorylates Tyr-183 preferentially. Inhibited by dual specificity CC phosphatases, such as DUSP1. {ECO:0000269|PubMed:11062067}. CC -!- SUBUNIT: Interacts with MECOM (By similarity). Interacts with DCLK2 (By CC similarity). Binds to at least four scaffolding proteins, MAPK8IP1/JIP- CC 1, MAPK8IP2/JIP-2, MAPK8IP3/JIP-3/JSAP1 and SPAG9/MAPK8IP4/JIP-4. These CC proteins also bind other components of the JNK signaling pathway (By CC similarity). Interacts with NFATC4 (PubMed:17875713). Interacts with CC ATF7; the interaction does not phosphorylate ATF7 but acts as a docking CC site for ATF7-associated partners such as JUN (PubMed:10376527). CC Interacts with BCL10 (PubMed:17189706). Interacts with CTNNB1 and GSK3B CC (PubMed:19675674). Interacts with MAPKBP1 (PubMed:28089251). Interacts CC with POU5F1; phosphorylates POU5F1 at 'Ser-355'. Found in a complex CC with SH3RF1, RAC2, MAP3K7/TAK1, MAP2K7/MKK7, MAPK8IP1/JIP1 and CC MAPK8/JNK1 (By similarity). {ECO:0000250|UniProtKB:P49186, CC ECO:0000250|UniProtKB:Q9WTU6, ECO:0000269|PubMed:10376527, CC ECO:0000269|PubMed:17189706, ECO:0000269|PubMed:17875713, CC ECO:0000269|PubMed:19675674, ECO:0000269|PubMed:28089251}. CC -!- INTERACTION: CC P45984; P49407: ARRB1; NbExp=9; IntAct=EBI-713568, EBI-743313; CC P45984; P32121: ARRB2; NbExp=9; IntAct=EBI-713568, EBI-714559; CC P45984; P15336: ATF2; NbExp=9; IntAct=EBI-713568, EBI-1170906; CC P45984; P0C671: BNIP5; NbExp=4; IntAct=EBI-713568, EBI-12806802; CC P45984; O95561: C1orf105; NbExp=5; IntAct=EBI-713568, EBI-10191951; CC P45984; Q6P1W5: C1orf94; NbExp=3; IntAct=EBI-713568, EBI-946029; CC P45984; Q8N7E2: CBLL2; NbExp=3; IntAct=EBI-713568, EBI-12196065; CC P45984; Q13042: CDC16; NbExp=3; IntAct=EBI-713568, EBI-994830; CC P45984; Q9C0F1: CEP44; NbExp=9; IntAct=EBI-713568, EBI-744115; CC P45984; Q13363-2: CTBP1; NbExp=3; IntAct=EBI-713568, EBI-10171858; CC P45984; O43602-2: DCX; NbExp=3; IntAct=EBI-713568, EBI-14148644; CC P45984; Q8N9I9: DTX3; NbExp=3; IntAct=EBI-713568, EBI-2340258; CC P45984; Q9Y6W6: DUSP10; NbExp=5; IntAct=EBI-713568, EBI-3443946; CC P45984; Q9BY84: DUSP16; NbExp=8; IntAct=EBI-713568, EBI-3443956; CC P45984; Q13115: DUSP4; NbExp=4; IntAct=EBI-713568, EBI-6591081; CC P45984; Q5JST6: EFHC2; NbExp=7; IntAct=EBI-713568, EBI-2349927; CC P45984; Q9H0I2: ENKD1; NbExp=3; IntAct=EBI-713568, EBI-744099; CC P45984; P14136: GFAP; NbExp=3; IntAct=EBI-713568, EBI-744302; CC P45984; Q9NYA3: GOLGA6A; NbExp=3; IntAct=EBI-713568, EBI-11163335; CC P45984; O15499: GSC2; NbExp=3; IntAct=EBI-713568, EBI-19954058; CC P45984; Q8IYA8: IHO1; NbExp=3; IntAct=EBI-713568, EBI-8638439; CC P45984; Q13352: ITGB3BP; NbExp=3; IntAct=EBI-713568, EBI-712105; CC P45984; Q9P2G9-2: KLHL8; NbExp=3; IntAct=EBI-713568, EBI-11959635; CC P45984; O00505: KPNA3; NbExp=3; IntAct=EBI-713568, EBI-358297; CC P45984; Q96JM7: L3MBTL3; NbExp=3; IntAct=EBI-713568, EBI-2686809; CC P45984; Q96JM7-2: L3MBTL3; NbExp=3; IntAct=EBI-713568, EBI-11985629; CC P45984; Q9UBR4-2: LHX3; NbExp=3; IntAct=EBI-713568, EBI-12039345; CC P45984; Q8TBB1: LNX1; NbExp=7; IntAct=EBI-713568, EBI-739832; CC P45984; Q8N448: LNX2; NbExp=3; IntAct=EBI-713568, EBI-2340947; CC P45984; Q9Y250: LZTS1; NbExp=3; IntAct=EBI-713568, EBI-1216080; CC P45984; P45985: MAP2K4; NbExp=3; IntAct=EBI-713568, EBI-447868; CC P45984; P45983: MAPK8; NbExp=5; IntAct=EBI-713568, EBI-286483; CC P45984; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-713568, EBI-348259; CC P45984; Q86YW9: MED12L; NbExp=3; IntAct=EBI-713568, EBI-3957138; CC P45984; P50221: MEOX1; NbExp=7; IntAct=EBI-713568, EBI-2864512; CC P45984; Q5VWP3-2: MLIP; NbExp=5; IntAct=EBI-713568, EBI-12320785; CC P45984; Q5HYW2: NHSL2; NbExp=5; IntAct=EBI-713568, EBI-2859639; CC P45984; Q02548: PAX5; NbExp=3; IntAct=EBI-713568, EBI-296331; CC P45984; Q9BYU1: PBX4; NbExp=3; IntAct=EBI-713568, EBI-10302990; CC P45984; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-713568, EBI-79165; CC P45984; P78424: POU6F2; NbExp=3; IntAct=EBI-713568, EBI-12029004; CC P45984; P37231: PPARG; NbExp=3; IntAct=EBI-713568, EBI-781384; CC P45984; Q96S79: RASL10B; NbExp=4; IntAct=EBI-713568, EBI-3919507; CC P45984; Q2I0M5: RSPO4; NbExp=3; IntAct=EBI-713568, EBI-12821217; CC P45984; Q8IYX7: SAXO1; NbExp=3; IntAct=EBI-713568, EBI-3957636; CC P45984; O00560: SDCBP; NbExp=3; IntAct=EBI-713568, EBI-727004; CC P45984; Q15427: SF3B4; NbExp=7; IntAct=EBI-713568, EBI-348469; CC P45984; P34896: SHMT1; NbExp=7; IntAct=EBI-713568, EBI-715117; CC P45984; A2RU48: SMCO3; NbExp=6; IntAct=EBI-713568, EBI-10173195; CC P45984; P40763: STAT3; NbExp=2; IntAct=EBI-713568, EBI-518675; CC P45984; Q8TDR4: TCP10L; NbExp=3; IntAct=EBI-713568, EBI-3923210; CC P45984; Q8IYF3: TEX11; NbExp=3; IntAct=EBI-713568, EBI-742397; CC P45984; Q8IYF3-3: TEX11; NbExp=3; IntAct=EBI-713568, EBI-11523345; CC P45984; O43379: WDR62; NbExp=6; IntAct=EBI-713568, EBI-714790; CC P45984; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-713568, EBI-14104088; CC P45984; P52744: ZNF138; NbExp=3; IntAct=EBI-713568, EBI-10746567; CC P45984; Q9BR84: ZNF559; NbExp=3; IntAct=EBI-713568, EBI-746605; CC P45984; O43257: ZNHIT1; NbExp=3; IntAct=EBI-713568, EBI-347522; CC P45984-1; P40763: STAT3; NbExp=3; IntAct=EBI-713586, EBI-518675; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19675674}. Nucleus CC {ECO:0000269|PubMed:19675674}. Note=Colocalizes with POU5F1 in the CC nucleus. {ECO:0000250|UniProtKB:Q9WTU6}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=Alpha-2; CC IsoId=P45984-1; Sequence=Displayed; CC Name=Alpha-1; CC IsoId=P45984-2; Sequence=VSP_004835; CC Name=Beta-1; CC IsoId=P45984-3; Sequence=VSP_004834, VSP_004835; CC Name=Beta-2; CC IsoId=P45984-4; Sequence=VSP_004834; CC Name=5; CC IsoId=P45984-5; Sequence=VSP_041908, VSP_041909; CC -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues CC whose phosphorylation activates the MAP kinases. CC -!- PTM: Dually phosphorylated on Thr-183 and Tyr-185 by MAP2K7 and MAP2K4, CC which activates the enzyme. Autophosphorylated in vitro. CC {ECO:0000269|PubMed:11062067}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr CC protein kinase family. MAP kinase subfamily. {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/426/JNK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L31951; AAA56831.1; -; mRNA. DR EMBL; U09759; AAA74740.1; -; mRNA. DR EMBL; U34821; AAC50606.1; -; mRNA. DR EMBL; U35002; AAC50608.1; -; mRNA. DR EMBL; U35003; AAC50609.1; -; mRNA. DR EMBL; EU927388; ACH57450.1; -; mRNA. DR EMBL; CR536580; CAG38817.1; -; mRNA. DR EMBL; AK289638; BAF82327.1; -; mRNA. DR EMBL; DQ066599; AAY46156.1; -; Genomic_DNA. DR EMBL; AB451302; BAG70116.1; -; mRNA. DR EMBL; AB451355; BAG70169.1; -; mRNA. DR EMBL; AC008610; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC104115; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471165; EAW53759.1; -; Genomic_DNA. DR EMBL; CH471165; EAW53757.1; -; Genomic_DNA. DR EMBL; CH471165; EAW53758.1; -; Genomic_DNA. DR EMBL; CH471165; EAW53762.1; -; Genomic_DNA. DR EMBL; BC032539; AAH32539.1; -; mRNA. DR CCDS; CCDS43409.1; -. [P45984-2] DR CCDS; CCDS43410.1; -. [P45984-3] DR CCDS; CCDS4453.1; -. [P45984-1] DR CCDS; CCDS4454.1; -. [P45984-4] DR CCDS; CCDS47356.1; -. [P45984-5] DR PIR; A55480; A55480. DR PIR; S71102; S71102. DR RefSeq; NP_001128516.1; NM_001135044.2. [P45984-5] DR RefSeq; NP_001295173.1; NM_001308244.1. DR RefSeq; NP_001351536.1; NM_001364607.2. [P45984-2] DR RefSeq; NP_001351537.1; NM_001364608.2. [P45984-1] DR RefSeq; NP_001351538.1; NM_001364609.2. [P45984-4] DR RefSeq; NP_001351539.1; NM_001364610.2. [P45984-5] DR RefSeq; NP_002743.3; NM_002752.4. [P45984-1] DR RefSeq; NP_620707.1; NM_139068.3. [P45984-2] DR RefSeq; NP_620708.1; NM_139069.3. [P45984-3] DR RefSeq; NP_620709.1; NM_139070.3. [P45984-4] DR PDB; 3E7O; X-ray; 2.14 A; A/B=7-362. DR PDB; 3NPC; X-ray; 2.35 A; A/B=1-364. DR PDB; 7CML; X-ray; 2.15 A; A/B=1-364. DR PDB; 7N8T; X-ray; 1.69 A; A=10-364. DR PDB; 8ELC; X-ray; 2.07 A; A=1-424. DR PDBsum; 3E7O; -. DR PDBsum; 3NPC; -. DR PDBsum; 7CML; -. DR PDBsum; 7N8T; -. DR PDBsum; 8ELC; -. DR AlphaFoldDB; P45984; -. DR SMR; P45984; -. DR BioGRID; 111587; 180. DR DIP; DIP-270N; -. DR ELM; P45984; -. DR FunCoup; P45984; 5816. DR IntAct; P45984; 118. DR MINT; P45984; -. DR STRING; 9606.ENSP00000394560; -. DR BindingDB; P45984; -. DR ChEMBL; CHEMBL4179; -. DR DrugBank; DB12432; CC-401. DR DrugBank; DB05660; D-JNKI-1. DR DrugBank; DB11718; Encorafenib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB15624; Halicin. DR DrugBank; DB01017; Minocycline. DR DrugBank; DB07020; N-{3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]phenyl}furan-2-carboxamide. DR DrugBank; DB16995; NP-51. DR DrugBank; DB01782; Pyrazolanthrone. DR DrugBank; DB11798; Tanzisertib. DR DrugCentral; P45984; -. DR GuidetoPHARMACOLOGY; 1497; -. DR GlyConnect; 1515; 1 N-Linked glycan (1 site). DR GlyCosmos; P45984; 1 site, 1 glycan. DR GlyGen; P45984; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (1 site). DR iPTMnet; P45984; -. DR MetOSite; P45984; -. DR PhosphoSitePlus; P45984; -. DR BioMuta; MAPK9; -. DR DMDM; 85700366; -. DR REPRODUCTION-2DPAGE; P45984; -. DR CPTAC; CPTAC-3146; -. DR CPTAC; CPTAC-893; -. DR CPTAC; CPTAC-894; -. DR jPOST; P45984; -. DR MassIVE; P45984; -. DR PaxDb; 9606-ENSP00000394560; -. DR PeptideAtlas; P45984; -. DR ProteomicsDB; 55698; -. [P45984-1] DR ProteomicsDB; 55699; -. [P45984-2] DR ProteomicsDB; 55700; -. [P45984-3] DR ProteomicsDB; 55701; -. [P45984-4] DR ProteomicsDB; 55702; -. [P45984-5] DR Pumba; P45984; -. DR Antibodypedia; 4557; 913 antibodies from 47 providers. DR DNASU; 5601; -. DR Ensembl; ENST00000343111.10; ENSP00000345524.6; ENSG00000050748.19. [P45984-3] DR Ensembl; ENST00000393360.7; ENSP00000377028.3; ENSG00000050748.19. [P45984-2] DR Ensembl; ENST00000425491.6; ENSP00000397422.2; ENSG00000050748.19. [P45984-5] DR Ensembl; ENST00000452135.7; ENSP00000394560.2; ENSG00000050748.19. [P45984-1] DR Ensembl; ENST00000455781.5; ENSP00000389338.1; ENSG00000050748.19. [P45984-4] DR GeneID; 5601; -. DR KEGG; hsa:5601; -. DR MANE-Select; ENST00000452135.7; ENSP00000394560.2; NM_002752.5; NP_002743.3. DR UCSC; uc003mls.5; human. [P45984-1] DR AGR; HGNC:6886; -. DR ClinPGx; PA30630; -. DR CTD; 5601; -. DR DisGeNET; 5601; -. DR GeneCards; MAPK9; -. DR HGNC; HGNC:6886; MAPK9. DR HPA; ENSG00000050748; Low tissue specificity. DR MIM; 602896; gene. DR OpenTargets; ENSG00000050748; -. DR VEuPathDB; HostDB:ENSG00000050748; -. DR eggNOG; KOG0665; Eukaryota. DR GeneTree; ENSGT00940000158327; -. DR HOGENOM; CLU_000288_181_1_1; -. DR InParanoid; P45984; -. DR OMA; GCRNILR; -. DR OrthoDB; 192887at2759; -. DR PAN-GO; P45984; 4 GO annotations based on evolutionary models. DR PhylomeDB; P45984; -. DR BRENDA; 2.7.11.24; 2681. DR PathwayCommons; P45984; -. DR Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence. DR Reactome; R-HSA-2871796; FCERI mediated MAPK activation. DR Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1. DR Reactome; R-HSA-450341; Activation of the AP-1 family of transcription factors. DR Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants. DR SignaLink; P45984; -. DR SIGNOR; P45984; -. DR Agora; ENSG00000050748; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5601; 8 hits in 1191 CRISPR screens. DR ChiTaRS; MAPK9; human. DR EvolutionaryTrace; P45984; -. DR GeneWiki; Mitogen-activated_protein_kinase_9; -. DR GenomeRNAi; 5601; -. DR Pharos; P45984; Tchem. DR PRO; PR:P45984; -. DR Proteomes; UP000005640; Chromosome 5. DR RNAct; P45984; protein. DR Bgee; ENSG00000050748; Expressed in middle temporal gyrus and 214 other cell types or tissues. DR ExpressionAtlas; P45984; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProt. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0005739; C:mitochondrion; IEA:Ensembl. DR GO; GO:0016607; C:nuclear speck; IDA:HPA. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004705; F:JUN kinase activity; IDA:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:Ensembl. DR GO; GO:0097190; P:apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:0034614; P:cellular response to reactive oxygen species; IDA:UniProt. DR GO; GO:0090398; P:cellular senescence; TAS:Reactome. DR GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome. DR GO; GO:0090594; P:inflammatory response to wounding; IDA:UniProt. DR GO; GO:0007254; P:JNK cascade; IDA:UniProtKB. DR GO; GO:0050804; P:modulation of chemical synaptic transmission; IEA:Ensembl. DR GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IEA:Ensembl. DR GO; GO:1900017; P:positive regulation of cytokine production involved in inflammatory response; IDA:UniProt. DR GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL. DR GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IMP:BHF-UCL. DR GO; GO:0071803; P:positive regulation of podosome assembly; IEA:Ensembl. DR GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl. DR GO; GO:0031398; P:positive regulation of protein ubiquitination; IEA:Ensembl. DR GO; GO:0061833; P:protein localization to tricellular tight junction; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IMP:UniProtKB. DR GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB. DR GO; GO:0046686; P:response to cadmium ion; IEA:Ensembl. DR GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW. DR CDD; cd07850; STKc_JNK; 1. DR FunFam; 1.10.510.10:FF:000009; Mitogen-activated protein kinase; 1. DR FunFam; 3.30.200.20:FF:000210; Mitogen-activated protein kinase; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR003527; MAP_kinase_CS. DR InterPro; IPR050117; MAPK. DR InterPro; IPR008351; MAPK_JNK. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24055; MITOGEN-ACTIVATED PROTEIN KINASE; 1. DR Pfam; PF00069; Pkinase; 1. DR PRINTS; PR01772; JNKMAPKINASE. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS01351; MAPK; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Biological rhythms; KW Cytoplasm; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..424 FT /note="Mitogen-activated protein kinase 9" FT /id="PRO_0000186273" FT DOMAIN 26..321 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 368..424 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 183..185 FT /note="TXY" FT COMPBIAS 388..417 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 151 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 32..40 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 55 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 183 FT /note="Phosphothreonine; by MAP2K7" FT /evidence="ECO:0000269|PubMed:11062067" FT MOD_RES 185 FT /note="Phosphotyrosine; by MAP2K4" FT /evidence="ECO:0000269|PubMed:11062067" FT VAR_SEQ 216..230 FT /note="GELVKGCVIFQGTDH -> AEMVLHKVLFPGRDY (in isoform Beta- FT 1 and isoform Beta-2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_004834" FT VAR_SEQ 230..242 FT /note="HIDQWNKVIEQLG -> RILPRDLGPAMLS (in isoform 5)" FT /evidence="ECO:0000303|PubMed:21110917" FT /id="VSP_041908" FT VAR_SEQ 243..424 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:21110917" FT /id="VSP_041909" FT VAR_SEQ 378..424 FT /note="DAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR -> A FT QMQQ (in isoform Alpha-1 and isoform Beta-1)" FT /evidence="ECO:0000305" FT /id="VSP_004835" FT VARIANT 13 FT /note="V -> M (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1762231480)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042260" FT VARIANT 56 FT /note="K -> N (in a head & Neck squamous cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042261" FT VARIANT 246 FT /note="A -> T (in dbSNP:rs35421153)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042262" FT VARIANT 268 FT /note="G -> A (in dbSNP:rs35693958)" FT /evidence="ECO:0000269|Ref.7" FT /id="VAR_025175" FT VARIANT 366 FT /note="R -> I (in dbSNP:rs55736180)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042263" FT CONFLICT 51 FT /note="N -> S (in Ref. 1; AAA56831 and 3; AAC50606/ FT AAC50608/AAC50609)" FT /evidence="ECO:0000305" FT CONFLICT 377 FT /note="S -> P (in Ref. 2; AAA74740)" FT /evidence="ECO:0000305" FT TURN 6..8 FT /evidence="ECO:0007829|PDB:7CML" FT STRAND 11..23 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 26..35 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 38..45 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 46..49 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 50..59 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 60..62 FT /evidence="ECO:0007829|PDB:8ELC" FT HELIX 64..79 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 88..92 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 98..100 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 103..109 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 112..114 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 115..118 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 119..121 FT /evidence="ECO:0007829|PDB:8ELC" FT HELIX 125..144 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 154..156 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 157..159 FT /evidence="ECO:0007829|PDB:7N8T" FT STRAND 165..167 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 176..178 FT /evidence="ECO:0007829|PDB:3NPC" FT STRAND 179..181 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 189..191 FT /evidence="ECO:0007829|PDB:7CML" FT HELIX 194..197 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 206..220 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 230..241 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 246..250 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 254..262 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 271..274 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 285..301 FT /evidence="ECO:0007829|PDB:7N8T" FT TURN 306..308 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 312..316 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 319..322 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 327..330 FT /evidence="ECO:0007829|PDB:8ELC" FT STRAND 342..344 FT /evidence="ECO:0007829|PDB:7N8T" FT HELIX 349..361 FT /evidence="ECO:0007829|PDB:7N8T" SQ SEQUENCE 424 AA; 48139 MW; 9C15DA79981290AF CRC64; MSDSKCDSQF YSVQVADSTF TVLKRYQQLK PIGSGAQGIV CAAFDTVLGI NVAVKKLSRP FQNQTHAKRA YRELVLLKCV NHKNIISLLN VFTPQKTLEE FQDVYLVMEL MDANLCQVIH MELDHERMSY LLYQMLCGIK HLHSAGIIHR DLKPSNIVVK SDCTLKILDF GLARTACTNF MMTPYVVTRY YRAPEVILGM GYKENVDIWS VGCIMGELVK GCVIFQGTDH IDQWNKVIEQ LGTPSAEFMK KLQPTVRNYV ENRPKYPGIK FEELFPDWIF PSESERDKIK TSQARDLLSK MLVIDPDKRI SVDEALRHPY ITVWYDPAEA EAPPPQIYDA QLEEREHAIE EWKELIYKEV MDWEERSKNG VVKDQPSDAA VSSNATPSQS SSINDISSMS TEQTLASDTD SSLDASTGPL EGCR // ID MOS_HUMAN Reviewed; 346 AA. AC P00540; Q3KPG9; Q3KPH0; DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot. DT 21-JUL-1986, sequence version 1. DT 28-JAN-2026, entry version 212. DE RecName: Full=Proto-oncogene serine/threonine-protein kinase mos {ECO:0000305}; DE EC=2.7.11.1; DE AltName: Full=Oocyte maturation factor mos; DE AltName: Full=Proto-oncogene c-Mos; GN Name=MOS {ECO:0000312|HGNC:HGNC:7199}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RC TISSUE=Placenta; RX PubMed=6287464; DOI=10.1073/pnas.79.13.4078; RA Watson R., Oskarsson M., Vande Woude G.F.; RT "Human DNA sequence homologous to the transforming gene (mos) of Moloney RT murine sarcoma virus."; RL Proc. Natl. Acad. Sci. U.S.A. 79:4078-4082(1982). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT SER-105. RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [3] RP FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, INTERACTION WITH MAP2K1, RP INVOLVEMENT IN OZEMA20, VARIANTS OZEMA20 LYS-95; THR-139; HIS-246 AND RP 320-CYS--GLY-346 DEL, AND CHARACTERIZATION OF VARIANTS OZEMA20 LYS-95; RP THR-139; HIS-246 AND 320-CYS--GLY-346 DEL. RX PubMed=34779126; DOI=10.15252/emmm.202114887; RA Zhang Y.L., Zheng W., Ren P., Hu H., Tong X., Zhang S.P., Li X., Wang H., RA Jiang J.C., Jin J., Yang W., Cao L., He Y., Ma Y., Zhang Y., Gu Y., Hu L., RA Luo K., Gong F., Lu G.X., Lin G., Fan H.Y., Zhang S.; RT "Biallelic mutations in MOS cause female infertility characterized by human RT early embryonic arrest and fragmentation."; RL EMBO Mol. Med. 13:e14887-e14887(2021). RN [4] RP VARIANTS [LARGE SCALE ANALYSIS] LEU-96; SER-105; THR-123 AND PRO-300. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [5] RP VARIANT OZEMA20 MET-197. RX PubMed=36403623; DOI=10.1080/09513590.2022.2147158; RA Jiao G., Lian H., Xing J., Chen L., Du Z., Liu X.; RT "MOS mutation causes female infertility with large polar body oocytes."; RL Gynecol. Endocrinol. 38:1158-1163(2022). RN [6] RP VARIANTS OZEMA20 LYS-95 AND HIS-319, CHARACTERIZATION OF VARIANTS OZEMA20 RP LYS-95 AND HIS-319, AND FUNCTION. RX PubMed=34997960; DOI=10.1093/humrep/deab281; RA Zeng Y., Shi J., Xu S., Shi R., Wu T., Li H., Xue X., Zhu Y., Chen B., RA Sang Q., Wang L.; RT "Bi-allelic mutations in MOS cause female infertility characterized by RT preimplantation embryonic arrest."; RL Hum. Reprod. 37:612-620(2022). RN [7] RP VARIANTS OZEMA20 LEU-199; CYS-264 AND VAL-292, CHARACTERIZATION LEU-199; RP CYS-264 AND VAL-292, FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH RP MAP2K1. RX PubMed=35670744; DOI=10.1093/humrep/deac120; RA Zhang Y.L., Zheng W., Ren P., Jin J., Hu Z., Liu Q., Fan H.Y., Gong F., RA Lu G.X., Lin G., Zhang S., Tong X.; RT "Biallelic variants in MOS cause large polar body in oocyte and human RT female infertility."; RL Hum. Reprod. 37:1932-1944(2022). CC -!- FUNCTION: Serine/threonine kinase involved in the regulation of MAPK CC signaling. Is an activator of the ERK1/2 signaling cascade playing an CC essential role in the stimulation of oocyte maturation. CC {ECO:0000269|PubMed:34779126, ECO:0000269|PubMed:34997960, CC ECO:0000269|PubMed:35670744}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts with MAP2K1/MEK1. {ECO:0000269|PubMed:34779126, CC ECO:0000269|PubMed:35670744}. CC -!- INTERACTION: CC P00540; P35609: ACTN2; NbExp=3; IntAct=EBI-1757866, EBI-77797; CC P00540; Q9NWX5: ASB6; NbExp=3; IntAct=EBI-1757866, EBI-6425205; CC P00540; Q8WXE1: ATRIP; NbExp=3; IntAct=EBI-1757866, EBI-747353; CC P00540; Q8TD16-2: BICD2; NbExp=3; IntAct=EBI-1757866, EBI-11975051; CC P00540; Q96GS4: BORCS6; NbExp=4; IntAct=EBI-1757866, EBI-10193358; CC P00540; Q13137: CALCOCO2; NbExp=8; IntAct=EBI-1757866, EBI-739580; CC P00540; Q8NA61: CBY2; NbExp=3; IntAct=EBI-1757866, EBI-741724; CC P00540; Q8NA61-2: CBY2; NbExp=3; IntAct=EBI-1757866, EBI-11524851; CC P00540; Q68D86: CCDC102B; NbExp=3; IntAct=EBI-1757866, EBI-10171570; CC P00540; Q96JN2-2: CCDC136; NbExp=3; IntAct=EBI-1757866, EBI-10171416; CC P00540; O95273: CCNDBP1; NbExp=3; IntAct=EBI-1757866, EBI-748961; CC P00540; Q16543: CDC37; NbExp=2; IntAct=EBI-1757866, EBI-295634; CC P00540; Q8WWB3: DYDC1; NbExp=3; IntAct=EBI-1757866, EBI-740680; CC P00540; Q86YF9: DZIP1; NbExp=3; IntAct=EBI-1757866, EBI-998108; CC P00540; Q13451: FKBP5; NbExp=5; IntAct=EBI-1757866, EBI-306914; CC P00540; P14136: GFAP; NbExp=3; IntAct=EBI-1757866, EBI-744302; CC P00540; Q08379: GOLGA2; NbExp=6; IntAct=EBI-1757866, EBI-618309; CC P00540; Q9NYA3: GOLGA6A; NbExp=3; IntAct=EBI-1757866, EBI-11163335; CC P00540; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-1757866, EBI-5916454; CC P00540; O75791: GRAP2; NbExp=3; IntAct=EBI-1757866, EBI-740418; CC P00540; Q9NSC5: HOMER3; NbExp=8; IntAct=EBI-1757866, EBI-748420; CC P00540; P07900: HSP90AA1; NbExp=2; IntAct=EBI-1757866, EBI-296047; CC P00540; P08238: HSP90AB1; NbExp=2; IntAct=EBI-1757866, EBI-352572; CC P00540; Q13422-7: IKZF1; NbExp=3; IntAct=EBI-1757866, EBI-11522367; CC P00540; Q8NC69: KCTD6; NbExp=3; IntAct=EBI-1757866, EBI-2511344; CC P00540; Q92845: KIFAP3; NbExp=3; IntAct=EBI-1757866, EBI-954040; CC P00540; Q9BVG8: KIFC3; NbExp=3; IntAct=EBI-1757866, EBI-2125614; CC P00540; A1A4E9: KRT13; NbExp=3; IntAct=EBI-1757866, EBI-10171552; CC P00540; P19012: KRT15; NbExp=6; IntAct=EBI-1757866, EBI-739566; CC P00540; Q7Z3Y8: KRT27; NbExp=3; IntAct=EBI-1757866, EBI-3044087; CC P00540; Q15323: KRT31; NbExp=3; IntAct=EBI-1757866, EBI-948001; CC P00540; Q14525: KRT33B; NbExp=3; IntAct=EBI-1757866, EBI-1049638; CC P00540; O76011: KRT34; NbExp=3; IntAct=EBI-1757866, EBI-1047093; CC P00540; Q6A162: KRT40; NbExp=3; IntAct=EBI-1757866, EBI-10171697; CC P00540; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-1757866, EBI-11749135; CC P00540; Q9BRK4: LZTS2; NbExp=3; IntAct=EBI-1757866, EBI-741037; CC P00540; P36507: MAP2K2; NbExp=3; IntAct=EBI-1757866, EBI-1056930; CC P00540; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-1757866, EBI-16439278; CC P00540; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-1757866, EBI-10172526; CC P00540; Q8TD10: MIPOL1; NbExp=3; IntAct=EBI-1757866, EBI-2548751; CC P00540; Q96QG7: MTMR9; NbExp=6; IntAct=EBI-1757866, EBI-744593; CC P00540; Q5JR59-3: MTUS2; NbExp=4; IntAct=EBI-1757866, EBI-11522433; CC P00540; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-1757866, EBI-22310682; CC P00540; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-1757866, EBI-79165; CC P00540; Q15172: PPP2R5A; NbExp=5; IntAct=EBI-1757866, EBI-641666; CC P00540; O43586: PSTPIP1; NbExp=3; IntAct=EBI-1757866, EBI-1050964; CC P00540; P53992: SEC24C; NbExp=4; IntAct=EBI-1757866, EBI-81134; CC P00540; Q9Y2D8: SSX2IP; NbExp=3; IntAct=EBI-1757866, EBI-2212028; CC P00540; Q9UNE7: STUB1; NbExp=2; IntAct=EBI-1757866, EBI-357085; CC P00540; Q05BL1: TP53BP2; NbExp=3; IntAct=EBI-1757866, EBI-11952721; CC P00540; Q13077: TRAF1; NbExp=6; IntAct=EBI-1757866, EBI-359224; CC P00540; Q12933: TRAF2; NbExp=3; IntAct=EBI-1757866, EBI-355744; CC P00540; P14373: TRIM27; NbExp=3; IntAct=EBI-1757866, EBI-719493; CC P00540; Q8N6Y0: USHBP1; NbExp=6; IntAct=EBI-1757866, EBI-739895; CC P00540; Q8N680: ZBTB2; NbExp=3; IntAct=EBI-1757866, EBI-2515601; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:35670744}. CC -!- TISSUE SPECIFICITY: Highly expressed in oocytes. Lower expression is CC detected in early embryo. {ECO:0000269|PubMed:34779126}. CC -!- DEVELOPMENTAL STAGE: Expression decreases after fertilization and is CC slightly increased in four-cell stage embryos. Expression gradually CC decreases from eight-cell to blastocyst embryos. CC {ECO:0000269|PubMed:34779126}. CC -!- DISEASE: Oocyte/zygote/embryo maturation arrest 20 (OZEMA20) CC [MIM:620383]: An autosomal recessive, female infertility disorder CC characterized by early embryonic arrest and fragmentation. Early embryo CC fragmentation is defined by the presence of anucleate cell fragments CC derived from the blastomeres. Excessive embryo fragmentation is CC associated with deleterious outcomes, including decreased implantation CC rate. {ECO:0000269|PubMed:34779126, ECO:0000269|PubMed:34997960, CC ECO:0000269|PubMed:35670744, ECO:0000269|PubMed:36403623}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; J00119; AAA52029.1; -; Genomic_DNA. DR EMBL; BC069569; AAH69569.1; -; mRNA. DR EMBL; BC069590; AAH69590.1; -; mRNA. DR EMBL; BC106737; AAI06738.1; -; mRNA. DR EMBL; BC106738; AAI06739.1; -; mRNA. DR CCDS; CCDS6164.1; -. DR PIR; A00649; TVHUMS. DR RefSeq; NP_005363.1; NM_005372.1. DR AlphaFoldDB; P00540; -. DR SMR; P00540; -. DR BioGRID; 110483; 74. DR FunCoup; P00540; 709. DR IntAct; P00540; 86. DR MINT; P00540; -. DR STRING; 9606.ENSP00000310722; -. DR ChEMBL; CHEMBL1075184; -. DR GlyGen; P00540; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P00540; -. DR PhosphoSitePlus; P00540; -. DR BioMuta; MOS; -. DR DMDM; 125497; -. DR jPOST; P00540; -. DR MassIVE; P00540; -. DR PaxDb; 9606-ENSP00000310722; -. DR PeptideAtlas; P00540; -. DR ProteomicsDB; 51265; -. DR Antibodypedia; 24550; 288 antibodies from 27 providers. DR DNASU; 4342; -. DR Ensembl; ENST00000311923.1; ENSP00000310722.1; ENSG00000172680.1. DR GeneID; 4342; -. DR KEGG; hsa:4342; -. DR MANE-Select; ENST00000311923.1; ENSP00000310722.1; NM_005372.1; NP_005363.1. DR UCSC; uc011leb.2; human. DR AGR; HGNC:7199; -. DR ClinPGx; PA30907; -. DR CTD; 4342; -. DR DisGeNET; 4342; -. DR GeneCards; MOS; -. DR HGNC; HGNC:7199; MOS. DR HPA; ENSG00000172680; Not detected. DR MalaCards; MOS; -. DR MIM; 190060; gene. DR MIM; 620383; phenotype. DR OpenTargets; ENSG00000172680; -. DR VEuPathDB; HostDB:ENSG00000172680; -. DR eggNOG; KOG0192; Eukaryota. DR GeneTree; ENSGT00940000160233; -. DR HOGENOM; CLU_000288_7_35_1; -. DR InParanoid; P00540; -. DR OMA; WQMTTKE; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P00540; 5 GO annotations based on evolutionary models. DR PhylomeDB; P00540; -. DR BRENDA; 2.7.10.2; 2681. DR PathwayCommons; P00540; -. DR SignaLink; P00540; -. DR SIGNOR; P00540; -. DR BioGRID-ORCS; 4342; 19 hits in 1185 CRISPR screens. DR GeneWiki; MOS_(gene); -. DR GenomeRNAi; 4342; -. DR Pharos; P00540; Tbio. DR PRO; PR:P00540; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; P00540; protein. DR Bgee; ENSG00000172680; Expressed in oocyte and 13 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; IMP:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004709; F:MAP kinase kinase kinase activity; ISS:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB. DR GO; GO:0006325; P:chromatin organization; ISS:UniProtKB. DR GO; GO:0051296; P:establishment of meiotic spindle orientation; ISS:UniProtKB. DR GO; GO:0000165; P:MAPK cascade; ISS:UniProtKB. DR GO; GO:0000212; P:meiotic spindle organization; ISS:UniProtKB. DR GO; GO:1902103; P:negative regulation of metaphase/anaphase transition of meiotic cell cycle; ISS:UniProtKB. DR GO; GO:0001556; P:oocyte maturation; IMP:UniProtKB. DR GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0040020; P:regulation of meiotic nuclear division; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; IBA:GO_Central. DR CDD; cd13979; STKc_Mos; 1. DR FunFam; 1.10.510.10:FF:000490; Proto-oncogene serine/threonine-protein kinase mos; 1. DR FunFam; 3.30.200.20:FF:000316; Proto-oncogene serine/threonine-protein kinase mos; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR InterPro; IPR051681; Ser/Thr_Kinases-Pseudokinases. DR PANTHER; PTHR44329; SERINE/THREONINE-PROTEIN KINASE TNNI3K-RELATED; 1. DR PANTHER; PTHR44329:SF285; V-MOS MOLONEY MURINE SARCOMA VIRAL ONCO HOMOLOG; 1. DR Pfam; PF00069; Pkinase; 1. DR PIRSF; PIRSF000654; Integrin-linked_kinase; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. PE 1: Evidence at protein level; KW ATP-binding; Cytoplasm; Disease variant; Kinase; Nucleotide-binding; KW Proteomics identification; Proto-oncogene; Reference proteome; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..346 FT /note="Proto-oncogene serine/threonine-protein kinase mos" FT /id="PRO_0000086344" FT DOMAIN 60..341 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT ACT_SITE 201 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 66..74 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 87 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT VARIANT 95 FT /note="N -> K (in OZEMA20; likely pathogenic; loss of FT function in oocyte maturation activation; results in FT severely decreased activation of the ERK1/ERK2 cascade; FT dbSNP:rs774064952)" FT /evidence="ECO:0000269|PubMed:34779126, FT ECO:0000269|PubMed:34997960" FT /id="VAR_088642" FT VARIANT 96 FT /note="R -> L (in dbSNP:rs34532635)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040813" FT VARIANT 105 FT /note="A -> S (in dbSNP:rs35392772)" FT /evidence="ECO:0000269|PubMed:15489334, FT ECO:0000269|PubMed:17344846" FT /id="VAR_040814" FT VARIANT 123 FT /note="A -> T (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040815" FT VARIANT 139 FT /note="M -> T (in OZEMA20; uncertain significance; results FT in decreased activation of the ERK1/ERK2 cascade)" FT /evidence="ECO:0000269|PubMed:34779126" FT /id="VAR_088643" FT VARIANT 197 FT /note="I -> M (in OZEMA20; uncertain significance)" FT /evidence="ECO:0000269|PubMed:36403623" FT /id="VAR_088644" FT VARIANT 199 FT /note="H -> L (in OZEMA20; likely pathogenic; loss of FT function in oocyte maturation activation; loss of FT activation of the ERK1/ERK2 cascade; no effect on FT localization to cytoplasm)" FT /evidence="ECO:0000269|PubMed:35670744" FT /id="VAR_088645" FT VARIANT 246 FT /note="R -> H (in OZEMA20; uncertain significance; results FT in decreased activation of the ERK1/ERK2 cascade; FT dbSNP:rs1563357810)" FT /evidence="ECO:0000269|PubMed:34779126" FT /id="VAR_088646" FT VARIANT 264 FT /note="S -> C (in OZEMA20; likely pathogenic; loss of FT function in oocyte maturation activation; loss of FT activation of the ERK1/ERK2 cascade; no effect on FT localization to cytoplasm)" FT /evidence="ECO:0000269|PubMed:35670744" FT /id="VAR_088647" FT VARIANT 292 FT /note="A -> V (in OZEMA20; likely pathogenic; loss of FT function in oocyte maturation activation; decreased FT activation of the ERK1/ERK2 cascade; no effect on FT localization to cytoplasm; dbSNP:rs1810519989)" FT /evidence="ECO:0000269|PubMed:35670744" FT /id="VAR_088648" FT VARIANT 300 FT /note="S -> P (in dbSNP:rs56300224)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_040816" FT VARIANT 319 FT /note="R -> H (in OZEMA20; likely pathogenic; results in FT decreased activation of the ERK1/ERK2 cascade)" FT /evidence="ECO:0000269|PubMed:34997960" FT /id="VAR_088649" FT VARIANT 320..346 FT /note="Missing (in OZEMA20; likely pathogenic; loss of FT function in oocyte maturation activation; loss of FT activation of the ERK1/ERK2 cascade; severely decreased FT interaction with MAP2K1)" FT /evidence="ECO:0000269|PubMed:34779126" FT /id="VAR_088650" SQ SEQUENCE 346 AA; 37820 MW; 68B1AB906ED4B308 CRC64; MPSPLALRPY LRSEFSPSVD ARPCSSPSEL PAKLLLGATL PRAPRLPRRL AWCSIDWEQV CLLQRLGAGG FGSVYKATYR GVPVAIKQVN KCTKNRLASR RSFWAELNVA RLRHDNIVRV VAASTRTPAG SNSLGTIIME FGGNVTLHQV IYGAAGHPEG DAGEPHCRTG GQLSLGKCLK YSLDVVNGLL FLHSQSIVHL DLKPANILIS EQDVCKISDF GCSEKLEDLL CFQTPSYPLG GTYTHRAPEL LKGEGVTPKA DIYSFAITLW QMTTKQAPYS GERQHILYAV VAYDLRPSLS AAVFEDSLPG QRLGDVIQRC WRPSAAQRPS ARLLLVDLTS LKAELG // ID PKN1_HUMAN Reviewed; 942 AA. AC Q16512; A8K7W5; B2R9R4; B3KVN3; Q15143; Q504U4; Q8IUV5; Q9UD44; DT 15-JUL-1999, integrated into UniProtKB/Swiss-Prot. DT 22-SEP-2009, sequence version 2. DT 28-JAN-2026, entry version 251. DE RecName: Full=Serine/threonine-protein kinase N1; DE EC=2.7.11.13 {ECO:0000269|PubMed:18066052}; DE AltName: Full=Protease-activated kinase 1; DE Short=PAK-1; DE AltName: Full=Protein kinase C-like 1; DE AltName: Full=Protein kinase C-like PKN; DE AltName: Full=Protein kinase PKN-alpha; DE AltName: Full=Protein-kinase C-related kinase 1; DE AltName: Full=Serine-threonine protein kinase N; GN Name=PKN1; Synonyms=PAK1, PKN, PRK1, PRKCL1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-644. RC TISSUE=Hippocampus; RX PubMed=8135837; DOI=10.1006/bbrc.1994.1313; RA Mukai H., Ono Y.; RT "A novel protein kinase with leucine zipper-like sequences: its catalytic RT domain is highly homologous to that of protein kinase C."; RL Biochem. Biophys. Res. Commun. 199:897-904(1994). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Fetal brain; RX PubMed=7851406; DOI=10.1111/j.1432-1033.1995.tb20395.x; RA Palmer R.H., Ridden J., Parker P.J.; RT "Cloning and expression patterns of two members of a novel protein-kinase- RT C-related kinase family."; RL Eur. J. Biochem. 227:344-351(1995). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS RP ILE-555 AND ILE-901. RC TISSUE=Kidney, Synovium, and Thymus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15057824; DOI=10.1038/nature02399; RA Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., RA Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., RA Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., RA Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A., RA Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., RA Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., RA Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., RA Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., RA Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., RA McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., RA Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., RA Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., RA She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., RA Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., RA Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., RA Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., RA Rubin E.M., Lucas S.M.; RT "The DNA sequence and biology of human chromosome 19."; RL Nature 428:529-535(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT RP ILE-901. RC TISSUE=Brain, and Placenta; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 700-800 (ISOFORMS 1/2), AND VARIANT VAL-718. RX PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4; RA Palmer R.H., Ridden J., Parker P.J.; RT "Identification of multiple, novel, protein kinase C-related gene RT products."; RL FEBS Lett. 356:5-8(1994). RN [7] RP FUNCTION. RX PubMed=8557118; DOI=10.1016/0014-5793(95)01454-3; RA Palmer R.H., Schonwasser D.C., Rahman D., Pappin D.J., Herget T., RA Parker P.J.; RT "PRK1 phosphorylates MARCKS at the PKC sites: serine 152, serine 156 and RT serine 163."; RL FEBS Lett. 378:281-285(1996). RN [8] RP FUNCTION. RX PubMed=8621664; DOI=10.1074/jbc.271.16.9816; RA Mukai H., Toshimori M., Shibata H., Kitagawa M., Shimakawa M., Miyahara M., RA Sunakawa H., Ono Y.; RT "PKN associates and phosphorylates the head-rod domain of neurofilament RT protein."; RL J. Biol. Chem. 271:9816-9822(1996). RN [9] RP ACTIVITY REGULATION, AND INTERACTION WITH RHOA. RX PubMed=8571126; DOI=10.1126/science.271.5249.645; RA Watanabe G., Saito Y., Madaule P., Ishizaki T., Fujisawa K., Morii N., RA Mukai H., Ono Y., Kakizuka A., Narumiya S.; RT "Protein kinase N (PKN) and PKN-related protein rhophilin as targets of RT small GTPase Rho."; RL Science 271:645-648(1996). RN [10] RP FUNCTION. RX PubMed=9175763; DOI=10.1006/bbrc.1997.6669; RA Matsuzawa K., Kosako H., Inagaki N., Shibata H., Mukai H., Ono Y., RA Amano M., Kaibuchi K., Matsuura Y., Azuma I., Inagaki M.; RT "Domain-specific phosphorylation of vimentin and glial fibrillary acidic RT protein by PKN."; RL Biochem. Biophys. Res. Commun. 234:621-625(1997). RN [11] RP SUBCELLULAR LOCATION, AND INTERACTION WITH RHOB. RX PubMed=9478917; DOI=10.1074/jbc.273.9.4811; RA Mellor H., Flynn P., Nobes C.D., Hall A., Parker P.J.; RT "PRK1 is targeted to endosomes by the small GTPase, RhoB."; RL J. Biol. Chem. 273:4811-4814(1998). RN [12] RP ACTIVITY REGULATION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF ASP-108; RP ASP-451; ASP-454; ASP-558 AND ASP-560. RX PubMed=9751706; DOI=10.1073/pnas.95.20.11566; RA Takahashi M., Mukai H., Toshimori M., Miyamoto M., Ono Y.; RT "Proteolytic activation of PKN by caspase-3 or related protease during RT apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 95:11566-11571(1998). RN [13] RP PHOSPHORYLATION AT THR-774 BY PDPK1, AND INTERACTION WITH PDPK1. RX PubMed=10792047; DOI=10.1073/pnas.090491897; RA Dong L.Q., Landa L.R., Wick M.J., Zhu L., Mukai H., Ono Y., Liu F.; RT "Phosphorylation of protein kinase N by phosphoinositide-dependent protein RT kinase-1 mediates insulin signals to the actin cytoskeleton."; RL Proc. Natl. Acad. Sci. U.S.A. 97:5089-5094(2000). RN [14] RP FUNCTION. RX PubMed=11104762; DOI=10.1074/jbc.m007427200; RA Taniguchi T., Kawamata T., Mukai H., Hasegawa H., Isagawa T., Yasuda M., RA Hashimoto T., Terashima A., Nakai M., Mori H., Ono Y., Tanaka C.; RT "Phosphorylation of tau is regulated by PKN."; RL J. Biol. Chem. 276:10025-10031(2001). RN [15] RP FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AR. RX PubMed=12514133; DOI=10.1093/emboj/cdg023; RA Metzger E., Muller J.M., Ferrari S., Buettner R., Schule R.; RT "A novel inducible transactivation domain in the androgen receptor: RT implications for PRK in prostate cancer."; RL EMBO J. 22:270-280(2003). RN [16] RP INTERACTION WITH S.TYPHIMURIUM SSPH1 (MICROBIAL INFECTION). RX PubMed=16611232; DOI=10.1111/j.1462-5822.2005.00670.x; RA Haraga A., Miller S.I.; RT "A Salmonella type III secretion effector interacts with the mammalian RT serine/threonine protein kinase PKN1."; RL Cell. Microbiol. 8:837-846(2006). RN [17] RP INTERACTION WITH CCNT2. RX PubMed=16331689; DOI=10.1002/jcp.20566; RA Cottone G., Baldi A., Palescandolo E., Manente L., Penta R., Paggi M.G., RA De Luca A.; RT "Pkn is a novel partner of cyclin T2a in muscle differentiation."; RL J. Cell. Physiol. 207:232-237(2006). RN [18] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533 AND SER-562, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [19] RP FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION. RX PubMed=17332740; DOI=10.1038/sj.emboj.7601637; RA Schmidt A., Durgan J., Magalhaes A., Hall A.; RT "Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit from RT cytokinesis."; RL EMBO J. 26:1624-1636(2007). RN [20] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-778, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18220336; DOI=10.1021/pr0705441; RA Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III; RT "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient RT phosphoproteomic analysis."; RL J. Proteome Res. 7:1346-1351(2008). RN [21] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205 AND SER-537, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [22] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-644. RX PubMed=18066052; DOI=10.1038/ncb1668; RA Metzger E., Yin N., Wissmann M., Kunowska N., Fischer K., Friedrichs N., RA Patnaik D., Higgins J.M., Potier N., Scheidtmann K.H., Buettner R., RA Schule R.; RT "Phosphorylation of histone H3 at threonine 11 establishes a novel RT chromatin mark for transcriptional regulation."; RL Nat. Cell Biol. 10:53-60(2008). RN [23] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537; SER-559; RP SER-562 AND SER-916, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [24] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19413330; DOI=10.1021/ac9004309; RA Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.; RT "Lys-N and trypsin cover complementary parts of the phosphoproteome in a RT refined SCX-based approach."; RL Anal. Chem. 81:4493-4501(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205; SER-533; SER-537; RP SER-559; SER-562; THR-914 AND SER-916, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [26] RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-448, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19608861; DOI=10.1126/science.1175371; RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., RA Olsen J.V., Mann M.; RT "Lysine acetylation targets protein complexes and co-regulates major RT cellular functions."; RL Science 325:834-840(2009). RN [27] RP FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=20188095; DOI=10.1016/j.febslet.2010.02.057; RA Harrison B.C., Huynh K., Lundgaard G.L., Helmke S.M., Perryman M.B., RA McKinsey T.A.; RT "Protein kinase C-related kinase targets nuclear localization signals in a RT subset of class IIa histone deacetylases."; RL FEBS Lett. 584:1103-1110(2010). RN [28] RP INTERACTION WITH PRKCB. RX PubMed=20228790; DOI=10.1038/nature08839; RA Metzger E., Imhof A., Patel D., Kahl P., Hoffmeyer K., Friedrichs N., RA Muller J.M., Greschik H., Kirfel J., Ji S., Kunowska N., RA Beisenherz-Huss C., Gunther T., Buettner R., Schule R.; RT "Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at RT histone H3K4."; RL Nature 464:792-796(2010). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537 AND SER-562, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [30] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [31] RP FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH AKAP13; MAPK14; ZAK AND RP MAP2K3. RX PubMed=21224381; DOI=10.1074/jbc.m110.185645; RA Cariolato L., Cavin S., Diviani D.; RT "A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling RT complex involved in alpha1-adrenergic receptor-induced p38 activation."; RL J. Biol. Chem. 286:7925-7937(2011). RN [32] RP FUNCTION IN CELL MIGRATION, AND TISSUE SPECIFICITY. RX PubMed=21754995; DOI=10.1371/journal.pone.0021732; RA Lachmann S., Jevons A., De Rycker M., Casamassima A., Radtke S., RA Collazos A., Parker P.J.; RT "Regulatory domain selectivity in the cell-type specific PKN-dependence of RT cell migration."; RL PLoS ONE 6:E21732-E21732(2011). RN [33] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-562, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [34] RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [35] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-69; SER-533; SER-537; RP SER-540; SER-562; SER-608 AND SER-916, AND IDENTIFICATION BY MASS RP SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [36] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-916, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [37] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98 IN COMPLEX WITH RHOA. RX PubMed=10619026; DOI=10.1016/s1097-2765(00)80389-5; RA Maesaki R., Ihara K., Shimizu T., Kuroda S., Kaibuchi K., Hakoshima T.; RT "The structural basis of Rho effector recognition revealed by the crystal RT structure of human RhoA complexed with the effector domain of PKN/PRK1."; RL Mol. Cell 4:793-803(1999). RN [38] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98. RX PubMed=10388627; DOI=10.1006/jsbi.1999.4114; RA Maesaki R., Shimizu T., Ihara K., Kuroda S., Kaibuchi K., Hakoshima T.; RT "Biochemical and crystallographic characterization of a Rho effector domain RT of the protein serine/threonine kinase N in a complex with RhoA."; RL J. Struct. Biol. 126:166-170(1999). RN [39] RP STRUCTURE BY NMR OF 116-199 IN COMPLEX WITH RAC1. RX PubMed=14514689; DOI=10.1074/jbc.m304313200; RA Owen D., Lowe P.N., Nietlispach D., Brosnan C.E., Chirgadze D.Y., RA Parker P.J., Blundell T.L., Mott H.R.; RT "Molecular dissection of the interaction between the small G proteins Rac1 RT and RhoA and protein kinase C-related kinase 1 (PRK1)."; RL J. Biol. Chem. 278:50578-50587(2003). RN [40] RP STRUCTURE BY NMR OF 122-199 IN COMPLEX WITH RAC1. RX PubMed=18006505; DOI=10.1074/jbc.m706760200; RA Modha R., Campbell L.J., Nietlispach D., Buhecha H.R., Owen D., Mott H.R.; RT "The Rac1 polybasic region is required for interaction with its effector RT PRK1."; RL J. Biol. Chem. 283:1492-1500(2008). RN [41] RP X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 122-199 IN COMPLEX WITH RP SALMONELLA SSPH1, UBIQUITINATION (MICROBIAL INFECTION), MUTAGENESIS OF RP ARG-181 AND ARG-185, FUNCTION AS ANDROGEN RECEPTOR COACTIVATOR, AND RP INTERACTION WITH SALMONELLA SSPH1 (MICROBIAL INFECTION). RX PubMed=24248594; DOI=10.1128/mcb.01360-13; RA Keszei A.F., Tang X., McCormick C., Zeqiraj E., Rohde J.R., Tyers M., RA Sicheri F.; RT "Structure of an SspH1-PKN1 complex reveals the basis for host substrate RT recognition and mechanism of activation for a bacterial E3 ubiquitin RT ligase."; RL Mol. Cell. Biol. 34:362-373(2014). RN [42] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-185; GLU-197; TRP-436; GLN-520; RP ILE-555; GLN-635; VAL-718; LEU-873; ILE-901 AND VAL-921. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). CC -!- FUNCTION: PKC-related serine/threonine-protein kinase involved in CC various processes such as regulation of the intermediate filaments of CC the actin cytoskeleton, cell migration, tumor cell invasion and CC transcription regulation. Part of a signaling cascade that begins with CC the activation of the adrenergic receptor ADRA1B and leads to the CC activation of MAPK14. Regulates the cytoskeletal network by CC phosphorylating proteins such as VIM and neurofilament proteins NEFH, CC NEFL and NEFM, leading to inhibit their polymerization. Phosphorylates CC 'Ser-575', 'Ser-637' and 'Ser-669' of MAPT/Tau, lowering its ability to CC bind to microtubules, resulting in disruption of tubulin assembly. Acts CC as a key coactivator of androgen receptor (AR)-dependent transcription, CC by being recruited to AR target genes and specifically mediating CC phosphorylation of 'Thr-11' of histone H3 (H3T11ph), a specific tag for CC epigenetic transcriptional activation that promotes demethylation of CC histone H3 'Lys-9' (H3K9me) by KDM4C/JMJD2C. Phosphorylates HDAC5, CC HDAC7 and HDAC9, leading to impair their import in the nucleus. CC Phosphorylates 'Thr-38' of PPP1R14A, 'Ser-159', 'Ser-163' and 'Ser-170' CC of MARCKS, and GFAP. Able to phosphorylate RPS6 in vitro. CC {ECO:0000269|PubMed:11104762, ECO:0000269|PubMed:12514133, CC ECO:0000269|PubMed:17332740, ECO:0000269|PubMed:18066052, CC ECO:0000269|PubMed:20188095, ECO:0000269|PubMed:21224381, CC ECO:0000269|PubMed:21754995, ECO:0000269|PubMed:24248594, CC ECO:0000269|PubMed:8557118, ECO:0000269|PubMed:8621664, CC ECO:0000269|PubMed:9175763}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:18066052}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; CC Evidence={ECO:0000269|PubMed:18066052}; CC -!- ACTIVITY REGULATION: Kinase activity is activated upon binding to Rho CC proteins (RHOA, RHOB and RAC1). Activated by lipids, particularly CC cardiolipin and to a lesser extent by other acidic phospholipids. CC Activated by caspase-3 (CASP3) cleavage during apoptosis. Two specific CC sites, Thr-774 (activation loop of the kinase domain) and Ser-916 (turn CC motif), need to be phosphorylated for its full activation. CC {ECO:0000269|PubMed:8571126, ECO:0000269|PubMed:9751706}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=20.6 uM for HDAC5 {ECO:0000269|PubMed:20188095}; CC -!- SUBUNIT: Interacts with ZFAND6 (By similarity). Interacts with AR CC (PubMed:12514133). Interacts with PRKCB (PubMed:20228790). Interacts CC (via REM 1 and REM 2 repeats) with RAC1 (PubMed:14514689, CC PubMed:18006505). Interacts (via REM 1 repeat) with RHOA CC (PubMed:10619026, PubMed:8571126). Interacts with RHOB CC (PubMed:9478917). Interacts (via C-terminus) with PDPK1 CC (PubMed:10792047). Interacts with CCNT2; enhances MYOD1-dependent CC transcription (PubMed:16331689). Component of a signaling complex CC containing at least AKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this CC complex, AKAP13 interacts directly with PKN1, which in turn recruits CC MAPK14, MAP2K3 and ZAK (PubMed:21224381). CC {ECO:0000250|UniProtKB:P70268, ECO:0000269|PubMed:10619026, CC ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:12514133, CC ECO:0000269|PubMed:14514689, ECO:0000269|PubMed:16331689, CC ECO:0000269|PubMed:18006505, ECO:0000269|PubMed:20228790, CC ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:8571126, CC ECO:0000269|PubMed:9478917}. CC -!- SUBUNIT: (Microbial infection) Interacts (via the second REM repeat) CC with S.typhimurium E3 ubiquitin-protein ligase SspH1 (via the leucine- CC rich repeat region) (PubMed:16611232, PubMed:24248594). CC {ECO:0000269|PubMed:16611232, ECO:0000269|PubMed:24248594}. CC -!- INTERACTION: CC Q16512; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-602382, EBI-10173507; CC Q16512; Q9ULX6: AKAP8L; NbExp=3; IntAct=EBI-602382, EBI-357530; CC Q16512; Q6PJH3: AKAP9; NbExp=3; IntAct=EBI-602382, EBI-11745576; CC Q16512; P05067: APP; NbExp=3; IntAct=EBI-602382, EBI-77613; CC Q16512; P15289: ARSA; NbExp=3; IntAct=EBI-602382, EBI-2117357; CC Q16512; Q14457: BECN1; NbExp=3; IntAct=EBI-602382, EBI-949378; CC Q16512; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-602382, EBI-2548012; CC Q16512; Q8WU43: C2orf15; NbExp=3; IntAct=EBI-602382, EBI-12904676; CC Q16512; Q96M89-2: CCDC138; NbExp=3; IntAct=EBI-602382, EBI-10972887; CC Q16512; Q15834: CCDC85B; NbExp=2; IntAct=EBI-602382, EBI-739674; CC Q16512; Q8IV13: CCNJL; NbExp=3; IntAct=EBI-602382, EBI-21668062; CC Q16512; Q01850: CDR2; NbExp=6; IntAct=EBI-602382, EBI-1181367; CC Q16512; Q86XR8-3: CEP57; NbExp=3; IntAct=EBI-602382, EBI-11752486; CC Q16512; Q8IYX8-2: CEP57L1; NbExp=3; IntAct=EBI-602382, EBI-10181988; CC Q16512; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-602382, EBI-739624; CC Q16512; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-602382, EBI-3867333; CC Q16512; Q9NRI5-2: DISC1; NbExp=3; IntAct=EBI-602382, EBI-11988027; CC Q16512; Q8IW40: DNAAF19; NbExp=3; IntAct=EBI-602382, EBI-10261970; CC Q16512; Q8WWB3: DYDC1; NbExp=3; IntAct=EBI-602382, EBI-740680; CC Q16512; P26641: EEF1G; NbExp=3; IntAct=EBI-602382, EBI-351467; CC Q16512; O00303: EIF3F; NbExp=3; IntAct=EBI-602382, EBI-711990; CC Q16512; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-602382, EBI-618189; CC Q16512; Q08379: GOLGA2; NbExp=6; IntAct=EBI-602382, EBI-618309; CC Q16512; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-602382, EBI-5916454; CC Q16512; P54257: HAP1; NbExp=3; IntAct=EBI-602382, EBI-712814; CC Q16512; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-602382, EBI-2514791; CC Q16512; Q9NSC5: HOMER3; NbExp=7; IntAct=EBI-602382, EBI-748420; CC Q16512; O75031: HSF2BP; NbExp=3; IntAct=EBI-602382, EBI-7116203; CC Q16512; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-602382, EBI-747204; CC Q16512; Q5TA45: INTS11; NbExp=3; IntAct=EBI-602382, EBI-748258; CC Q16512; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-602382, EBI-743960; CC Q16512; Q86T90: KIAA1328; NbExp=3; IntAct=EBI-602382, EBI-3437878; CC Q16512; P19012: KRT15; NbExp=3; IntAct=EBI-602382, EBI-739566; CC Q16512; P08779: KRT16; NbExp=3; IntAct=EBI-602382, EBI-356410; CC Q16512; P08727: KRT19; NbExp=3; IntAct=EBI-602382, EBI-742756; CC Q16512; Q15323: KRT31; NbExp=6; IntAct=EBI-602382, EBI-948001; CC Q16512; O76011: KRT34; NbExp=5; IntAct=EBI-602382, EBI-1047093; CC Q16512; Q92764: KRT35; NbExp=3; IntAct=EBI-602382, EBI-1058674; CC Q16512; O76013-2: KRT36; NbExp=3; IntAct=EBI-602382, EBI-11958506; CC Q16512; O76014: KRT37; NbExp=3; IntAct=EBI-602382, EBI-1045716; CC Q16512; Q9BV99: LRRC61; NbExp=3; IntAct=EBI-602382, EBI-2350424; CC Q16512; Q9NYL2-1: MAP3K20; NbExp=2; IntAct=EBI-602382, EBI-687346; CC Q16512; P53778: MAPK12; NbExp=2; IntAct=EBI-602382, EBI-602406; CC Q16512; O15344: MID1; NbExp=3; IntAct=EBI-602382, EBI-2340316; CC Q16512; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-602382, EBI-10172526; CC Q16512; Q8N108-16: MIER1; NbExp=3; IntAct=EBI-602382, EBI-25830642; CC Q16512; Q8TD10: MIPOL1; NbExp=3; IntAct=EBI-602382, EBI-2548751; CC Q16512; Q13064: MKRN3; NbExp=3; IntAct=EBI-602382, EBI-2340269; CC Q16512; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-602382, EBI-11522433; CC Q16512; P07196: NEFL; NbExp=3; IntAct=EBI-602382, EBI-475646; CC Q16512; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-602382, EBI-79165; CC Q16512; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-602382, EBI-302345; CC Q16512; P78424: POU6F2; NbExp=3; IntAct=EBI-602382, EBI-12029004; CC Q16512; P28070: PSMB4; NbExp=3; IntAct=EBI-602382, EBI-603350; CC Q16512; Q96QF0-7: RAB3IP; NbExp=3; IntAct=EBI-602382, EBI-11984839; CC Q16512; Q9UJW9: SERTAD3; NbExp=3; IntAct=EBI-602382, EBI-748621; CC Q16512; Q9H7B4: SMYD3; NbExp=3; IntAct=EBI-602382, EBI-347919; CC Q16512; Q96R06: SPAG5; NbExp=3; IntAct=EBI-602382, EBI-413317; CC Q16512; Q9Y2D8: SSX2IP; NbExp=3; IntAct=EBI-602382, EBI-2212028; CC Q16512; Q9NZ72: STMN3; NbExp=3; IntAct=EBI-602382, EBI-725557; CC Q16512; O75558: STX11; NbExp=3; IntAct=EBI-602382, EBI-714135; CC Q16512; A1L190: SYCE3; NbExp=3; IntAct=EBI-602382, EBI-10283466; CC Q16512; Q8WTV1: THAP3; NbExp=3; IntAct=EBI-602382, EBI-17438286; CC Q16512; Q13077: TRAF1; NbExp=3; IntAct=EBI-602382, EBI-359224; CC Q16512; Q12933: TRAF2; NbExp=3; IntAct=EBI-602382, EBI-355744; CC Q16512; P14373: TRIM27; NbExp=3; IntAct=EBI-602382, EBI-719493; CC Q16512; Q9BZW7: TSGA10; NbExp=3; IntAct=EBI-602382, EBI-744794; CC Q16512; Q8IWV8-2: UBR2; NbExp=3; IntAct=EBI-602382, EBI-17923957; CC Q16512; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-602382, EBI-739895; CC Q16512; P08670: VIM; NbExp=3; IntAct=EBI-602382, EBI-353844; CC Q16512; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-602382, EBI-11419867; CC Q16512; Q9UNY5: ZNF232; NbExp=3; IntAct=EBI-602382, EBI-749023; CC Q16512; Q96MN9-2: ZNF488; NbExp=3; IntAct=EBI-602382, EBI-25831733; CC Q16512; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-602382, EBI-745520; CC Q16512; Q9UGI0: ZRANB1; NbExp=3; IntAct=EBI-602382, EBI-527853; CC Q16512; A1JU68: yopM; Xeno; NbExp=2; IntAct=EBI-602382, EBI-26365850; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17332740, CC ECO:0000269|PubMed:9478917}. Nucleus {ECO:0000269|PubMed:12514133}. CC Endosome {ECO:0000269|PubMed:9478917}. Cell membrane CC {ECO:0000250|UniProtKB:Q63433}; Peripheral membrane protein CC {ECO:0000250|UniProtKB:Q63433}. Cleavage furrow CC {ECO:0000269|PubMed:17332740}. Midbody {ECO:0000269|PubMed:17332740}. CC Note=Associates with chromatin in a ligand-dependent manner. CC Localization to endosomes is mediated via its interaction with RHOB. CC Association to the cell membrane is dependent on Ser-377 CC phosphorylation. Accumulates during telophase at the cleavage furrow CC and finally concentrates around the midbody in cytokinesis. CC {ECO:0000250|UniProtKB:Q63433, ECO:0000269|PubMed:17332740}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=Q16512-1; Sequence=Displayed; CC Name=2; CC IsoId=Q16512-2; Sequence=VSP_038143; CC Name=3; CC IsoId=Q16512-3; Sequence=VSP_039213, VSP_039214; CC -!- TISSUE SPECIFICITY: Found ubiquitously. Expressed in heart, brain, CC placenta, lung, skeletal muscle, kidney and pancreas. Expressed in CC numerous tumor cell lines, especially in breast tumor cells. CC {ECO:0000269|PubMed:21754995}. CC -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG). CC -!- PTM: Autophosphorylated; preferably on serine. Phosphorylated during CC mitosis. {ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:17332740}. CC -!- PTM: Activated by limited proteolysis with trypsin. {ECO:0000250}. CC -!- PTM: (Microbial infection) In case of infection, polyubiquitinated by CC the bacterial E3 ubiquitin-protein ligase SspH1, leading to its CC proteasomal degradation. {ECO:0000269|PubMed:24248594}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr CC protein kinase family. PKC subfamily. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; D26181; BAA05169.1; -; mRNA. DR EMBL; S75546; AAB33345.1; -; mRNA. DR EMBL; U33053; AAC50209.1; -; mRNA. DR EMBL; AK123007; BAG53845.1; -; mRNA. DR EMBL; AK292130; BAF84819.1; -; mRNA. DR EMBL; AK313886; BAG36611.1; -; mRNA. DR EMBL; AC008569; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC040061; AAH40061.1; -; mRNA. DR EMBL; BC094766; AAH94766.1; -; mRNA. DR CCDS; CCDS42513.1; -. [Q16512-1] DR CCDS; CCDS42514.1; -. [Q16512-2] DR PIR; JC2129; JC2129. DR PIR; S51162; S51162. DR RefSeq; NP_002732.3; NM_002741.3. [Q16512-1] DR RefSeq; NP_998725.1; NM_213560.3. [Q16512-2] DR PDB; 1CXZ; X-ray; 2.20 A; B=13-98. DR PDB; 1URF; NMR; -; A=122-199. DR PDB; 2RMK; NMR; -; B=122-199. DR PDB; 4NKG; X-ray; 2.90 A; B/D=122-199. DR PDB; 4OTD; X-ray; 2.00 A; A=605-942. DR PDB; 4OTG; X-ray; 2.60 A; A=605-942. DR PDB; 4OTH; X-ray; 1.80 A; A=605-942. DR PDB; 4OTI; X-ray; 1.93 A; A=605-942. DR PDBsum; 1CXZ; -. DR PDBsum; 1URF; -. DR PDBsum; 2RMK; -. DR PDBsum; 4NKG; -. DR PDBsum; 4OTD; -. DR PDBsum; 4OTG; -. DR PDBsum; 4OTH; -. DR PDBsum; 4OTI; -. DR AlphaFoldDB; Q16512; -. DR SMR; Q16512; -. DR BioGRID; 111571; 147. DR CORUM; Q16512; -. DR DIP; DIP-34240N; -. DR ELM; Q16512; -. DR FunCoup; Q16512; 2793. DR IntAct; Q16512; 116. DR MINT; Q16512; -. DR STRING; 9606.ENSP00000343325; -. DR BindingDB; Q16512; -. DR ChEMBL; CHEMBL3384; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q16512; -. DR GuidetoPHARMACOLOGY; 1520; -. DR GlyConnect; 1737; 1 N-Linked glycan (1 site). DR GlyCosmos; Q16512; 3 sites, 2 glycans. DR GlyGen; Q16512; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (2 sites). DR iPTMnet; Q16512; -. DR MetOSite; Q16512; -. DR PhosphoSitePlus; Q16512; -. DR BioMuta; PKN1; -. DR DMDM; 259016304; -. DR CPTAC; CPTAC-3003; -. DR jPOST; Q16512; -. DR MassIVE; Q16512; -. DR PaxDb; 9606-ENSP00000343325; -. DR PeptideAtlas; Q16512; -. DR ProteomicsDB; 60877; -. [Q16512-1] DR ProteomicsDB; 60878; -. [Q16512-2] DR ProteomicsDB; 60879; -. [Q16512-3] DR Pumba; Q16512; -. DR Antibodypedia; 1296; 250 antibodies from 36 providers. DR DNASU; 5585; -. DR Ensembl; ENST00000242783.11; ENSP00000242783.7; ENSG00000123143.14. [Q16512-1] DR Ensembl; ENST00000342216.8; ENSP00000343325.4; ENSG00000123143.14. [Q16512-2] DR GeneID; 5585; -. DR KEGG; hsa:5585; -. DR MANE-Select; ENST00000242783.11; ENSP00000242783.7; NM_002741.5; NP_002732.3. DR UCSC; uc002myp.4; human. [Q16512-1] DR AGR; HGNC:9405; -. DR ClinPGx; PA33769; -. DR CTD; 5585; -. DR DisGeNET; 5585; -. DR GeneCards; PKN1; -. DR HGNC; HGNC:9405; PKN1. DR HPA; ENSG00000123143; Low tissue specificity. DR MalaCards; PKN1; -. DR MIM; 601032; gene. DR OpenTargets; ENSG00000123143; -. DR VEuPathDB; HostDB:ENSG00000123143; -. DR eggNOG; KOG0694; Eukaryota. DR GeneTree; ENSGT00940000154990; -. DR HOGENOM; CLU_000288_132_1_1; -. DR InParanoid; Q16512; -. DR OMA; CTELRIE; -. DR OrthoDB; 63267at2759; -. DR PAN-GO; Q16512; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q16512; -. DR BRENDA; 2.7.11.13; 2681. DR PathwayCommons; Q16512; -. DR Reactome; R-HSA-5625740; RHO GTPases activate PKNs. DR Reactome; R-HSA-5625886; Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. DR Reactome; R-HSA-8980692; RHOA GTPase cycle. DR Reactome; R-HSA-9013026; RHOB GTPase cycle. DR Reactome; R-HSA-9013106; RHOC GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR SABIO-RK; Q16512; -. DR SignaLink; Q16512; -. DR SIGNOR; Q16512; -. DR Agora; ENSG00000123143; -. DR BioGRID-ORCS; 5585; 15 hits in 1195 CRISPR screens. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; PKN1; human. DR EvolutionaryTrace; Q16512; -. DR GeneWiki; Protein_kinase_N1; -. DR GenomeRNAi; 5585; -. DR Pharos; Q16512; Tchem. DR PRO; PR:Q16512; -. DR Proteomes; UP000005640; Chromosome 19. DR RNAct; Q16512; protein. DR Bgee; ENSG00000123143; Expressed in apex of heart and 142 other cell types or tissues. DR ExpressionAtlas; Q16512; baseline and differential. DR GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005768; C:endosome; IDA:UniProtKB. DR GO; GO:0030496; C:midbody; IDA:UniProtKB. DR GO; GO:0005654; C:nucleoplasm; TAS:Reactome. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0032991; C:protein-containing complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0003682; F:chromatin binding; IDA:UniProtKB. DR GO; GO:0004697; F:diacylglycerol-dependent serine/threonine kinase activity; EXP:Reactome. DR GO; GO:0042393; F:histone binding; IDA:UniProtKB. DR GO; GO:0042826; F:histone deacetylase binding; IDA:UniProtKB. DR GO; GO:0035402; F:histone H3T11 kinase activity; IDA:UniProtKB. DR GO; GO:0050681; F:nuclear androgen receptor binding; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; TAS:ProtInc. DR GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB. DR GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB. DR GO; GO:0001783; P:B cell apoptotic process; IEA:Ensembl. DR GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl. DR GO; GO:0010631; P:epithelial cell migration; IMP:UniProtKB. DR GO; GO:0006972; P:hyperosmotic response; IEA:Ensembl. DR GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central. DR GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl. DR GO; GO:0043687; P:post-translational protein modification; IDA:UniProtKB. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0060765; P:regulation of androgen receptor signaling pathway; TAS:Reactome. DR GO; GO:2000145; P:regulation of cell motility; IMP:UniProtKB. DR GO; GO:0002634; P:regulation of germinal center formation; IEA:Ensembl. DR GO; GO:0002637; P:regulation of immunoglobulin production; IEA:Ensembl. DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB. DR GO; GO:0003014; P:renal system process; IEA:Ensembl. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0048536; P:spleen development; IEA:Ensembl. DR CDD; cd08687; C2_PKN-like; 1. DR CDD; cd11630; HR1_PKN1_2; 1. DR CDD; cd11636; HR1_PKN1_3; 1. DR CDD; cd11622; HR1_PKN_1; 1. DR CDD; cd05589; STKc_PKN; 1. DR FunFam; 1.10.287.160:FF:000001; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.287.160:FF:000002; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.287.160:FF:000003; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 3.30.200.20:FF:000058; Putative serine/threonine-protein kinase N2; 1. DR FunFam; 1.10.510.10:FF:000038; serine/threonine-protein kinase N2 isoform X1; 1. DR Gene3D; 1.10.287.160; HR1 repeat; 3. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00416; -. DR InterPro; IPR000961; AGC-kinase_C. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR037784; C2_PKN. DR InterPro; IPR011072; HR1_rho-bd. DR InterPro; IPR036274; HR1_rpt_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR017892; Pkinase_C. DR InterPro; IPR037317; PKN1_HR1_2. DR InterPro; IPR037313; PKN_HR1_1. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1. DR Pfam; PF02185; HR1; 3. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF00433; Pkinase_C; 1. DR SMART; SM00742; Hr1; 3. DR SMART; SM00133; S_TK_X; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF46585; HR1 repeat; 3. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS51285; AGC_KINASE_CTER; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1. DR PROSITE; PS51860; REM_1; 3. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative splicing; ATP-binding; KW Cell membrane; Chromatin regulator; Coiled coil; Cytoplasm; Endosome; KW Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; KW Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transcription; Transcription regulation; KW Transferase; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT CHAIN 2..942 FT /note="Serine/threonine-protein kinase N1" FT /id="PRO_0000055719" FT DOMAIN 25..100 FT /note="REM-1 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 112..193 FT /note="REM-1 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 201..280 FT /note="REM-1 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01207" FT DOMAIN 307..470 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT DOMAIN 615..874 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 875..942 FT /note="AGC-kinase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00618" FT REGION 102..121 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 181..185 FT /note="Important for interaction with bacterial SspH1 and FT SspH1-mediated polyubiquitination" FT /evidence="ECO:0000269|PubMed:24248594" FT REGION 341..363 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 553..603 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 581..596 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 740 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10027" FT BINDING 621..629 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 644 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 108..109 FT /note="Cleavage; by caspase-3" FT SITE 454..455 FT /note="Cleavage; by caspase-3" FT SITE 558..559 FT /note="Cleavage; by caspase-3" FT MOD_RES 2 FT /note="N-acetylalanine" FT /evidence="ECO:0007744|PubMed:19413330, FT ECO:0007744|PubMed:22814378" FT MOD_RES 69 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 205 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18691976, FT ECO:0007744|PubMed:19690332" FT MOD_RES 374 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63433" FT MOD_RES 448 FT /note="N6-acetyllysine" FT /evidence="ECO:0007744|PubMed:19608861" FT MOD_RES 533 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 537 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163" FT MOD_RES 540 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 559 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 562 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332, FT ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT MOD_RES 608 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 774 FT /note="Phosphothreonine; by PDPK1" FT /evidence="ECO:0000269|PubMed:10792047" FT MOD_RES 778 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:18220336" FT MOD_RES 914 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:19690332" FT MOD_RES 916 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT VAR_SEQ 1..7 FT /note="MASDAVQ -> MAEANNPSEQELE (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_038143" FT VAR_SEQ 603 FT /note="S -> R (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_039213" FT VAR_SEQ 604..942 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_039214" FT VARIANT 185 FT /note="R -> C (in a metastatic melanoma sample; somatic FT mutation; dbSNP:rs267605306)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042337" FT VARIANT 197 FT /note="A -> E (in dbSNP:rs1287763348)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042338" FT VARIANT 436 FT /note="R -> W (in dbSNP:rs35132656)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042339" FT VARIANT 520 FT /note="R -> Q (in dbSNP:rs56273055)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042340" FT VARIANT 555 FT /note="L -> I (in dbSNP:rs34309238)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:17344846" FT /id="VAR_042341" FT VARIANT 635 FT /note="R -> Q (in dbSNP:rs35416389)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042342" FT VARIANT 718 FT /note="I -> V (in dbSNP:rs2230539)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7988719" FT /id="VAR_042343" FT VARIANT 873 FT /note="F -> L (in a breast infiltrating ductal carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042344" FT VARIANT 901 FT /note="V -> I (in dbSNP:rs10846)" FT /evidence="ECO:0000269|PubMed:14702039, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846" FT /id="VAR_014937" FT VARIANT 921 FT /note="A -> V (in a colorectal adenocarcinoma sample; FT somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_042345" FT MUTAGEN 108 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF1 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 181 FT /note="R->A: Abolishes interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 181 FT /note="R->K: Decreases interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 185 FT /note="R->A: Abolishes interaction with bacterial SspH1." FT /evidence="ECO:0000269|PubMed:24248594" FT MUTAGEN 451 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of 70 kDa fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 454 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of 70 kDa fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 558 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF3 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 560 FT /note="D->A: Abolishes cleavage by caspase-3 and formation FT of AF3 fragment." FT /evidence="ECO:0000269|PubMed:9751706" FT MUTAGEN 644 FT /note="K->E: Abolishes Serine/threonine-protein kinase FT activity." FT /evidence="ECO:0000269|PubMed:18066052, FT ECO:0000269|PubMed:8135837" FT MUTAGEN 644 FT /note="K->R: Substantial reduction of autophosphorylation." FT /evidence="ECO:0000269|PubMed:18066052, FT ECO:0000269|PubMed:8135837" FT CONFLICT 191 FT /note="G -> D (in Ref. 2; AAB33345/AAC50209)" FT /evidence="ECO:0000305" FT CONFLICT 562 FT /note="S -> P (in Ref. 3; BAG36611)" FT /evidence="ECO:0000305" FT CONFLICT 736 FT /note="I -> T (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="T -> A (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 800 FT /note="G -> A (in Ref. 6; no nucleotide entry)" FT /evidence="ECO:0000305" FT CONFLICT 812 FT /note="E -> G (in Ref. 3; BAG36611)" FT /evidence="ECO:0000305" FT CONFLICT 887 FT /note="L -> P (in Ref. 3; BAG53845)" FT /evidence="ECO:0000305" FT HELIX 15..18 FT /evidence="ECO:0007829|PDB:1CXZ" FT HELIX 29..66 FT /evidence="ECO:0007829|PDB:1CXZ" FT HELIX 71..95 FT /evidence="ECO:0007829|PDB:1CXZ" FT TURN 122..124 FT /evidence="ECO:0007829|PDB:1URF" FT HELIX 126..151 FT /evidence="ECO:0007829|PDB:4NKG" FT TURN 157..159 FT /evidence="ECO:0007829|PDB:4NKG" FT HELIX 160..187 FT /evidence="ECO:0007829|PDB:4NKG" FT STRAND 194..196 FT /evidence="ECO:0007829|PDB:2RMK" FT HELIX 612..614 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 615..624 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 627..634 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 635..637 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 640..647 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 648..653 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 657..671 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 672..674 FT /evidence="ECO:0007829|PDB:4OTG" FT STRAND 681..686 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 688..696 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 700..702 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 703..706 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 707..709 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 714..733 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 743..745 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 746..748 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 750..752 FT /evidence="ECO:0007829|PDB:4OTG" FT STRAND 754..756 FT /evidence="ECO:0007829|PDB:4OTH" FT STRAND 763..765 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 779..781 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 784..788 FT /evidence="ECO:0007829|PDB:4OTD" FT HELIX 794..810 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 820..829 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 840..849 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 854..856 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 862..864 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 865..869 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 872..874 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 879..883 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 906..909 FT /evidence="ECO:0007829|PDB:4OTH" FT HELIX 926..930 FT /evidence="ECO:0007829|PDB:4OTH" FT TURN 931..934 FT /evidence="ECO:0007829|PDB:4OTH" SQ SEQUENCE 942 AA; 103932 MW; 61360295EC70BB8E CRC64; MASDAVQSEP RSWSLLEQLG LAGADLAAPG VQQQLELERE RLRREIRKEL KLKEGAENLR RATTDLGRSL GPVELLLRGS SRRLDLLHQQ LQELHAHVVL PDPAATHDGP QSPGAGGPTC SATNLSRVAG LEKQLAIELK VKQGAENMIQ TYSNGSTKDR KLLLTAQQML QDSKTKIDII RMQLRRALQA GQLENQAAPD DTQGSPDLGA VELRIEELRH HFRVEHAVAE GAKNVLRLLS AAKAPDRKAV SEAQEKLTES NQKLGLLREA LERRLGELPA DHPKGRLLRE ELAAASSAAF STRLAGPFPA THYSTLCKPA PLTGTLEVRV VGCRDLPETI PWNPTPSMGG PGTPDSRPPF LSRPARGLYS RSGSLSGRSS LKAEAENTSE VSTVLKLDNT VVGQTSWKPC GPNAWDQSFT LELERARELE LAVFWRDQRG LCALKFLKLE DFLDNERHEV QLDMEPQGCL VAEVTFRNPV IERIPRLRRQ KKIFSKQQGK AFQRARQMNI DVATWVRLLR RLIPNATGTG TFSPGASPGS EARTTGDISV EKLNLGTDSD SSPQKSSRDP PSSPSSLSSP IQESTAPELP SETQETPGPA LCSPLRKSPL TLEDFKFLAV LGRGHFGKVL LSEFRPSGEL FAIKALKKGD IVARDEVESL MCEKRILAAV TSAGHPFLVN LFGCFQTPEH VCFVMEYSAG GDLMLHIHSD VFSEPRAIFY SACVVLGLQF LHEHKIVYRD LKLDNLLLDT EGYVKIADFG LCKEGMGYGD RTSTFCGTPE FLAPEVLTDT SYTRAVDWWG LGVLLYEMLV GESPFPGDDE EEVFDSIVND EVRYPRFLSA EAIGIMRRLL RRNPERRLGS SERDAEDVKK QPFFRTLGWE ALLARRLPPP FVPTLSGRTD VSNFDEEFTG EAPTLSPPRD ARPLTAAEQA AFLDFDFVAG GC // ID PTEN_HUMAN Reviewed; 403 AA. AC P60484; B2R904; F2YHV0; O00633; O02679; Q6ICT7; DT 16-FEB-2004, integrated into UniProtKB/Swiss-Prot. DT 16-FEB-2004, sequence version 1. DT 28-JAN-2026, entry version 224. DE RecName: Full=Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN {ECO:0000305|PubMed:9256433, ECO:0000305|PubMed:9811831}; DE EC=3.1.3.16 {ECO:0000269|PubMed:9256433}; DE EC=3.1.3.48 {ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433}; DE EC=3.1.3.67 {ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; DE AltName: Full=Inositol polyphosphate 3-phosphatase {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE EC=3.1.3.- {ECO:0000305|PubMed:11418101, ECO:0000305|PubMed:9593664}; DE AltName: Full=Mutated in multiple advanced cancers 1; DE AltName: Full=Phosphatase and tensin homolog; GN Name=PTEN; Synonyms=MMAC1, TEP1; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, RP SUBCELLULAR LOCATION, AND INDUCTION. RC TISSUE=Epithelium; RX PubMed=9187108; RA Li D.M., Sun H.; RT "TEP1, encoded by a candidate tumor suppressor locus, is a novel protein RT tyrosine phosphatase regulated by transforming growth factor beta."; RL Cancer Res. 57:2124-2129(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS RP GLIOMA SER-15; GLU-36; ARG-42; TRP-57 AND THR-319 DEL. RX PubMed=9090379; DOI=10.1038/ng0497-356; RA Steck P.A., Pershouse M.A., Jasser S.A., Lin H., Yung W.K.A., Ligon A.H., RA Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., RA Swedlund B., Teng D.H.-F., Tavtigian S.V.; RT "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome RT 10q23.3 that is mutated in multiple advanced cancers."; RL Nat. Genet. 15:356-363(1997). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT GLIOBLASTOMA ARG-129, AND RP VARIANT PROSTATE CANCER LEU-134. RX PubMed=9072974; DOI=10.1126/science.275.5308.1943; RA Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., RA Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., RA Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R.; RT "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, RT breast, and prostate cancer."; RL Science 275:1943-1947(1997). RN [4] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RX PubMed=10817502; DOI=10.1054/bjoc.2000.1211; RA Hamilton J.A., Stewart L.M.D., Ajayi L., Gray I.C., Gray N.E., RA Roberts K.G., Watson G.J., Kaisary A.V., Snary D.; RT "The expression profile for the tumour suppressor gene PTEN and associated RT polymorphic markers."; RL Br. J. Cancer 82:1671-1676(2000). RN [5] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Wang S., Li J., Liaw D., Bose S., Podsypanina K., Parsons R.; RL Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA]. RA Jensen K., de la Bastide M., Parsons R., Parnell L.D., Dedhia N., RA Gottesman T., Gnoj L., Kaplan N., Lodhi M., Johnson A.F., Shohdy N., RA Hasegawa A., Haberman K., Huang E.N., Schutz K., Calma C., Granat S., RA Wigler M.H., McCombie W.R.; RT "Genomic sequence of PTEN/MMAC1."; RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases. RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). RA Yang C.-W., Hsu Y.-F.; RT "Homo sapiens phosphatase and tensin homolog mRNA splicing variants."; RL Submitted (JAN-2011) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases. RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [10] RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-290. RG NIEHS SNPs program; RL Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases. RN [11] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. RN [12] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RC TISSUE=Lung; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [13] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANTS GLIOMA RP TRP-57; ENDOMETRIAL CANCER TYR-123; GLIOBLASTOMA ARG-129; CWS1 ARG-129; RP PROSTATE CANCER LEU-134; GLIOBLASTOMA ARG-165; BREAST CANCER PRO-167 AND BZ RP ARG-170. RX PubMed=9256433; DOI=10.1073/pnas.94.17.9052; RA Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., RA Parsons R., Tonks N.K.; RT "P-TEN, the tumor suppressor from human chromosome 10q23, is a dual- RT specificity phosphatase."; RL Proc. Natl. Acad. Sci. U.S.A. 94:9052-9057(1997). RN [14] RP FUNCTION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT CWS1 SER-124. RX PubMed=9593664; DOI=10.1074/jbc.273.22.13375; RA Maehama T., Dixon J.E.; RT "The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second RT messenger, phosphatidylinositol 3,4,5-trisphosphate."; RL J. Biol. Chem. 273:13375-13378(1998). RN [15] RP FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF ARG-130, AND CHARACTERIZATION RP OF VARIANTS CWS1 SER-124 AND CWS1 GLU-129. RX PubMed=9811831; DOI=10.1073/pnas.95.23.13513; RA Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., RA Hemmings B.A., Wigler M.H., Downes C.P., Tonks N.K.; RT "The lipid phosphatase activity of PTEN is critical for its tumor RT suppressor function."; RL Proc. Natl. Acad. Sci. U.S.A. 95:13513-13518(1998). RN [16] RP FUNCTION, MUTAGENESIS OF ASP-92 AND CYS-124, AND CHARACTERIZATION OF RP VARIANT GLU-129. RX PubMed=9616126; DOI=10.1126/science.280.5369.1614; RA Tamura M., Gu J., Matsumoto K., Aota S., Parsons R., Yamada K.M.; RT "Inhibition of cell migration, spreading, and focal adhesions by tumor RT suppressor PTEN."; RL Science 280:1614-1617(1998). RN [17] RP FUNCTION, DOMAIN, AND CHARACTERIZATION OF VARIANTS THR-319 DEL; GLN-345 AND RP ILE-348. RX PubMed=10468583; DOI=10.1073/pnas.96.18.10182; RA Georgescu M.-M., Kirsch K.H., Akagi T., Shishido T., Hanafusa H.; RT "The tumor-suppressor activity of PTEN is regulated by its carboxyl- RT terminal region."; RL Proc. Natl. Acad. Sci. U.S.A. 96:10182-10187(1999). RN [18] RP INTERACTION WITH DLG1 AND MAST2, AND PHOSPHORYLATION AT THR-401. RX PubMed=10646847; RA Adey N.B., Huang L., Ormonde P.A., Baumgard M.L., Pero R., Byreddy D.V., RA Tavtigian S.V., Bartel P.L.; RT "Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both RT inhibits and stimulates PDZ binding."; RL Cancer Res. 60:35-37(2000). RN [19] RP INTERACTION WITH MAGI3. RX PubMed=10748157; DOI=10.1074/jbc.m909741199; RA Wu Y., Dowbenko D., Spencer S., Laura R., Lee J., Gu Q., Lasky L.A.; RT "Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, RT a novel membrane-associated guanylate kinase."; RL J. Biol. Chem. 275:21477-21485(2000). RN [20] RP INTERACTION WITH MAGI2. RX PubMed=10760291; DOI=10.1073/pnas.97.8.4233; RA Wu X., Hepner K., Castelino-Prabhu S., Do D., Kaye M.B., Yuan X.-J., RA Wood J., Ross C., Sawyers C.L., Whang Y.E.; RT "Evidence for regulation of the PTEN tumor suppressor by a membrane- RT localized multi-PDZ domain containing scaffold protein MAGI-2."; RL Proc. Natl. Acad. Sci. U.S.A. 97:4233-4238(2000). RN [21] RP FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES. RX PubMed=11418101; DOI=10.1016/s0014-5793(01)02500-5; RA Caffrey J.J., Darden T., Wenk M.R., Shears S.B.; RT "Expanding coincident signaling by PTEN through its inositol 1,3,4,5,6- RT pentakisphosphate 3-phosphatase activity."; RL FEBS Lett. 499:6-10(2001). RN [22] RP PHOSPHORYLATION AT SER-370; SER-380; THR-382; THR-383 AND SER-385. RX PubMed=11035045; DOI=10.1074/jbc.m009134200; RA Torres J., Pulido R.; RT "The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at RT its C terminus. Implications for PTEN stability to proteasome-mediated RT degradation."; RL J. Biol. Chem. 276:993-998(2001). RN [23] RP FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH MAGI2. RX PubMed=11707428; DOI=10.1074/jbc.c100556200; RA Vazquez F., Grossman S.R., Takahashi Y., Rokas M.V., Nakamura N., RA Sellers W.R.; RT "Phosphorylation of the PTEN tail acts as an inhibitory switch by RT preventing its recruitment into a protein complex."; RL J. Biol. Chem. 276:48627-48630(2001). RN [24] RP PHOSPHORYLATION AT THR-366; SER-370 AND SER-385. RX PubMed=12297295; DOI=10.1016/s0014-5793(02)03274-x; RA Miller S., Lou D., Seldin D., Lane W., Neel B.; RT "Direct identification of PTEN phosphorylation sites."; RL FEBS Lett. 528:145-153(2002). RN [25] RP INTERACTION WITH NOP53, REGION, AND CHARACTERIZATION OF VARIANTS CWS1 RP VAL-341; GLU-343 AND GLN-345. RX PubMed=15355975; DOI=10.1074/jbc.c400377200; RA Okahara F., Ikawa H., Kanaho Y., Maehama T.; RT "Regulation of PTEN phosphorylation and stability by a tumor suppressor RT candidate protein."; RL J. Biol. Chem. 279:45300-45303(2004). RN [26] RP INTERACTION WITH STK11, SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY STK11. RX PubMed=15987703; DOI=10.1093/hmg/ddi225; RA Mehenni H., Lin-Marq N., Buchet-Poyau K., Reymond A., Collart M.A., RA Picard D., Antonarakis S.E.; RT "LKB1 interacts with and phosphorylates PTEN: a functional link between two RT proteins involved in cancer predisposing syndromes."; RL Hum. Mol. Genet. 14:2209-2219(2005). RN [27] RP INTERACTION WITH MAGI2; MAGI3; MAST1; MAST2 AND MAST3, MUTAGENESIS OF RP VAL-403, AND PHOSPHORYLATION. RX PubMed=15951562; DOI=10.1074/jbc.m504761200; RA Valiente M., Andres-Pons A., Gomar B., Torres J., Gil A., Tapparel C., RA Antonarakis S.E., Pulido R.; RT "Binding of PTEN to specific PDZ domains contributes to PTEN protein RT stability and phosphorylation by microtubule-associated serine/threonine RT kinases."; RL J. Biol. Chem. 280:28936-28943(2005). RN [28] RP FUNCTION. RX PubMed=15979280; DOI=10.1016/j.cellsig.2005.05.017; RA Deleu S., Choi K., Pesesse X., Cho J., Sulis M.L., Parsons R., Shears S.B.; RT "Physiological levels of PTEN control the size of the cellular RT Ins(1,3,4,5,6)P(5) pool."; RL Cell. Signal. 18:488-498(2006). RN [29] RP CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND FUNCTION. RX PubMed=16824732; DOI=10.1016/j.cellsig.2006.05.010; RA Vandeput F., Backers K., Villeret V., Pesesse X., Erneux C.; RT "The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5- RT trisphosphate 5-phosphatase activity."; RL Cell. Signal. 18:2193-2199(2006). RN [30] RP INTERACTION WITH NEDD4. RX PubMed=17218260; DOI=10.1016/j.cell.2006.11.039; RA Wang X., Trotman L.C., Koppie T., Alimonti A., Chen Z., Gao Z., Wang J., RA Erdjument-Bromage H., Tempst P., Cordon-Cardo C., Pandolfi P.P., Jiang X.; RT "NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN."; RL Cell 128:129-139(2007). RN [31] RP FUNCTION, INTERACTION WITH USP7, UBIQUITINATION AT LYS-13 AND LYS-289, RP DEUBIQUITINATION BY USP7, SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-13 AND RP LYS-289, AND CHARACTERIZATION OF VARIANT CWS1 GLU-289. RX PubMed=18716620; DOI=10.1038/nature07290; RA Song M.S., Salmena L., Carracedo A., Egia A., Lo-Coco F., RA Teruya-Feldstein J., Pandolfi P.P.; RT "The deubiquitinylation and localization of PTEN are regulated by a HAUSP- RT PML network."; RL Nature 455:813-817(2008). RN [32] RP INTERACTION WITH FRK, PHOSPHORYLATION AT TYR-336, AND MUTAGENESIS OF RP TYR-336. RX PubMed=19345329; DOI=10.1016/j.ccr.2009.02.012; RA Yim E.-K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B., RA Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.-Y.; RT "Rak functions as a tumor suppressor by regulating PTEN protein stability RT and function."; RL Cancer Cell 15:304-314(2009). RN [33] RP UBIQUITINATION BY XIAP/BIRC4, SUBCELLULAR LOCATION, AND INTERACTION WITH RP XIAP/BIRC4. RX PubMed=19473982; DOI=10.1074/jbc.c109.009522; RA Van Themsche C., Leblanc V., Parent S., Asselin E.; RT "X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN RT ubiquitination, content, and compartmentalization."; RL J. Biol. Chem. 284:20462-20466(2009). RN [34] RP PHOSPHORYLATION AT THR-366 AND SER-370, AND MUTAGENESIS OF THR-366 AND RP SER-370. RX PubMed=20940307; DOI=10.1074/jbc.m110.166462; RA Xu D., Yao Y., Jiang X., Lu L., Dai W.; RT "Regulation of PTEN stability and activity by Plk3."; RL J. Biol. Chem. 285:39935-39942(2010). RN [35] RP INTERACTION WITH NDFIP1 AND NDFIP2. RX PubMed=20534535; DOI=10.1073/pnas.0911714107; RA Mund T., Pelham H.R.; RT "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin RT ligase activators Ndfip1 and Ndfip2."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010). RN [36] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [37] RP FUNCTION IN CELL MIGRATION. RX PubMed=22279049; DOI=10.1101/gad.177642.111; RA Stohr N., Kohn M., Lederer M., Glass M., Reinke C., Singer R.H., RA Huttelmaier S.; RT "IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling."; RL Genes Dev. 26:176-189(2012). RN [38] RP ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=22814378; DOI=10.1073/pnas.1210303109; RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.; RT "N-terminal acetylome analyses and functional insights of the N-terminal RT acetyltransferase NatB."; RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012). RN [39] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, FUNCTION (ISOFORM RP ALPHA), AND SUBCELLULAR LOCATION (ISOFORM ALPHA). RX PubMed=23744781; DOI=10.1126/science.1234907; RA Hopkins B.D., Fine B., Steinbach N., Dendy M., Rapp Z., Shaw J., Pappas K., RA Yu J.S., Hodakoski C., Mense S., Klein J., Pegno S., Sulis M.L., RA Goldstein H., Amendolara B., Lei L., Maurer M., Bruce J., Canoll P., RA Hibshoosh H., Parsons R.; RT "A secreted PTEN phosphatase that enters cells to alter signaling and RT survival."; RL Science 341:399-402(2013). RN [40] RP INTERACTION WITH PPP1R16B. RX PubMed=25007873; DOI=10.1152/ajprenal.00070.2014; RA Obeidat M., Li L., Ballermann B.J.; RT "TIMAP promotes angiogenesis by suppressing PTEN-mediated Akt inhibition in RT human glomerular endothelial cells."; RL Am. J. Physiol. 307:F623-F633(2014). RN [41] RP ALTERNATIVE INITIATION (ISOFORM ALPHA), CTG START CODON, SUBCELLULAR RP LOCATION (ISOFORM ALPHA), AND MUTAGENESIS OF MET-1. RX PubMed=24768297; DOI=10.1016/j.cmet.2014.03.023; RA Liang H., He S., Yang J., Jia X., Wang P., Chen X., Zhang Z., Zou X., RA McNutt M.A., Shen W.H., Yin Y.; RT "PTENalpha, a PTEN isoform translated through alternative initiation, RT regulates mitochondrial function and energy metabolism."; RL Cell Metab. 19:836-848(2014). RN [42] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-366, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [43] RP INTERACTION WITH NDFIP1, AND SUBCELLULAR LOCATION. RX PubMed=25801959; DOI=10.1093/jmcb/mjv020; RA Howitt J., Low L.H., Putz U., Doan A., Lackovic J., Goh C.P., Gunnersen J., RA Silke J., Tan S.S.; RT "Ndfip1 represses cell proliferation by controlling Pten localization and RT signaling specificity."; RL J. Mol. Cell Biol. 7:119-131(2015). RN [44] RP FUNCTION, INTERACTION WITH TNS3 AND PI3K, PHOSPHORYLATION AT THR-319 AND RP THR-321, AND MUTAGENESIS OF SER-229; THR-232; THR-319 AND THR-321. RX PubMed=26166433; DOI=10.1038/ncomms8721; RA Cao X., Kaneko T., Li J.S., Liu A.D., Voss C., Li S.S.; RT "A phosphorylation switch controls the spatiotemporal activation of Rho RT GTPases in directional cell migration."; RL Nat. Commun. 6:7721-7721(2015). RN [45] RP FUNCTION, AND UBIQUITINATION. RX PubMed=31492966; DOI=10.1007/s00018-019-03280-5; RA Zhang J., Zhang Y.L., Zhao L.W., Pi S.B., Zhang S.Y., Tong C., Fan H.Y.; RT "The CRL4-DCAF13 ubiquitin E3 ligase supports oocyte meiotic resumption by RT targeting PTEN degradation."; RL Cell. Mol. Life Sci. 77:2181-2197(2020). RN [46] RP FUNCTION, AND ISGYLATION. RX PubMed=37279284; DOI=10.1126/scisignal.abm1756; RA Du X., Sheng J., Chen Y., He S., Yang Y., Huang Y., Fu Y., Lie L., Han Z., RA Zhu B., Liu H., Wen Q., Zhou X., Zhou C., Hu S., Ma L.; RT "The E3 ligase HERC5 promotes antimycobacterial responses in macrophages by RT ISGylating the phosphatase PTEN."; RL Sci. Signal. 16:eabm1756-eabm1756(2023). RN [47] RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 8-353 IN COMPLEX WITH RP L(+)-TARTRATE, SUBUNIT, DOMAIN, MUTAGENESIS OF ASP-92; HIS-93; LYS-125; RP LYS-128; THR-167; GLN-171; 263-LYS--ALA-269 AND 327-LYS--ALA-335, AND RP CATALYTIC ACTIVITY. RX PubMed=10555148; DOI=10.1016/s0092-8674(00)81663-3; RA Lee J.-O., Yang H., Georgescu M.-M., Di Cristofano A., Maehama T., Shi Y., RA Dixon J.E., Pandolfi P., Pavletich N.P.; RT "Crystal structure of the PTEN tumor suppressor: implications for its RT phosphoinositide phosphatase activity and membrane association."; RL Cell 99:323-334(1999). RN [48] RP VARIANT CWS1 ASN-137 INS. RX PubMed=9345101; DOI=10.1086/301607; RA Tsou H.C., Teng D.H.-F., Ping X.L., Brancolini V., Davis T., Hu R., RA Xie X.X., Gruener A.C., Schrager C.A., Christiano A.M., Eng C., Steck P., RA Ott J., Tavtigian S.V., Peacocke M.; RT "The role of MMAC1 mutations in early-onset breast cancer: causative in RT association with Cowden syndrome and excluded in BRCA1-negative cases."; RL Am. J. Hum. Genet. 61:1036-1043(1997). RN [49] RP VARIANTS CWS1 GLU-343 AND LEU-347. RX PubMed=9399897; DOI=10.1086/301639; RA Lynch E.D., Ostermeyer E.A., Lee M.K., Arena J.F., Ji H., Dann J., RA Swisshelm K., Suchard D., MacLeod P.M., Kvinnsland S., Gjertsen B.T., RA Heimdal K., Lubs H., Moeller P., King M.-C.; RT "Inherited mutations in PTEN that are associated with breast cancer, Cowden RT disease, and juvenile polyposis."; RL Am. J. Hum. Genet. 61:1254-1260(1997). RN [50] RP VARIANTS GLIOBLASTOMA TYR-107; PRO-121; ARG-129; ARG-165 AND GLN-345. RX PubMed=9331071; RA Wang S.I., Puc J., Li J., Bruce J.N., Cairns P., Sidransky D., Parsons R.; RT "Somatic mutations of PTEN in glioblastoma multiforme."; RL Cancer Res. 57:4183-4186(1997). RN [51] RP VARIANTS CWS1 ARG-123 AND ARG-124. RX PubMed=9259288; DOI=10.1093/hmg/6.8.1383; RA Nelen M.R., van Staveren W.C.G., Peeters E.A.J., Ben-Hassel M., RA Gorlin R.J., Hamm H., Lindboe C.F., Fryns J.-P., Sijmons R.H., Woods D.G., RA Mariman E.C.M., Padberg G.W., Kremer H.; RT "Germline mutations in the PTEN/MMAC1 gene in patients with Cowden RT disease."; RL Hum. Mol. Genet. 6:1383-1387(1997). RN [52] RP VARIANT CWS1 GLU-129. RX PubMed=9140396; DOI=10.1038/ng0597-64; RA Liaw D., Marsh D.J., Li J., Dahia P.L.M., Wang S.I., Zheng Z., Bose S., RA Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R.; RT "Germline mutations of the PTEN gene in Cowden disease, an inherited breast RT and thyroid cancer syndrome."; RL Nat. Genet. 16:64-67(1997). RN [53] RP VARIANT CWS1 ARG-170. RX PubMed=9241266; DOI=10.1038/ng0897-333; RA Marsh D.J., Dahia P.L.M., Zheng Z., Liaw D., Parsons R., Gorlin R.J., RA Eng C.; RT "Germline mutations in PTEN are present in Bannayan-Zonana syndrome."; RL Nat. Genet. 16:333-334(1997). RN [54] RP VARIANTS ENDOMETRIAL HYPERPLASIA ARG-36; LEU-130; CYS-173; ALA-191 AND RP ILE-348. RX PubMed=9635567; RA Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C., RA Berchuck A., Futreal P.A.; RT "Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias."; RL Cancer Res. 58:2500-2503(1998). RN [55] RP VARIANT CWS1 GLU-289. RX PubMed=9797362; DOI=10.1016/s0016-5085(98)70078-2; RA Chi S.-G., Kim H.-J., Park B.-J., Min H.-J., Park J.-H., Kim Y.-W., RA Dong S.-H., Kim B.-H., Lee J.-I., Chang Y.-W., Chang R., Kim W.-K., RA Yang M.-H.; RT "Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in RT patients with Cowden disease."; RL Gastroenterology 115:1084-1089(1998). RN [56] RP VARIANTS CWS1 HIS-68 AND PRO-112. RX PubMed=9600246; DOI=10.1007/s004390050723; RA Tsou H.C., Ping X.L., Xie X.X., Gruener A.C., Zhang H., Nini R., RA Swisshelm K., Sybert V., Diamond T.M., Sutphen R., Peacocke M.; RT "The genetic basis of Cowden's syndrome: three novel mutations in RT PTEN/MMAC1/TEP1."; RL Hum. Genet. 102:467-473(1998). RN [57] RP VARIANTS CWS1 ARG-67 AND VAL-165. RX PubMed=9467011; DOI=10.1093/hmg/7.3.507; RA Marsh D.J., Coulon V., Lunetta K.L., Rocca-Serra P., Dahia P.L.M., RA Zheng Z., Liaw D., Caron S., Duboue B., Lin A.Y., Richardson A.-L., RA Bonnetblanc J.-M., Bressieux J.-M., Cabarrot-Moreau A., Chompret A., RA Demange L., Eeles R.A., Yahanda A.M., Fearon E.R., Fricker J.-P., RA Gorlin R.J., Hodgson S.V., Huson S., Lacombe D., Leprat F., Odent S., RA Toulouse C., Olopade O.I., Sobol H., Tishler S., Woods C.G., Robinson B.G., RA Weber H.C., Parsons R., Peacocke M., Longy M., Eng C.; RT "Mutation spectrum and genotype-phenotype analyses in Cowden disease and RT Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN RT mutation."; RL Hum. Mol. Genet. 7:507-515(1998). RN [58] RP VARIANT CWS1 TYR-136. RX PubMed=9735393; DOI=10.3892/ijo.13.4.665; RA Scala S., Bruni P., Lo Muzio L., Mignogna M., Viglietto G., Fusco A.; RT "Novel mutation of the PTEN gene in an Italian Cowden's disease kindred."; RL Int. J. Oncol. 13:665-668(1998). RN [59] RP VARIANT CWS1 PRO-70. RX PubMed=9832031; DOI=10.1136/jmg.35.11.881; RA Marsh D.J., Dahia P.L.M., Caron S., Kum J.B., Frayling I.M., RA Tomlinson I.P.M., Hughes K.S., Eeles R.A., Hodgson S.V., Murday V.A., RA Houlston R., Eng C.; RT "Germline PTEN mutations in Cowden syndrome-like families."; RL J. Med. Genet. 35:881-885(1998). RN [60] RP VARIANT CWS1 ARG-35. RX PubMed=9425889; DOI=10.1038/ng0198-12; RA Olschwang S., Serova-Sinilnikova O.M., Lenoir G.M., Thomas G.; RT "PTEN germ-line mutations in juvenile polyposis coli."; RL Nat. Genet. 18:12-14(1998). RN [61] RP VARIANT CWS1 GLN-130. RX PubMed=9915974; DOI=10.1086/302207; RA Kurose K., Araki T., Matsunaka T., Takada Y., Emi M.; RT "Variant manifestation of Cowden disease in Japan: hamartomatous polyposis RT of the digestive tract with mutation of the PTEN gene."; RL Am. J. Hum. Genet. 64:308-310(1999). RN [62] RP VARIANT CWS1/LDD PRO-112. RX PubMed=10051160; RX DOI=10.1002/(sici)1096-8628(19990212)82:4<290::aid-ajmg3>3.0.co;2-0; RA Sutphen R., Diamond T.M., Minton S.E., Peacocke M., Tsou H.C., Root A.W.; RT "Severe Lhermitte-Duclos disease with unique germline mutation of PTEN."; RL Am. J. Med. Genet. 82:290-293(1999). RN [63] RP VARIANTS CWS1 ILE-33 DEL; ARG-123; ARG-124 AND GLU-165. RX PubMed=10234502; DOI=10.1038/sj.ejhg.5200289; RA Nelen M.R., Kremer H., Konings I.B.M., Schoute F., van Essen A.J., Koch R., RA Woods C.G., Fryns J.-P., Hamel B.C.J., Hoefsloot L.H., Peeters E.A.J., RA Padberg G.W.; RT "Novel PTEN mutations in patients with Cowden disease: absence of clear RT genotype-phenotype correlations."; RL Eur. J. Hum. Genet. 7:267-273(1999). RN [64] RP VARIANTS CWS1 ASP-34; HIS-68; TYR-105; VAL-135; ARG-170 AND LEU-246. RX PubMed=10400993; DOI=10.1093/hmg/8.8.1461; RA Marsh D.J., Kum J.B., Lunetta K.L., Bennett M.J., Gorlin R.J., Ahmed S.F., RA Bodurtha J., Crowe C., Curtis M.A., Dasouki M., Dunn T., Feit H., RA Geraghty M.T., Graham J.M. Jr., Hodgson S.V., Hunter A., Korf B.R., RA Manchester D., Miesfeldt S., Murday V.A., Nathanson K.L., Parisi M., RA Pober B., Romano C., Tolmie J.L., Trembath R., Winter R.M., Zackai E.H., RA Zori R.T., Weng L.-P., Dahia P.L.M., Eng C.; RT "PTEN mutation spectrum and genotype-phenotype correlations in Bannayan- RT Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome."; RL Hum. Mol. Genet. 8:1461-1472(1999). RN [65] RP CHARACTERIZATION OF VARIANTS ASN-10; CYS-16; GLU-20; SER-27; ARG-61; RP HIS-68; ARG-112; PRO-121; ARG-129; GLY-130; ILE-133; LEU-134; ARG-165; RP ASN-170; CYS-173; HIS-173; PRO-173; ASN-174; PHE-227; CYS-251; GLN-345; RP GLY-369 AND ILE-401, AND CHARACTERIZATION OF VARIANTS CWS1 TYR-71; TYR-93; RP PHE-105; TYR-107; PRO-112; ARG-124; GLU-129; LEU-130; GLN-130; TYR-136; RP CYS-155; ARG-170; GLU-289; GLY-331; VAL-341; ASN-342; GLU-343 AND LEU-347. RX PubMed=10866302; RA Han S.-Y., Kato H., Kato S., Suzuki T., Shibata H., Ishii S., Shiiba K., RA Matsuno S., Kanamaru R., Ishioka C.; RT "Functional evaluation of PTEN missense mutations using in vitro RT phosphoinositide phosphatase assay."; RL Cancer Res. 60:3147-3151(2000). RN [66] RP VARIANT CWS1 ARG-36. RX PubMed=10772390; DOI=10.1034/j.1600-0625.2000.009002152.x; RA Celebi J.T., Ping X.L., Zhang H., Remington T., Sulica V.I., Tsou H.C., RA Peacocke M.; RT "Germline PTEN mutations in three families with Cowden syndrome."; RL Exp. Dermatol. 9:152-156(2000). RN [67] RP VARIANTS MULTIPLE CANCERS LEU-119 AND LEU-158. RX PubMed=10807691; DOI=10.1136/jmg.37.5.336; RA De Vivo I., Gertig D.M., Nagase S., Hankinson S.E., O'Brien R., RA Speizer F.E., Parsons R., Hunter D.J.; RT "Novel germline mutations in the PTEN tumour suppressor gene found in women RT with multiple cancers."; RL J. Med. Genet. 37:336-341(2000). RN [68] RP VARIANTS MALIGNANT MELANOMA ASN-19 AND ILE-217. RX PubMed=10978354; DOI=10.1136/jmg.37.9.653; RA Celebi J.T., Shendrik I., Silvers D.N., Peacocke M.; RT "Identification of PTEN mutations in metastatic melanoma specimens."; RL J. Med. Genet. 37:653-657(2000). RN [69] RP CHARACTERIZATION OF VARIANTS CWS1 SER-124 AND GLU-129. RX PubMed=11230179; DOI=10.1093/hmg/10.6.599; RA Weng L.-P., Brown J.L., Eng C.; RT "PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein RT phosphatase activity and up-regulating p27 via its lipid phosphatase RT activity in a breast cancer model."; RL Hum. Mol. Genet. 10:599-604(2001). RN [70] RP VARIANT ASP-61. RX PubMed=11748304; DOI=10.1136/jmg.38.12.820; RA Reardon W., Zhou X.-P., Eng C.; RT "A novel germline mutation of the PTEN gene in a patient with macrocephaly, RT ventricular dilatation, and features of VATER association."; RL J. Med. Genet. 38:820-823(2001). RN [71] RP VARIANTS CWS1 ASP-34; GLY-47; HIS-68; TYR-105; VAL-135 AND ARG-170. RX PubMed=11494117; DOI=10.1038/sj.neo.7900154; RA Marsh D.J., Theodosopoulos G., Howell V., Richardson A.-L., Benn D.E., RA Proos A.L., Eng C., Robinson B.G.; RT "Rapid mutation scanning of genes associated with familial cancer syndromes RT using denaturing high-performance liquid chromatography."; RL Neoplasia 3:236-244(2001). RN [72] RP VARIANT GLM2 GLN-234, AND CHARACTERIZATION OF VARIANT GLM2 GLN-234. RX PubMed=12085208; DOI=10.1038/sj.bjc.6600206; RA Staal F.J.T., van der Luijt R.B., Baert M.R.M., van Drunen J., RA van Bakel H., Peters E., de Valk I., van Amstel H.K.P., Taphoorn M.J.B., RA Jansen G.H., van Veelen C.W.M., Burgering B., Staal G.E.J.; RT "A novel germline mutation of PTEN associated with brain tumours of RT multiple lineages."; RL Br. J. Cancer 86:1586-1591(2002). RN [73] RP VARIANT HNSCC GLY-121. RX PubMed=11801303; DOI=10.1016/s0165-4608(01)00509-x; RA Poetsch M., Lorenz G., Kleist B.; RT "Detection of new PTEN/MMAC1 mutations in head and neck squamous cell RT carcinomas with loss of chromosome 10."; RL Cancer Genet. Cytogenet. 132:20-24(2002). RN [74] RP DISCUSSION OF PTEN INVOLVEMENT IN PROTEUS SYNDROME. RX PubMed=12471211; DOI=10.1136/jmg.39.12.937; RA Smith J.M., Kirk E.P.E., Theodosopoulos G., Marshall G.M., Walker J., RA Rogers M., Field M., Brereton J.J., Marsh D.J.; RT "Germline mutation of the tumour suppressor PTEN in Proteus syndrome."; RL J. Med. Genet. 39:937-940(2002). RN [75] RP VARIANTS MCEPHAS ARG-93; SER-241 AND GLY-252. RX PubMed=15805158; DOI=10.1136/jmg.2004.024646; RA Butler M.G., Dasouki M.J., Zhou X.-P., Talebizadeh Z., Brown M., RA Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R., Eng C.; RT "Subset of individuals with autism spectrum disorders and extreme RT macrocephaly associated with germline PTEN tumour suppressor gene RT mutations."; RL J. Med. Genet. 42:318-321(2005). RN [76] RP VARIANT ENDMC GLU-36. RX PubMed=16506206; DOI=10.1002/ijc.21862; RA Bilbao C., Rodriguez G., Ramirez R., Falcon O., Leon L., Chirino R., RA Rivero J.F., Falcon O. Jr., Diaz-Chico B.N., Diaz-Chico J.C., Perucho M.; RT "The relationship between microsatellite instability and PTEN gene RT mutations in endometrial cancer."; RL Int. J. Cancer 119:563-570(2006). RN [77] RP INVOLVEMENT IN CHROMOSOME 10Q23 DELETION SYNDROME. RX PubMed=17436248; DOI=10.1086/513607; RA Balciuniene J., Feng N., Iyadurai K., Hirsch B., Charnas L., Bill B.R., RA Easterday M.C., Staaf J., Oseth L., Czapansky-Beilman D., Avramopoulos D., RA Thomas G.H., Borg A., Valle D., Schimmenti L.A., Selleck S.B.; RT "Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with RT cognitive and behavioral abnormalities."; RL Am. J. Hum. Genet. 80:938-947(2007). RN [78] RP VARIANT VAL-132. RX PubMed=16752378; DOI=10.1002/ajmg.a.31273; RA Tekin M., Hismi B.O., Fitoz S., Yalcinkaya F., Ekim M., Kansu A., Ertem M., RA Deda G., Tutar E., Arsan S., Zhou X.-P., Pilarski R., Eng C., Akar N.; RT "A germline PTEN mutation with manifestations of prenatal onset and RT verrucous epidermal nevus."; RL Am. J. Med. Genet. A 140:1472-1475(2006). RN [79] RP VARIANTS CWS1 SER-15; ASP-34; ARG-36; ARG-61; HIS-68; GLU-129; GLY-130; RP LEU-130; GLN-130; TYR-136; ARG-165; ARG-170; GLY-252 AND LEU-347. RX PubMed=21659347; DOI=10.1136/jmg.2011.088807; RA Pilarski R., Stephens J.A., Noss R., Fisher J.L., Prior T.W.; RT "Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan- RT Riley-Ruvalcaba syndrome clinical features."; RL J. Med. Genet. 48:505-512(2011). RN [80] RP VARIANTS MCEPHAS ILE-131 AND ASN-167. RX PubMed=23160955; DOI=10.1126/science.1227764; RA O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G., RA Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B., RA Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K., RA Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M., RA Bernier R., Eichler E.E., Shendure J.; RT "Multiplex targeted sequencing identifies recurrently mutated genes in RT autism spectrum disorders."; RL Science 338:1619-1622(2012). RN [81] RP VARIANTS CWS1 ARG-61; TYR-93; GLY-130; GLN-130; LEU-130 AND CYS-173. RX PubMed=24778394; DOI=10.1200/jco.2013.53.6656; RA Ngeow J., Stanuch K., Mester J.L., Barnholtz-Sloan J.S., Eng C.; RT "Second malignant neoplasms in patients with Cowden syndrome with RT underlying germline PTEN mutations."; RL J. Clin. Oncol. 32:1818-1824(2014). RN [82] RP VARIANT MCEPHAS 65-TYR--VAL-403 DEL. RX PubMed=26637798; DOI=10.1016/j.neuron.2015.11.009; RA D'Gama A.M., Pochareddy S., Li M., Jamuar S.S., Reiff R.E., Lam A.T., RA Sestan N., Walsh C.A.; RT "Targeted DNA Sequencing from Autism Spectrum Disorder Brains Implicates RT Multiple Genetic Mechanisms."; RL Neuron 88:910-917(2015). RN [83] RP VARIANT PROSTATE CANCER GLY-126, CHARACTERIZATION OF VARIANT GLY-126, RP MUTAGENESIS OF ALA-126, AND FUNCTION. RX PubMed=26504226; DOI=10.1073/pnas.1422504112; RA Costa H.A., Leitner M.G., Sos M.L., Mavrantoni A., Rychkova A., RA Johnson J.R., Newton B.W., Yee M.C., De La Vega F.M., Ford J.M., RA Krogan N.J., Shokat K.M., Oliver D., Halaszovich C.R., Bustamante C.D.; RT "Discovery and functional characterization of a neomorphic PTEN mutation."; RL Proc. Natl. Acad. Sci. U.S.A. 112:13976-13981(2015). RN [84] RP VARIANT ASN-174. RX PubMed=39316756; DOI=10.1158/0008-5472.can-23-2216; RA Plitt G., Brewer T., Yehia L., Rabinowitz L., Griffith C.C., Eng C.; RT "The genomic landscape of benign and malignant thyroid tumors from RT individuals carrying germline PTEN variants is distinct from sporadic RT thyroid cancers."; RL Cancer Res. 84:3657-3668(2024). CC -!- FUNCTION: Dual-specificity protein phosphatase, dephosphorylating CC tyrosine-, serine- and threonine-phosphorylated proteins CC (PubMed:9187108, PubMed:9256433, PubMed:9616126). Also functions as a CC lipid phosphatase, removing the phosphate in the D3 position of the CC inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5- CC trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and CC PtdIns3P/phosphatidylinositol 3-phosphate with a preference for CC PtdIns(3,4,5)P3 (PubMed:16824732, PubMed:26504226, PubMed:9593664, CC PubMed:9811831). Furthermore, this enzyme can also act as a cytosolic CC inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6 CC pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5- CC tetrakisphosphate (PubMed:11418101, PubMed:15979280). Antagonizes the CC PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides CC and thereby modulating cell cycle progression and cell survival CC (PubMed:31492966, PubMed:37279284). The unphosphorylated form CC cooperates with MAGI2 to suppress AKT1 activation (PubMed:11707428). In CC motile cells, suppresses the formation of lateral pseudopods and CC thereby promotes cell polarization and directed movement CC (PubMed:22279049). Dephosphorylates tyrosine-phosphorylated focal CC adhesion kinase and inhibits cell migration and integrin-mediated cell CC spreading and focal adhesion formation (PubMed:22279049). Required for CC growth factor-induced epithelial cell migration; growth factor CC stimulation induces PTEN phosphorylation which changes its binding CC preference from the p85 regulatory subunit of the PI3K kinase complex CC to DLC1 and results in translocation of the PTEN-DLC1 complex to the CC posterior of migrating cells to promote RHOA activation CC (PubMed:26166433). Meanwhile, TNS3 switches binding preference from CC DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge CC of migrating cells to activate RAC1 activation (PubMed:26166433). Plays CC a role as a key modulator of the AKT-mTOR signaling pathway controlling CC the tempo of the process of newborn neurons integration during adult CC neurogenesis, including correct neuron positioning, dendritic CC development and synapse formation (By similarity). Involved in the CC regulation of synaptic function in excitatory hippocampal synapses. CC Recruited to the postsynaptic membrane upon NMDA receptor activation, CC is required for the modulation of synaptic activity during plasticity. CC Enhancement of lipid phosphatase activity is able to drive depression CC of AMPA receptor-mediated synaptic responses, activity required for CC NMDA receptor-dependent long-term depression (LTD) (By similarity). May CC be a negative regulator of insulin signaling and glucose metabolism in CC adipose tissue. The nuclear monoubiquitinated form possesses greater CC apoptotic potential, whereas the cytoplasmic nonubiquitinated form CC induces less tumor suppressive ability (PubMed:10468583, CC PubMed:18716620). {ECO:0000250|UniProtKB:O08586, CC ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:11418101, ECO:0000269|PubMed:11707428, CC ECO:0000269|PubMed:15979280, ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:22279049, CC ECO:0000269|PubMed:26166433, ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:31492966, ECO:0000269|PubMed:37279284, CC ECO:0000269|PubMed:9187108, ECO:0000269|PubMed:9256433, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9616126, CC ECO:0000269|PubMed:9811831}. CC -!- FUNCTION: [Isoform alpha]: Functional kinase, like isoform 1 it CC antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in CC mitochondrial energetic metabolism by promoting COX activity and ATP CC production, via collaboration with isoform 1 in increasing protein CC levels of PINK1. {ECO:0000269|PubMed:23744781}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:25017, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57836, CC ChEBI:CHEBI:58456; EC=3.1.3.67; CC Evidence={ECO:0000269|PubMed:16824732, ECO:0000269|PubMed:9811831}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25018; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] + CC phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:83421; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20630; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] + CC phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:61977; EC=3.1.3.16; CC Evidence={ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:47005; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + CC phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978; EC=3.1.3.48; Evidence={ECO:0000269|PubMed:9187108, CC ECO:0000269|PubMed:9256433}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10685; CC Evidence={ECO:0000305|PubMed:9256433}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5- CC trisphosphate) + H2O = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo- CC inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43552, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83416, CC ChEBI:CHEBI:83419; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43553; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol- CC 3,4,5-trisphosphate) + H2O = 1,2-dihexadecanoyl-sn-glycero-3-phospho- CC (1D-myo-inositol-4,5-bisphosphate) + phosphate; Xref=Rhea:RHEA:43560, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:83420, CC ChEBI:CHEBI:83423; Evidence={ECO:0000269|PubMed:16824732, CC ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43561; CC Evidence={ECO:0000305|PubMed:16824732}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5,6-pentakisphosphate + H2O = 1D-myo- CC inositol 1,4,5,6-tetrakisphosphate + phosphate; Xref=Rhea:RHEA:77143, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57627, CC ChEBI:CHEBI:57733; Evidence={ECO:0000269|PubMed:11418101}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77144; CC Evidence={ECO:0000269|PubMed:11418101}; CC -!- CATALYTIC ACTIVITY: CC Reaction=1D-myo-inositol 1,3,4,5-tetrakisphosphate + H2O = 1D-myo- CC inositol 1,4,5-trisphosphate + phosphate; Xref=Rhea:RHEA:77155, CC ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:57895, CC ChEBI:CHEBI:203600; Evidence={ECO:0000269|PubMed:9593664}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:77156; CC Evidence={ECO:0000305|PubMed:9593664}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Enzymatic activity is enhanced in the presence of CC phosphatidylserine. {ECO:0000269|PubMed:16824732}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=26 uM for PtdIns(3,4,5)P3 {ECO:0000269|PubMed:11418101}; CC KM=11.5 uM for 1D-myo-inositol 1,3,4-trisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=4.6 uM for 1D-myo-inositol 1,3,4,5-tetrakisphosphate CC {ECO:0000269|PubMed:11418101}; CC KM=7.1 uM for 1D-myo-inositol 1,3,4,5,6-pentakisphosphate CC {ECO:0000269|PubMed:11418101}; CC Vmax=60 nmol/min/mg enzyme with PtdIns(3,4,5)P3 as substrate CC {ECO:0000269|PubMed:11418101}; CC Vmax=24 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4-trisphosphate CC as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=112 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5- CC tetrakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC Vmax=67 nmol/min/mg enzyme with 1D-myo-inositol 1,3,4,5,6- CC pentakisphosphate as substrate {ECO:0000269|PubMed:11418101}; CC -!- SUBUNIT: Monomer. The unphosphorylated form interacts with the second CC PDZ domain of MAGI2 and with DLG1 and MAST2 in vitro (PubMed:10646847, CC PubMed:10760291, PubMed:11707428). Interacts with MAGI2, MAGI3, MAST1 CC and MAST3, but neither with MAST4 nor with DLG5; interaction with MAGI2 CC increases protein stability (PubMed:10748157, PubMed:15951562). CC Interacts with NEDD4 (PubMed:17218260). Interacts with NDFIP1 and CC NDFIP2; in the presence of NEDD4 or ITCH, this interaction promotes CC PTEN ubiquitination (PubMed:20534535, PubMed:25801959). Interacts (via CC C2 domain) with FRK (PubMed:19345329). Interacts with USP7; the CC interaction is direct (PubMed:18716620). Interacts with ROCK1 (By CC similarity). Interacts with XIAP/BIRC4 (PubMed:19473982). Interacts CC with STK11; the interaction phosphorylates PTEN (PubMed:15987703). CC Interacts with PPP1R16B (PubMed:25007873). Interacts with NOP53; CC regulates PTEN phosphorylation and increases its stability CC (PubMed:15355975). Interacts (via PDZ domain-binding motif) with DLG4; CC the interaction is induced by NMDA and is required for PTEN location at CC postsynaptic density (By similarity). Interacts with the regulatory p85 CC subunit of the PI3K kinase complex and with Rho GTPase-activating CC protein DLC1; in resting cells, interacts (via C2 tensin-type domain) CC with p85 but, following growth factor stimulation, PTEN is CC phosphorylated which leads to weakened interaction with p85 and CC enhanced interaction (via C2 tensin-type domain) with DLC1 while p85 CC interaction with TNS3 increases (PubMed:26166433). CC {ECO:0000250|UniProtKB:O08586, ECO:0000250|UniProtKB:O54857, CC ECO:0000269|PubMed:10555148, ECO:0000269|PubMed:10646847, CC ECO:0000269|PubMed:10748157, ECO:0000269|PubMed:10760291, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:17218260, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19345329, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:20534535, ECO:0000269|PubMed:25007873, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:26166433}. CC -!- INTERACTION: CC P60484; Q9ULX6: AKAP8L; NbExp=2; IntAct=EBI-696162, EBI-357530; CC P60484; Q9NZN5-2: ARHGEF12; NbExp=4; IntAct=EBI-696162, EBI-10984307; CC P60484; P35226: BMI1; NbExp=7; IntAct=EBI-696162, EBI-2341576; CC P60484; P30260: CDC27; NbExp=7; IntAct=EBI-696162, EBI-994813; CC P60484; Q9P0U4: CXXC1; NbExp=2; IntAct=EBI-696162, EBI-949911; CC P60484; Q16643: DBN1; NbExp=5; IntAct=EBI-696162, EBI-351394; CC P60484; Q12959: DLG1; NbExp=2; IntAct=EBI-696162, EBI-357481; CC P60484; Q15700: DLG2; NbExp=2; IntAct=EBI-696162, EBI-80426; CC P60484; P78352: DLG4; NbExp=3; IntAct=EBI-696162, EBI-80389; CC P60484; P42685: FRK; NbExp=7; IntAct=EBI-696162, EBI-1383583; CC P60484; Q9HD26: GOPC; NbExp=4; IntAct=EBI-696162, EBI-349832; CC P60484; A4D2P6: GRID2IP; NbExp=4; IntAct=EBI-696162, EBI-15893226; CC P60484; Q92743: HTRA1; NbExp=4; IntAct=EBI-696162, EBI-352256; CC P60484; Q96QZ7: MAGI1; NbExp=5; IntAct=EBI-696162, EBI-924464; CC P60484; Q86UL8: MAGI2; NbExp=6; IntAct=EBI-696162, EBI-311035; CC P60484; Q5TCQ9: MAGI3; NbExp=9; IntAct=EBI-696162, EBI-310506; CC P60484; Q9Y2H9: MAST1; NbExp=4; IntAct=EBI-696162, EBI-3385920; CC P60484; Q6P0Q8: MAST2; NbExp=4; IntAct=EBI-696162, EBI-493777; CC P60484; O60307: MAST3; NbExp=4; IntAct=EBI-696162, EBI-311420; CC P60484; O75970: MPDZ; NbExp=4; IntAct=EBI-696162, EBI-821405; CC P60484; Q9Y6Q9: NCOA3; NbExp=2; IntAct=EBI-696162, EBI-81196; CC P60484; P46934: NEDD4; NbExp=4; IntAct=EBI-696162, EBI-726944; CC P60484; O14745: NHERF1; NbExp=9; IntAct=EBI-696162, EBI-349787; CC P60484; Q15599: NHERF2; NbExp=6; IntAct=EBI-696162, EBI-1149760; CC P60484; Q8NI35: PATJ; NbExp=3; IntAct=EBI-696162, EBI-724390; CC P60484; P09619: PDGFRB; NbExp=3; IntAct=EBI-696162, EBI-641237; CC P60484; Q9H5P4: PDZD7; NbExp=4; IntAct=EBI-696162, EBI-20859318; CC P60484; Q9NRD5: PICK1; NbExp=2; IntAct=EBI-696162, EBI-79165; CC P60484; P62136: PPP1CA; NbExp=2; IntAct=EBI-696162, EBI-357253; CC P60484; Q06830: PRDX1; NbExp=7; IntAct=EBI-696162, EBI-353193; CC P60484; P60484: PTEN; NbExp=19; IntAct=EBI-696162, EBI-696162; CC P60484; Q14160: SCRIB; NbExp=4; IntAct=EBI-696162, EBI-357345; CC P60484; Q13424: SNTA1; NbExp=4; IntAct=EBI-696162, EBI-717191; CC P60484; Q13884: SNTB1; NbExp=5; IntAct=EBI-696162, EBI-295843; CC P60484; Q9NY99: SNTG2; NbExp=3; IntAct=EBI-696162, EBI-8556870; CC P60484; Q96L92: SNX27; NbExp=4; IntAct=EBI-696162, EBI-2514865; CC P60484; O43791: SPOP; NbExp=4; IntAct=EBI-696162, EBI-743549; CC P60484; Q62696: Dlg1; Xeno; NbExp=2; IntAct=EBI-696162, EBI-389325; CC P60484; O88382: Magi2; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696179; CC P60484; Q9JK71: Magi3; Xeno; NbExp=3; IntAct=EBI-696162, EBI-696226; CC P60484; Q9R1L5: Mast1; Xeno; NbExp=3; IntAct=EBI-696162, EBI-491771; CC P60484; Q60592: Mast2; Xeno; NbExp=4; IntAct=EBI-696162, EBI-493888; CC P60484; Q9JHL1: Nherf2; Xeno; NbExp=2; IntAct=EBI-696162, EBI-538451; CC P60484-1; Q19T08: ECSCR; NbExp=4; IntAct=EBI-15722967, EBI-15778214; CC P60484-1; Q5T2D3: OTUD3; NbExp=9; IntAct=EBI-15722967, EBI-16170539; CC P60484-1; P60484-1: PTEN; NbExp=3; IntAct=EBI-15722967, EBI-15722967; CC P60484-1; Q93009: USP7; NbExp=5; IntAct=EBI-15722967, EBI-302474; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19473982, CC ECO:0000269|PubMed:25801959, ECO:0000269|PubMed:9187108}. Nucleus CC {ECO:0000269|PubMed:15987703, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982, ECO:0000269|PubMed:25801959}. Nucleus, PML CC body {ECO:0000269|PubMed:18716620}. Cell projection, dendritic spine CC {ECO:0000250|UniProtKB:O54857}. Postsynaptic density CC {ECO:0000250|UniProtKB:O54857}. Note=Monoubiquitinated form is nuclear. CC Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in CC PML nuclear bodies (PubMed:18716620). XIAP/BIRC4 promotes its nuclear CC localization (PubMed:19473982). Associares with the postsynaptic CC density in response to NMDAR activation (By similarity). CC {ECO:0000250|UniProtKB:O54857, ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- SUBCELLULAR LOCATION: [Isoform alpha]: Secreted CC {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. Note=May be CC secreted via a classical signal peptide and reenter into cells with the CC help of a poly-Arg motif. {ECO:0000269|PubMed:23744781, CC ECO:0000269|PubMed:24768297}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing, Alternative initiation; Named isoforms=3; CC Name=1; Synonyms=55kDa; CC IsoId=P60484-1; Sequence=Displayed; CC Name=alpha; Synonyms=70kDa, PTEN-long; CC IsoId=P60484-2; Sequence=VSP_055420; CC Name=3; CC IsoId=P60484-3; Sequence=VSP_055421, VSP_055422, VSP_055423; CC -!- TISSUE SPECIFICITY: Expressed at a relatively high level in all adult CC tissues, including heart, brain, placenta, lung, liver, muscle, kidney CC and pancreas. {ECO:0000269|PubMed:9090379}. CC -!- INDUCTION: Down-regulated by TGFB1. {ECO:0000269|PubMed:9187108}. CC -!- DOMAIN: The C2 domain binds phospholipid membranes in vitro in a CC Ca(2+)-independent manner; this binding is important for its tumor CC suppressor function. {ECO:0000269|PubMed:10468583, CC ECO:0000269|PubMed:10555148}. CC -!- PTM: Constitutively phosphorylated by CK2 under normal conditions. CC Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11. CC Phosphorylation results in an inhibited activity towards PIP3. CC Phosphorylation can both inhibit or promote PDZ-binding. CC Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from CC ubiquitin-mediated degradation probably by inhibiting its binding to CC NEDD4. Phosphorylation by ROCK1 is essential for its stability and CC activity. Phosphorylation by PLK3 promotes its stability and prevents CC its degradation by the proteasome. Phosphorylated on Thr-319 and Thr- CC 321 in the C2-type tensin domain following EGF stimulation which CC changes its binding preference from the p85 regulatory subunit of the CC PI3K kinase complex to DLC1 (PubMed:26166433). CC {ECO:0000269|PubMed:10646847, ECO:0000269|PubMed:11035045, CC ECO:0000269|PubMed:11707428, ECO:0000269|PubMed:12297295, CC ECO:0000269|PubMed:15951562, ECO:0000269|PubMed:15987703, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:19345329, CC ECO:0000269|PubMed:20940307, ECO:0000269|PubMed:26166433}. CC -!- PTM: Monoubiquitinated; monoubiquitination is increased in presence of CC retinoic acid. Deubiquitinated by USP7; leading to its nuclear CC exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino CC acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated CC by XIAP/BIRC4. {ECO:0000269|PubMed:18716620, CC ECO:0000269|PubMed:19473982}. CC -!- PTM: Ubiquitinated by the DCX(DCAF13) E3 ubiquitin ligase complex, CC leading to its degradation. {ECO:0000269|PubMed:31492966}. CC -!- PTM: ISGylated. ISGylation promotes PTEN degradation. CC {ECO:0000269|PubMed:37279284}. CC -!- DISEASE: Cowden syndrome 1 (CWS1) [MIM:158350]: An autosomal dominant CC hamartomatous polyposis syndrome with age-related penetrance. Cowden CC syndrome is characterized by hamartomatous lesions affecting CC derivatives of ectodermal, mesodermal and endodermal layers, CC macrocephaly, facial trichilemmomas (benign tumors of the hair follicle CC infundibulum), acral keratoses, papillomatous papules, and elevated CC risk for development of several types of malignancy, particularly CC breast carcinoma in women and thyroid carcinoma in both men and women. CC Colon cancer and renal cell carcinoma have also been reported. CC Hamartomas can be found in virtually every organ, but most commonly in CC the skin, gastrointestinal tract, breast and thyroid. CC {ECO:0000269|PubMed:10051160, ECO:0000269|PubMed:10234502, CC ECO:0000269|PubMed:10400993, ECO:0000269|PubMed:10772390, CC ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11230179, CC ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:15355975, CC ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:21659347, CC ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9140396, CC ECO:0000269|PubMed:9241266, ECO:0000269|PubMed:9259288, CC ECO:0000269|PubMed:9345101, ECO:0000269|PubMed:9399897, CC ECO:0000269|PubMed:9425889, ECO:0000269|PubMed:9467011, CC ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9600246, CC ECO:0000269|PubMed:9735393, ECO:0000269|PubMed:9797362, CC ECO:0000269|PubMed:9811831, ECO:0000269|PubMed:9832031, CC ECO:0000269|PubMed:9915974}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Lhermitte-Duclos disease (LDD) [MIM:158350]: A rare disease CC characterized by the occurrence of a slowly enlarging mass within the CC cerebellar cortex corresponding histologically to a cerebellar CC hamartoma. It manifests, most commonly in the third and fourth decades CC of life, with increased intracranial pressure, headache, nausea, CC cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual CC disturbances and other cranial nerve palsies. Various associated CC abnormalities may be present such as megalencephaly, microgyria, CC hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part CC of the PTEN hamartoma tumor syndromes spectrum that also includes CC Cowden syndrome. Note=The disease is caused by variants affecting the CC gene represented in this entry. CC -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC) CC [MIM:275355]: A non-melanoma skin cancer affecting the head and neck. CC The hallmark of cutaneous SCC is malignant transformation of normal CC epidermal keratinocytes. {ECO:0000269|PubMed:11801303}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of CC endometrium, the mucous lining of the uterus. Most endometrial cancers CC are adenocarcinomas, cancers that begin in cells that make and release CC mucus and other fluids. {ECO:0000269|PubMed:16506206}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Note=PTEN mutations are found in a subset of patients with CC Proteus syndrome, a genetically heterogeneous condition. The molecular CC diagnosis of PTEN mutation positive cases classifies Proteus syndrome CC patients as part of the PTEN hamartoma syndrome spectrum. As such, CC patients surviving the early years of Proteus syndrome are likely at a CC greater risk of developing malignancies. CC -!- DISEASE: Glioma 2 (GLM2) [MIM:613028]: Gliomas are benign or malignant CC central nervous system neoplasms derived from glial cells. They CC comprise astrocytomas and glioblastoma multiforme that are derived from CC astrocytes, oligodendrogliomas derived from oligodendrocytes and CC ependymomas derived from ependymocytes. {ECO:0000269|PubMed:12085208}. CC Note=Disease susceptibility is associated with variants affecting the CC gene represented in this entry. CC -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy originating in CC tissues of the prostate. Most prostate cancers are adenocarcinomas that CC develop in the acini of the prostatic ducts. Other rare histopathologic CC types of prostate cancer that occur in approximately 5% of patients CC include small cell carcinoma, mucinous carcinoma, prostatic ductal CC carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal CC cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell CC carcinoma and neuroendocrine carcinoma. {ECO:0000269|PubMed:26504226, CC ECO:0000269|PubMed:9072974}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]: Patients CC have autism spectrum disorders and macrocephaly, with head CC circumferences ranging from +2.5 to +8 SD for age and sex (average head CC circumference +4.0 SD). {ECO:0000269|PubMed:15805158, CC ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:26637798}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=A microdeletion of chromosome 10q23 involving BMPR1A and CC PTEN is a cause of chromosome 10q23 deletion syndrome, which shows CC overlapping features of the following three disorders: Bannayan-Zonana CC syndrome, Cowden disease and juvenile polyposis syndrome. CC -!- MISCELLANEOUS: [Isoform alpha]: Produced by alternative initiation at CC an upstream CTG start codon. May contain a signal peptide at positions CC 1-21. {ECO:0000269|PubMed:23744781, ECO:0000269|PubMed:24768297}. CC -!- SIMILARITY: Belongs to the PTEN phosphatase protein family. CC {ECO:0000305}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/158/PTEN"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U96180; AAB66902.1; -; mRNA. DR EMBL; U92436; AAC51182.1; -; mRNA. DR EMBL; U93051; AAC51183.1; -; mRNA. DR EMBL; AF143315; AAD38372.1; -; Genomic_DNA. DR EMBL; AF143312; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143313; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF143314; AAD38372.1; JOINED; Genomic_DNA. DR EMBL; AF000734; AAC08699.1; -; Genomic_DNA. DR EMBL; AF000726; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000727; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000728; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000729; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000730; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000731; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000732; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF000733; AAC08699.1; JOINED; Genomic_DNA. DR EMBL; AF067844; AAD13528.1; -; Genomic_DNA. DR EMBL; JF268690; ADZ48535.1; -; mRNA. DR EMBL; CR450306; CAG29302.1; -; mRNA. DR EMBL; AK313581; BAG36351.1; -; mRNA. DR EMBL; DQ073384; AAY57327.1; -; Genomic_DNA. DR EMBL; CH471066; EAW50174.1; -; Genomic_DNA. DR EMBL; BC005821; AAH05821.1; -; mRNA. DR CCDS; CCDS31238.1; -. [P60484-1] DR RefSeq; NP_000305.3; NM_000314.6. [P60484-1] DR RefSeq; NP_001291647.1; NM_001304718.1. DR PDB; 1D5R; X-ray; 2.10 A; A=8-353. DR PDB; 2KYL; NMR; -; B=391-403. DR PDB; 4O1V; X-ray; 2.00 A; B=354-368. DR PDB; 5BUG; X-ray; 2.40 A; A/B/C/D=14-351. DR PDB; 5BZX; X-ray; 2.50 A; A/B/C/D=14-351. DR PDB; 5BZZ; X-ray; 2.20 A; A/B/C/D=14-351. DR PDB; 7JTX; X-ray; 3.23 A; A=7-395. DR PDB; 7JUK; X-ray; 3.15 A; A=7-353, A=378-390. DR PDB; 7JUL; X-ray; 2.53 A; A=7-353, A=378-390. DR PDB; 7JVX; X-ray; 3.20 A; A=1-403. DR PDB; 7PC7; X-ray; 2.10 A; E/F=394-403. DR PDB; 8X3S; X-ray; 1.87 A; B=29-41. DR PDBsum; 1D5R; -. DR PDBsum; 2KYL; -. DR PDBsum; 4O1V; -. DR PDBsum; 5BUG; -. DR PDBsum; 5BZX; -. DR PDBsum; 5BZZ; -. DR PDBsum; 7JTX; -. DR PDBsum; 7JUK; -. DR PDBsum; 7JUL; -. DR PDBsum; 7JVX; -. DR PDBsum; 7PC7; -. DR PDBsum; 8X3S; -. DR AlphaFoldDB; P60484; -. DR SMR; P60484; -. DR BioGRID; 111700; 852. DR ComplexPortal; CPX-3153; PTEN phosphatase complex. DR CORUM; P60484; -. DR DIP; DIP-35019N; -. DR ELM; P60484; -. DR FunCoup; P60484; 3633. DR IntAct; P60484; 439. DR MINT; P60484; -. DR STRING; 9606.ENSP00000361021; -. DR BindingDB; P60484; -. DR ChEMBL; CHEMBL2052032; -. DR DrugBank; DB04327; Phosphatidylethanolamine. DR GuidetoPHARMACOLOGY; 2497; -. DR SwissLipids; SLP:000000849; -. DR TCDB; 1.A.51.2.4; the voltage-gated proton channel (vpc) family. DR CarbonylDB; P60484; -. DR DEPOD; PTEN; -. DR GlyGen; P60484; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; P60484; -. DR MetOSite; P60484; -. DR PhosphoSitePlus; P60484; -. DR BioMuta; PTEN; -. DR DMDM; 42560209; -. DR CPTAC; CPTAC-5746; -. DR CPTAC; CPTAC-5747; -. DR CPTAC; CPTAC-5748; -. DR CPTAC; non-CPTAC-5426; -. DR CPTAC; non-CPTAC-5429; -. DR CPTAC; non-CPTAC-5430; -. DR CPTAC; non-CPTAC-5566; -. DR CPTAC; non-CPTAC-5567; -. DR jPOST; P60484; -. DR MassIVE; P60484; -. DR PaxDb; 9606-ENSP00000361021; -. DR PeptideAtlas; P60484; -. DR ProteomicsDB; 57209; -. [P60484-1] DR Pumba; P60484; -. DR Antibodypedia; 3420; 1732 antibodies from 53 providers. DR CPTC; P60484; 8 antibodies. DR DNASU; 5728; -. DR Ensembl; ENST00000371953.8; ENSP00000361021.3; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000644628.2; ENSP00000494918.2; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000688308.1; ENSP00000508752.1; ENSG00000171862.16. [P60484-1] DR Ensembl; ENST00000710385.1; ENSP00000518242.1; ENSG00000284792.2. [P60484-1] DR Ensembl; ENST00000710387.1; ENSP00000518244.1; ENSG00000284792.2. [P60484-2] DR GeneID; 5728; -. DR KEGG; hsa:5728; -. DR MANE-Select; ENST00000371953.8; ENSP00000361021.3; NM_000314.8; NP_000305.3. DR UCSC; uc001kfb.4; human. [P60484-1] DR AGR; HGNC:9588; -. DR CIViC; 5728; 123 evidence items across 65 molecular profiles. DR ClinPGx; PA33942; -. DR CTD; 5728; -. DR DisGeNET; 5728; -. DR GeneCards; PTEN; -. DR GeneReviews; PTEN; -. DR HGNC; HGNC:9588; PTEN. DR HPA; ENSG00000171862; Low tissue specificity. DR MalaCards; PTEN; -. DR MIM; 137800; phenotype. DR MIM; 158350; phenotype. DR MIM; 176807; phenotype. DR MIM; 275355; phenotype. DR MIM; 601728; gene. DR MIM; 605309; phenotype. DR MIM; 608089; phenotype. DR MIM; 612242; phenotype. DR MIM; 613028; phenotype. DR OpenTargets; ENSG00000171862; -. DR Orphanet; 109; Bannayan-Riley-Ruvalcaba syndrome. DR Orphanet; 201; Cowden syndrome. DR Orphanet; 145; Hereditary breast and/or ovarian cancer syndrome. DR Orphanet; 79076; Juvenile polyposis of infancy. DR Orphanet; 65285; Lhermitte-Duclos disease. DR Orphanet; 210548; Macrocephaly-intellectual disability-autism syndrome. DR Orphanet; 2969; Proteus-like syndrome. DR Orphanet; 137608; Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome. DR Orphanet; 494547; Squamous cell carcinoma of the hypopharynx. DR Orphanet; 494550; Squamous cell carcinoma of the larynx. DR Orphanet; 502366; Squamous cell carcinoma of the lip. DR Orphanet; 500464; Squamous cell carcinoma of the nasal cavity and paranasal sinuses. DR Orphanet; 502363; Squamous cell carcinoma of the oral cavity. DR Orphanet; 500478; Squamous cell carcinoma of the oropharynx. DR VEuPathDB; HostDB:ENSG00000171862; -. DR eggNOG; KOG2283; Eukaryota. DR GeneTree; ENSGT00940000154335; -. DR HOGENOM; CLU_020105_5_2_1; -. DR InParanoid; P60484; -. DR OMA; CKKFKQR; -. DR OrthoDB; 16692at2759; -. DR PAN-GO; P60484; 12 GO annotations based on evolutionary models. DR PhylomeDB; P60484; -. DR BioCyc; MetaCyc:HS10404-MONOMER; -. DR BRENDA; 3.1.3.16; 2681. DR BRENDA; 3.1.3.67; 2681. DR PathwayCommons; P60484; -. DR Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane. DR Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol. DR Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network. DR Reactome; R-HSA-202424; Downstream TCR signaling. DR Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes. DR Reactome; R-HSA-5674404; PTEN Loss of Function in Cancer. DR Reactome; R-HSA-5689880; Ub-specific processing proteases. DR Reactome; R-HSA-5689896; Ovarian tumor domain proteases. DR Reactome; R-HSA-8943723; Regulation of PTEN mRNA translation. DR Reactome; R-HSA-8948747; Regulation of PTEN localization. DR Reactome; R-HSA-8948751; Regulation of PTEN stability and activity. DR Reactome; R-HSA-8986944; Transcriptional Regulation by MECP2. DR SignaLink; P60484; -. DR SIGNOR; P60484; -. DR Agora; ENSG00000171862; -. DR BioGRID-ORCS; 5728; 85 hits in 1159 CRISPR screens. DR CD-CODE; 8C2F96ED; Centrosome. DR CD-CODE; B5B9A610; PML body. DR ChiTaRS; PTEN; human. DR EvolutionaryTrace; P60484; -. DR GeneWiki; PTEN_(gene); -. DR GenomeRNAi; 5728; -. DR Pharos; P60484; Tchem. DR PRO; PR:P60484; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P60484; protein. DR Bgee; ENSG00000171862; Expressed in sperm and 191 other cell types or tissues. DR ExpressionAtlas; P60484; baseline and differential. DR GO; GO:0016324; C:apical plasma membrane; IMP:UniProtKB. DR GO; GO:0042995; C:cell projection; IDA:UniProtKB. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:HPA. DR GO; GO:0043197; C:dendritic spine; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0035749; C:myelin sheath adaxonal region; ISS:BHF-UCL. DR GO; GO:0043005; C:neuron projection; ISS:BHF-UCL. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell. DR GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell. DR GO; GO:0043220; C:Schmidt-Lanterman incisure; ISS:BHF-UCL. DR GO; GO:0097225; C:sperm midpiece; IDA:HPA. DR GO; GO:0097228; C:sperm principal piece; IDA:HPA. DR GO; GO:0010997; F:anaphase-promoting complex binding; IPI:BHF-UCL. DR GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL. DR GO; GO:0019899; F:enzyme binding; IPI:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0030351; F:inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051717; F:inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW. DR GO; GO:0140678; F:molecular function inhibitor activity; IMP:DisProt. DR GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB. DR GO; GO:0052866; F:phosphatidylinositol phosphate phosphatase activity; IDA:UniProt. DR GO; GO:0016314; F:phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0051800; F:phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; IDA:UniProtKB. DR GO; GO:0004438; F:phosphatidylinositol-3-phosphate phosphatase activity; IDA:UniProtKB. DR GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:BHF-UCL. DR GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB. DR GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB. DR GO; GO:1990757; F:ubiquitin ligase activator activity; ISS:BHF-UCL. DR GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:MGI. DR GO; GO:0030534; P:adult behavior; ISS:BHF-UCL. DR GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW. DR GO; GO:0016477; P:cell migration; ISS:UniProtKB. DR GO; GO:0048870; P:cell motility; IBA:GO_Central. DR GO; GO:0071257; P:cellular response to electrical stimulus; IMP:BHF-UCL. DR GO; GO:0007417; P:central nervous system development; ISS:UniProtKB. DR GO; GO:0032286; P:central nervous system myelin maintenance; ISS:BHF-UCL. DR GO; GO:0021955; P:central nervous system neuron axonogenesis; ISS:BHF-UCL. DR GO; GO:0060997; P:dendritic spine morphogenesis; ISS:BHF-UCL. DR GO; GO:0021542; P:dentate gyrus development; ISS:BHF-UCL. DR GO; GO:0048853; P:forebrain morphogenesis; ISS:BHF-UCL. DR GO; GO:0007507; P:heart development; ISS:UniProtKB. DR GO; GO:0007611; P:learning or memory; ISS:BHF-UCL. DR GO; GO:0045475; P:locomotor rhythm; ISS:BHF-UCL. DR GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL. DR GO; GO:0042711; P:maternal behavior; ISS:BHF-UCL. DR GO; GO:0033555; P:multicellular organismal response to stress; ISS:BHF-UCL. DR GO; GO:0050771; P:negative regulation of axonogenesis; ISS:BHF-UCL. DR GO; GO:1902807; P:negative regulation of cell cycle G1/S phase transition; IDA:UniProtKB. DR GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB. DR GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL. DR GO; GO:0045792; P:negative regulation of cell size; ISS:BHF-UCL. DR GO; GO:2000773; P:negative regulation of cellular senescence; ISS:BHF-UCL. DR GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IMP:BHF-UCL. DR GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:UniProtKB. DR GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IDA:BHF-UCL. DR GO; GO:0051548; P:negative regulation of keratinocyte migration; IMP:BHF-UCL. DR GO; GO:0010977; P:negative regulation of neuron projection development; ISS:ARUK-UCL. DR GO; GO:0046621; P:negative regulation of organ growth; ISS:BHF-UCL. DR GO; GO:0045668; P:negative regulation of osteoblast differentiation; IDA:UniProt. DR GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IMP:UniProtKB. DR GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProt. DR GO; GO:2000808; P:negative regulation of synaptic vesicle clustering; ISS:BHF-UCL. DR GO; GO:1904706; P:negative regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL. DR GO; GO:1903690; P:negative regulation of wound healing, spreading of epidermal cells; IMP:BHF-UCL. DR GO; GO:0007270; P:neuron-neuron synaptic transmission; ISS:BHF-UCL. DR GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome. DR GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IDA:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:BHF-UCL. DR GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:BHF-UCL. DR GO; GO:1902533; P:positive regulation of intracellular signal transduction; IMP:BHF-UCL. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL. DR GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; IDA:BHF-UCL. DR GO; GO:0097107; P:postsynaptic density assembly; ISS:BHF-UCL. DR GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL. DR GO; GO:0097105; P:presynaptic membrane assembly; ISS:BHF-UCL. DR GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB. DR GO; GO:0050821; P:protein stabilization; IDA:BHF-UCL. DR GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0051896; P:regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IBA:GO_Central. DR GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB. DR GO; GO:0060024; P:rhythmic synaptic transmission; ISS:BHF-UCL. DR GO; GO:0035176; P:social behavior; ISS:BHF-UCL. DR GO; GO:0007056; P:spindle assembly involved in female meiosis; IDA:UniProt. DR GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL. DR GO; GO:0060074; P:synapse maturation; ISS:BHF-UCL. DR CDD; cd14509; PTP_PTEN; 1. DR DisProt; DP03296; -. DR DisProt; DP03399; -. [P60484-2] DR FunFam; 2.60.40.1110:FF:000003; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR FunFam; 3.90.190.10:FF:000029; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; 1. DR Gene3D; 2.60.40.1110; -; 1. DR Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 1. DR InterPro; IPR017361; Bifunc_PIno_P3_Pase/Pase_PTEN. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR051281; Dual-spec_lipid-protein_phosph. DR InterPro; IPR029021; Prot-tyrosine_phosphatase-like. DR InterPro; IPR045101; PTP_PTEN. DR InterPro; IPR014020; Tensin_C2-dom. DR InterPro; IPR029023; Tensin_phosphatase. DR InterPro; IPR016130; Tyr_Pase_AS. DR InterPro; IPR003595; Tyr_Pase_cat. DR InterPro; IPR000387; Tyr_Pase_dom. DR PANTHER; PTHR12305; PHOSPHATASE WITH HOMOLOGY TO TENSIN; 1. DR PANTHER; PTHR12305:SF81; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 3-PHOSPHATASE AND DUAL-SPECIFICITY PROTEIN PHOSPHATASE PTEN; 1. DR Pfam; PF10409; PTEN_C2; 1. DR Pfam; PF22785; Tc-R-P; 1. DR PIRSF; PIRSF038025; PTEN; 1. DR SMART; SM01326; PTEN_C2; 1. DR SMART; SM00404; PTPc_motif; 1. DR SMART; SM01301; PTPlike_phytase; 1. DR SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR PROSITE; PS51182; C2_TENSIN; 1. DR PROSITE; PS51181; PPASE_TENSIN; 1. DR PROSITE; PS50056; TYR_PHOSPHATASE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Acetylation; Alternative initiation; Alternative splicing; KW Apoptosis; Autism spectrum disorder; Cell projection; Cytoplasm; KW Disease variant; Hydrolase; Isopeptide bond; Lipid metabolism; KW Lipid-binding; Neurogenesis; Nucleus; Phosphoprotein; Protein phosphatase; KW Proteomics identification; Reference proteome; Secreted; Synapse; KW Tumor suppressor; Ubl conjugation. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0007744|PubMed:22814378" FT CHAIN 2..403 FT /note="Phosphatidylinositol 3,4,5-trisphosphate 3- FT phosphatase and dual-specificity protein phosphatase PTEN" FT /id="PRO_0000215904" FT DOMAIN 14..185 FT /note="Phosphatase tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT DOMAIN 190..350 FT /note="C2 tensin-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00589" FT REGION 338..348 FT /note="Required for interaction with NOP53" FT /evidence="ECO:0000269|PubMed:15355975" FT REGION 352..403 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 401..403 FT /note="PDZ domain-binding" FT /evidence="ECO:0000250|UniProtKB:O08586" FT COMPBIAS 360..369 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 383..393 FT /note="Acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 124 FT /note="Phosphocysteine intermediate" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00590" FT MOD_RES 2 FT /note="N-acetylthreonine" FT /evidence="ECO:0007744|PubMed:22814378" FT MOD_RES 294 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:O08586" FT MOD_RES 319 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 321 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:26166433" FT MOD_RES 336 FT /note="Phosphotyrosine; by FRK" FT /evidence="ECO:0000269|PubMed:19345329" FT MOD_RES 366 FT /note="Phosphothreonine; by GSK3-beta and PLK3" FT /evidence="ECO:0000269|PubMed:12297295, FT ECO:0000269|PubMed:20940307, ECO:0007744|PubMed:24275569" FT MOD_RES 370 FT /note="Phosphoserine; by CK2 and PLK3" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295, ECO:0000269|PubMed:20940307" FT MOD_RES 380 FT /note="Phosphoserine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 382 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 383 FT /note="Phosphothreonine; by ROCK1 and CK2" FT /evidence="ECO:0000269|PubMed:11035045" FT MOD_RES 385 FT /note="Phosphoserine; by CK2" FT /evidence="ECO:0000269|PubMed:11035045, FT ECO:0000269|PubMed:12297295" FT MOD_RES 401 FT /note="Phosphothreonine" FT /evidence="ECO:0000269|PubMed:10646847" FT CROSSLNK 13 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT CROSSLNK 289 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:18716620" FT VAR_SEQ 1 FT /note="M -> MERGGEAAAAAAAAAAAPGRGSESPVTISRAGNAGELVSPLLLPPTR FT RRRRRHIQGPGPVLNLPCAAAAPPVARAPEAAGGGSRSEDYSSSPHSAAAAARPLAAEE FT KQAQSLQPSSSRRSSHYPAAVQSQAAAERGASATAKSRAISILQKKPRHQQLLPSLSSF FT FFSHRLPDM (in isoform alpha)" FT /evidence="ECO:0000305" FT /id="VSP_055420" FT VAR_SEQ 55..70 FT /note="RFLDSKHKNHYKIYNL -> S (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055421" FT VAR_SEQ 165..190 FT /note="GVTIPSQRRYVYYYSYLLKNHLDYRP -> ADPTGGIPDKGIIVIGDGSSMD FT VIAP (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055422" FT VAR_SEQ 191..403 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_055423" FT VARIANT 10 FT /note="S -> N (retains phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the ability to FT bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026248" FT VARIANT 15 FT /note="R -> S (in CWS1; also found in glioma; FT dbSNP:rs1064794096)" FT /evidence="ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007457" FT VARIANT 16 FT /note="Y -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains the ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026249" FT VARIANT 19 FT /note="D -> N (in malignant melanoma; somatic mutation; FT dbSNP:rs121909233)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018100" FT VARIANT 20 FT /note="G -> E (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains phosphatase activity towards FT PtdIns(3,4,5)P3; dbSNP:rs1064795967)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026250" FT VARIANT 27 FT /note="Y -> S (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs886041877)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026251" FT VARIANT 33 FT /note="Missing (in CWS1; dbSNP:rs1554893765)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008733" FT VARIANT 34 FT /note="A -> D (in CWS1)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117, ECO:0000269|PubMed:21659347" FT /id="VAR_008734" FT VARIANT 35 FT /note="M -> R (in CWS1; dbSNP:rs121909225)" FT /evidence="ECO:0000269|PubMed:9425889" FT /id="VAR_008036" FT VARIANT 36 FT /note="G -> E (in ENDMC; also found in glioma; FT dbSNP:rs1554893792)" FT /evidence="ECO:0000269|PubMed:16506206, FT ECO:0000269|PubMed:9090379" FT /id="VAR_007458" FT VARIANT 36 FT /note="G -> R (in CWS1; also found in a patient with FT endometrial hyperplasia; dbSNP:rs786204854)" FT /evidence="ECO:0000269|PubMed:10772390, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9635567" FT /id="VAR_026252" FT VARIANT 42 FT /note="L -> R (in glioma; retains phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:9090379" FT /id="VAR_007459" FT VARIANT 47 FT /note="R -> G (in CWS1; dbSNP:rs786204855)" FT /evidence="ECO:0000269|PubMed:11494117" FT /id="VAR_011587" FT VARIANT 57 FT /note="L -> W (in glioma; likely pathogenic; loss of FT protein phosphatase activity; dbSNP:rs786202398)" FT /evidence="ECO:0000269|PubMed:9090379, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007460" FT VARIANT 61 FT /note="H -> D (found in a patient with congenital cardiac FT disease, macrocephaly, ventriculomegaly, skeletal defects, FT anal atresia, tracheoesophageal fistula, renal anomalies; FT likely pathogenic; dbSNP:rs121909236)" FT /evidence="ECO:0000269|PubMed:11748304" FT /id="VAR_018101" FT VARIANT 61 FT /note="H -> R (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs398123316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026253" FT VARIANT 65..403 FT /note="Missing (in MCEPHAS)" FT /evidence="ECO:0000269|PubMed:26637798" FT /id="VAR_078705" FT VARIANT 67 FT /note="I -> R (in CWS1)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_007461" FT VARIANT 68 FT /note="Y -> H (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains the FT ability to bind phospholipid membranes; dbSNP:rs398123317)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9600246" FT /id="VAR_007462" FT VARIANT 70 FT /note="L -> P (in CWS1; dbSNP:rs121909226)" FT /evidence="ECO:0000269|PubMed:9832031" FT /id="VAR_018102" FT VARIANT 71 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026254" FT VARIANT 93 FT /note="H -> R (in MCEPHAS; dbSNP:rs121909238)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032634" FT VARIANT 93 FT /note="H -> Y (in CWS1; dbSNP:rs786204927)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394" FT /id="VAR_026255" FT VARIANT 105 FT /note="C -> F (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026256" FT VARIANT 105 FT /note="C -> Y (in CWS1; dbSNP:rs587782343)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008735" FT VARIANT 107 FT /note="D -> Y (in CWS1; also found in glioblastoma; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs57374291)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026257" FT VARIANT 112 FT /note="L -> P (in CWS1 and LDD; loss of phosphatase FT activity towards Ins(1,3,4,5)P4; dbSNP:rs121909230)" FT /evidence="ECO:0000269|PubMed:10051160, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9600246" FT /id="VAR_007807" FT VARIANT 112 FT /note="L -> R (loss of phosphatase activity towards FT Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026258" FT VARIANT 119 FT /note="V -> L (in multiple cancers; dbSNP:rs139767111)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011588" FT VARIANT 121 FT /note="A -> G (in HNSCC; dbSNP:rs121909237)" FT /evidence="ECO:0000269|PubMed:11801303" FT /id="VAR_018103" FT VARIANT 121 FT /note="A -> P (in glioblastoma; loss of phosphatase FT activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026259" FT VARIANT 123 FT /note="H -> R (in CWS1; dbSNP:rs121909222)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:9259288" FT /id="VAR_007463" FT VARIANT 123 FT /note="H -> Y (in endometrial cancer; loss of protein FT phosphatase activity; dbSNP:rs786204931)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026260" FT VARIANT 124 FT /note="C -> R (in CWS1; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:10234502, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:9259288" FT /id="VAR_007464" FT VARIANT 124 FT /note="C -> S (in CWS1; phosphatase-dead protein with FT neither lipid nor protein phosphatase activity; loss of FT phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase FT activity; dbSNP:rs121909223)" FT /evidence="ECO:0000269|PubMed:11230179, FT ECO:0000269|PubMed:9593664, ECO:0000269|PubMed:9811831" FT /id="VAR_018104" FT VARIANT 126 FT /note="A -> G (in a patient with prostate cancer; reduced FT phosphatase activity towards PtdIns(3,4,5); shifts its FT activity from phosphatidylinositol phosphate 3-phosphatase FT to phosphatidylinositol phosphate 5-phosphatase; disrupts FT PI3K/ATK signaling; reduced cell migration)" FT /evidence="ECO:0000269|PubMed:26504226" FT /id="VAR_076551" FT VARIANT 129 FT /note="G -> E (in CWS1; no lipid phosphatase activity but FT retains protein phosphatase activity; retains ability to FT inhibit focal adhesion formation; dbSNP:rs121909218)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:11230179, ECO:0000269|PubMed:21659347, FT ECO:0000269|PubMed:9140396, ECO:0000269|PubMed:9616126, FT ECO:0000269|PubMed:9811831" FT /id="VAR_007465" FT VARIANT 129 FT /note="G -> R (in glioblastoma; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs786204929)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_007466" FT VARIANT 130 FT /note="R -> G (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; FT dbSNP:rs121909224)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394" FT /id="VAR_026261" FT VARIANT 130 FT /note="R -> L (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9635567" FT /id="VAR_007467" FT VARIANT 130 FT /note="R -> Q (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; dbSNP:rs121909229)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:24778394, FT ECO:0000269|PubMed:9915974" FT /id="VAR_007468" FT VARIANT 131 FT /note="T -> I (in MCEPHAS; dbSNP:rs397514560)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076762" FT VARIANT 132 FT /note="G -> V (in one patient with clinical findings FT suggesting hamartoma tumor syndrome; dbSNP:rs121909241)" FT /evidence="ECO:0000269|PubMed:16752378" FT /id="VAR_032635" FT VARIANT 133 FT /note="V -> I (loss of phosphatase activity towards FT Ins(1,3,4,5)P3)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026262" FT VARIANT 134 FT /note="M -> L (in prostate cancer; no effect on protein FT phosphatase activity; reduced phosphatase activity towards FT Ins(1,3,4,5)P3 but retains PtdIns(3,4,5)P3 phosphatase FT activity)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:9072974, ECO:0000269|PubMed:9256433" FT /id="VAR_007469" FT VARIANT 135 FT /note="I -> V (in CWS1; dbSNP:rs587782360)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:11494117" FT /id="VAR_008736" FT VARIANT 136 FT /note="C -> Y (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P3; dbSNP:rs786204859)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9735393" FT /id="VAR_007808" FT VARIANT 137 FT /note="A -> AN (in CWS1)" FT /evidence="ECO:0000269|PubMed:9345101" FT /id="VAR_008737" FT VARIANT 155 FT /note="Y -> C (in CWS1; loss of phosphatase activity FT towards Ins(1,3,4,5)P4; dbSNP:rs1060500126)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026263" FT VARIANT 158 FT /note="V -> L (in multiple cancers)" FT /evidence="ECO:0000269|PubMed:10807691" FT /id="VAR_011589" FT VARIANT 165 FT /note="G -> E (in CWS1)" FT /evidence="ECO:0000269|PubMed:10234502" FT /id="VAR_008739" FT VARIANT 165 FT /note="G -> R (in CWS1; also found in glioblastoma; FT severely reduced protein phosphatase activity; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; retains FT ability to bind phospholipid membranes; dbSNP:rs587782603)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9256433, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026264" FT VARIANT 165 FT /note="G -> V (in CWS1; dbSNP:rs786204863)" FT /evidence="ECO:0000269|PubMed:9467011" FT /id="VAR_008738" FT VARIANT 167 FT /note="T -> N (in MCEPHAS; dbSNP:rs397514559)" FT /evidence="ECO:0000269|PubMed:23160955" FT /id="VAR_076763" FT VARIANT 167 FT /note="T -> P (in breast cancer; severely reduced protein FT phosphatase activity)" FT /evidence="ECO:0000269|PubMed:9256433" FT /id="VAR_026265" FT VARIANT 170 FT /note="S -> N (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026266" FT VARIANT 170 FT /note="S -> R (in CWS1; severely reduced protein FT phosphatase activity; loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121909221)" FT /evidence="ECO:0000269|PubMed:10400993, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:11494117, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9241266, FT ECO:0000269|PubMed:9256433" FT /id="VAR_007470" FT VARIANT 173 FT /note="R -> C (in CWS1; also found in endometrial FT hyperplasia; loss of phosphatase activity towards FT Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3; retains ability to bind FT phospholipid membranes; dbSNP:rs121913293)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:24778394, ECO:0000269|PubMed:9635567" FT /id="VAR_026267" FT VARIANT 173 FT /note="R -> H (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026268" FT VARIANT 173 FT /note="R -> P (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; dbSNP:rs121913294)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026269" FT VARIANT 174 FT /note="Y -> N (found in a thyroid tumor; somatic variant; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs587782316)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:39316756" FT /id="VAR_026270" FT VARIANT 191 FT /note="V -> A (in endometrial hyperplasia)" FT /evidence="ECO:0000269|PubMed:9635567" FT /id="VAR_026271" FT VARIANT 217 FT /note="V -> I (in malignant melanoma; somatic mutation; FT dbSNP:rs121909234)" FT /evidence="ECO:0000269|PubMed:10978354" FT /id="VAR_018105" FT VARIANT 227 FT /note="S -> F (reduced phosphatase activity towards FT Ins(1,3,4,5)P4; retains PtdIns(3,4,5)P3 phosphatase FT activity; dbSNP:rs905615413)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026272" FT VARIANT 234 FT /note="R -> Q (in GLM2; uncertain significance; not capable FT of inducing apoptosis; induced increased cell FT proliferation; led to high constitutive AKT1 activation FT which could not be increased further by stimulation with FT insulin; dbSNP:rs121909235)" FT /evidence="ECO:0000269|PubMed:12085208" FT /id="VAR_018106" FT VARIANT 241 FT /note="F -> S (in MCEPHAS; dbSNP:rs121909240)" FT /evidence="ECO:0000269|PubMed:15805158" FT /id="VAR_032636" FT VARIANT 246 FT /note="P -> L (in CWS1; dbSNP:rs587782350)" FT /evidence="ECO:0000269|PubMed:10400993" FT /id="VAR_008740" FT VARIANT 251 FT /note="G -> C (loss of phosphatase activity towards FT Ins(1,3,4,5)P4; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026273" FT VARIANT 252 FT /note="D -> G (in MCEPHAS and CWS1; dbSNP:rs121909239)" FT /evidence="ECO:0000269|PubMed:15805158, FT ECO:0000269|PubMed:21659347" FT /id="VAR_032637" FT VARIANT 289 FT /note="K -> E (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes; predominantly nuclear; FT dbSNP:rs562015640)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:18716620, ECO:0000269|PubMed:9797362" FT /id="VAR_008741" FT VARIANT 290 FT /note="V -> L (in dbSNP:rs35600253)" FT /evidence="ECO:0000269|Ref.10" FT /id="VAR_025167" FT VARIANT 319 FT /note="Missing (in glioma; reduced tumor suppressor FT activity; fails to inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9090379" FT /id="VAR_026274" FT VARIANT 331 FT /note="D -> G (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026275" FT VARIANT 341 FT /note="F -> V (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4; FT dbSNP:rs1554825652)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975" FT /id="VAR_026276" FT VARIANT 342 FT /note="K -> N (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4 but PtdIns(3,4,5)P3 phosphatase FT activity is similar to wild-type; dbSNP:rs398123314)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026277" FT VARIANT 343 FT /note="V -> E (in CWS1; loss of interaction with NOP53; FT decreased phosphorylation at S-380; decreased stability; FT loss of phosphatase activity towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:15355975, ECO:0000269|PubMed:9399897" FT /id="VAR_008742" FT VARIANT 345 FT /note="L -> Q (in glioblastoma; reduced tumor suppressor FT activity; loss of interaction with NOP53; decreased FT phosphorylation at S-380; decreased stability; loss of FT phosphatase activity towards Ins(1,3,4,5)P4; reduced FT ability to inactivate AKT/PKB; retains ability to bind FT phospholipid membranes)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:10866302, ECO:0000269|PubMed:15355975, FT ECO:0000269|PubMed:9331071" FT /id="VAR_026278" FT VARIANT 347 FT /note="F -> L (in CWS1; reduced phosphatase activity FT towards Ins(1,3,4,5)P4)" FT /evidence="ECO:0000269|PubMed:10866302, FT ECO:0000269|PubMed:21659347, ECO:0000269|PubMed:9399897" FT /id="VAR_008743" FT VARIANT 348 FT /note="T -> I (in endometrial hyperplasia; reduced FT phosphatase activity towards PtdIns(3,4,5)P3; mildly FT reduced tumor suppressor activity; reduced ability to FT inactivate AKT/PKB)" FT /evidence="ECO:0000269|PubMed:10468583, FT ECO:0000269|PubMed:9635567" FT /id="VAR_026279" FT VARIANT 369 FT /note="V -> G (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026280" FT VARIANT 401 FT /note="T -> I (retains Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3 FT phosphatase activity; retains ability to bind phospholipid FT membranes)" FT /evidence="ECO:0000269|PubMed:10866302" FT /id="VAR_026281" FT MUTAGEN 1 FT /note="M->I: Prevents expression of isoform 1 and increased FT expression of isoform alpha." FT /evidence="ECO:0000269|PubMed:24768297" FT MUTAGEN 13 FT /note="K->E: Nuclear. Cytoplasmic; when associated with E- FT 289. Shows less tumor suppressive ability; when associated FT with E-289." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 92 FT /note="D->A: 700-fold reduction in phosphatase activity FT towards PtdIns(3,4,5)P3. Loss of protein phosphatase FT activity. Unable to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:10555148, FT ECO:0000269|PubMed:9616126" FT MUTAGEN 93 FT /note="H->A: 75% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3. Modest reduction in phosphatase activity FT towards PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 124 FT /note="C->A: Loss of protein phosphatase activity. Unable FT to inhibit focal adhesion formation." FT /evidence="ECO:0000269|PubMed:9616126" FT MUTAGEN 125 FT /note="K->M: Reduced phosphatase activity towards FT PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(3)P." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 126 FT /note="A->P: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->S: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 126 FT /note="A->V: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3 and PtdIns(3,4)P2." FT /evidence="ECO:0000269|PubMed:26504226" FT MUTAGEN 128 FT /note="K->M: 85% reduction in phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 128 FT /note="K->R: Does not reduce phosphatase activity towards FT PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 130 FT /note="R->M: Does not affect the ability to inhibit AKT/PKB FT activation." FT /evidence="ECO:0000269|PubMed:9811831" FT MUTAGEN 167 FT /note="T->A,D: 60% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 171 FT /note="Q->A,E: 75% reduction in phosphatase activity FT towards PtdIns(3,4,5)P3." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 229 FT /note="S->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 232 FT /note="T->A: No effect on interaction with DLC1 or p85." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 263..269 FT /note="KMLKKDK->AAGAADA: Reduces the growth suppression FT activity and cells show anchorage-independent growth. FT Reduces binding to phospholipid membranes in vitro. FT Phosphatase activity towards PtdIns(3,4,5)P3 is not FT affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 289 FT /note="K->E: Cytoplasmic; when associated with E-13. Shows FT less tumor suppressive ability; when associated with E-13." FT /evidence="ECO:0000269|PubMed:18716620" FT MUTAGEN 319 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-321." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 319 FT /note="T->Y: Constitutive interaction with DLC1 and FT interaction with p85 following EGF stimulation." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->A: Reduces phosphorylation of the C2 tensin-like FT domain and abolishes interaction with DLC1 following EGF FT stimulation. Abolishes phosphorylation of the C2 tensin- FT like domain; when associated with A-319." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 321 FT /note="T->E: Constitutive interaction with DLC1." FT /evidence="ECO:0000269|PubMed:26166433" FT MUTAGEN 327..335 FT /note="KANKDKANR->AAGADAANA: Reduces growth suppression FT activity and promotes anchorage-independent growth. Reduces FT binding to phospholipid membranes in vitro; phosphatase FT activity towards PtdIns(3,4,5)P3 is not affected." FT /evidence="ECO:0000269|PubMed:10555148" FT MUTAGEN 336 FT /note="Y->F: Significantly lower phosphatase activity, FT reduced protein stability and decreased growth-inhibitory FT effect." FT /evidence="ECO:0000269|PubMed:19345329" FT MUTAGEN 366 FT /note="T->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 370 FT /note="S->A: Decreased stability." FT /evidence="ECO:0000269|PubMed:20940307" FT MUTAGEN 401 FT /note="T->A: Loss of DLG1-binding. No effect on MAGI2- and FT MAST2-binding." FT MUTAGEN 402 FT /note="K->A: No effect on MAGI2-, MAST2- and DLG1-binding." FT MUTAGEN 402 FT /note="K->W: Loss of DLG1-, MAGI2-, MAGI3- and MAST2- FT binding. Decrease of protein stability." FT MUTAGEN 403 FT /note="V->A: Loss of DLG1-, MAGI2-, MAGI3-, MAST1-, FT MAST2- and MAST3-binding." FT /evidence="ECO:0000269|PubMed:15951562" FT HELIX 8..10 FT /evidence="ECO:0007829|PDB:7JUL" FT TURN 19..22 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 23..29 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 32..35 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 39..41 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 44..47 FT /evidence="ECO:0007829|PDB:5BZZ" FT HELIX 50..60 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 61..63 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 65..73 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 78..80 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 81..83 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 85..90 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 98..100 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 101..112 FT /evidence="ECO:0007829|PDB:1D5R" FT TURN 113..115 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 118..123 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 125..128 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 129..141 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 148..159 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 161..163 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 169..184 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 192..202 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 206..209 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 213..219 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 222..226 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 232..235 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 238..259 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 262..264 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 268..276 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 277..279 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 280..284 FT /evidence="ECO:0007829|PDB:5BZZ" FT STRAND 310..312 FT /evidence="ECO:0007829|PDB:5BZX" FT STRAND 315..321 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 322..324 FT /evidence="ECO:0007829|PDB:1D5R" FT HELIX 328..330 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 335..337 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 342..349 FT /evidence="ECO:0007829|PDB:1D5R" FT STRAND 395..403 FT /evidence="ECO:0007829|PDB:2KYL" SQ SEQUENCE 403 AA; 47166 MW; 75F97C3DD6802BA9 CRC64; MTAIIKEIVS RNKRRYQEDG FDLDLTYIYP NIIAMGFPAE RLEGVYRNNI DDVVRFLDSK HKNHYKIYNL CAERHYDTAK FNCRVAQYPF EDHNPPQLEL IKPFCEDLDQ WLSEDDNHVA AIHCKAGKGR TGVMICAYLL HRGKFLKAQE ALDFYGEVRT RDKKGVTIPS QRRYVYYYSY LLKNHLDYRP VALLFHKMMF ETIPMFSGGT CNPQFVVCQL KVKIYSSNSG PTRREDKFMY FEFPQPLPVC GDIKVEFFHK QNKMLKKDKM FHFWVNTFFI PGPEETSEKV ENGSLCDQEI DSICSIERAD NDKEYLVLTL TKNDLDKANK DKANRYFSPN FKVKLYFTKT VEEPSNPEAS SSTSVTPDVS DNEPDHYRYS DTTDSDPENE PFDEDQHTQI TKV // ID SPEG_HUMAN Reviewed; 3267 AA. AC Q15772; A8K0G6; A8MRU0; Q27J74; Q695L1; Q6FGA6; Q6ZQW1; Q6ZTL8; Q9P2P9; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 16-DEC-2008, sequence version 4. DT 28-JAN-2026, entry version 210. DE RecName: Full=Striated muscle preferentially expressed protein kinase; DE EC=2.7.11.1; DE AltName: Full=Aortic preferentially expressed protein 1; DE Short=APEG-1; GN Name=SPEG; Synonyms=APEG1, KIAA1297; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY, SUBCELLULAR RP LOCATION, AND INDUCTION. RX PubMed=8663449; DOI=10.1074/jbc.271.29.17354; RA Hsieh C.-M., Yoshizumi M., Endege W.O., Kho C.-J., Jain M.K., Kashiki S., RA de Los Santos R., Lee W.-S., Perrella M.A., Lee M.-E.; RT "APEG-1, a novel gene preferentially expressed in aortic smooth muscle RT cells, is down-regulated by vascular injury."; RL J. Biol. Chem. 271:17354-17359(1996). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Cerebellum, and Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RA Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.; RT "Cloning of human full open reading frames in Gateway(TM) system entry RT vector (pDONR201)."; RL Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15815621; DOI=10.1038/nature03466; RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P., RA Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C., RA Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L., RA Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A., RA Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J., RA Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M., RA Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T., RA Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S., RA Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K., RA McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C., RA Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S., RA Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C., RA Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M., RA Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C., RA Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J., RA Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X., RA Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M., RA Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C., RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S., RA Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H., RA Wilson R.K.; RT "Generation and annotation of the DNA sequences of human chromosomes 2 and RT 4."; RL Nature 434:724-731(2005). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 12-129 (ISOFORM 1), AND ALTERNATIVE PROMOTER RP USAGE. RX PubMed=16545539; DOI=10.1016/j.ygeno.2006.01.009; RA Tam J.L.Y., Triantaphyllopoulos K., Todd H., Raguz S., de Wit T., RA Morgan J.E., Partridge T.A., Makrinou E., Grosveld F., Antoniou M.; RT "The human desmin locus: gene organization and LCR-mediated transcriptional RT control."; RL Genomics 87:733-746(2006). RN [8] RP NUCLEOTIDE SEQUENCE [MRNA] OF 130-3267 (ISOFORM 1), TISSUE SPECIFICITY, AND RP VARIANT THR-2687. RX PubMed=15185077; DOI=10.1007/s00427-004-0413-5; RA Sutter S.B., Raeker M.O., Borisov A.B., Russell M.W.; RT "Orthologous relationship of obscurin and Unc-89: phylogeny of a novel RT family of tandem myosin light chain kinases."; RL Dev. Genes Evol. 214:352-359(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 982-3267 (ISOFORM 1), AND VARIANT RP THR-2687. RC TISSUE=Brain; RX PubMed=10718198; DOI=10.1093/dnares/7.1.65; RA Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XVI. The RT complete sequences of 150 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 7:65-73(2000). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-488, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [11] RP X-RAY CRYSTALLOGRAPHY (0.96 ANGSTROMS) OF 864-962, AND SUBUNIT. RX PubMed=16354304; DOI=10.1186/1472-6807-5-21; RA Manjasetty B.A., Niesen F.H., Scheich C., Roske Y., Goetz F., Behlke J., RA Sievert V., Heinemann U., Bussow K.; RT "X-ray structure of engineered human aortic preferentially expressed RT protein-1 (APEG-1)."; RL BMC Struct. Biol. 5:21-21(2005). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] HIS-206; CYS-934; GLN-966; LEU-1103; RP VAL-1135; ASP-1178; TRP-1234; GLN-1340; CYS-1621; TRP-1903; THR-2687; RP MET-2742 AND ARG-3079. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [13] RP INTERACTION WITH MTM1, INVOLVEMENT IN CNM5, AND VARIANT CNM5 VAL-2757. RX PubMed=25087613; DOI=10.1016/j.ajhg.2014.07.004; RA Agrawal P.B., Pierson C.R., Joshi M., Liu X., Ravenscroft G., RA Moghadaszadeh B., Talabere T., Viola M., Swanson L.C., Haliloglu G., RA Talim B., Yau K.S., Allcock R.J., Laing N.G., Perrella M.A., Beggs A.H.; RT "SPEG interacts with myotubularin, and its deficiency causes centronuclear RT myopathy with dilated cardiomyopathy."; RL Am. J. Hum. Genet. 95:218-226(2014). CC -!- FUNCTION: Isoform 3 may have a role in regulating the growth and CC differentiation of arterial smooth muscle cells. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC -!- SUBUNIT: Interacts with MTM1. Isoform 3 is found as a monomer or CC homodimer. {ECO:0000269|PubMed:16354304, ECO:0000269|PubMed:25087613}. CC -!- INTERACTION: CC Q15772; Q99873: PRMT1; NbExp=3; IntAct=EBI-1384196, EBI-78738; CC Q15772-4; O75031: HSF2BP; NbExp=3; IntAct=EBI-12175897, EBI-7116203; CC Q15772-4; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-12175897, EBI-16439278; CC Q15772-4; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-12175897, EBI-79165; CC Q15772-4; Q99873-3: PRMT1; NbExp=3; IntAct=EBI-12175897, EBI-17165527; CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Nucleus. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative promoter usage, Alternative splicing; Named isoforms=4; CC Name=4; CC IsoId=Q15772-5; Sequence=Displayed; CC Name=2; CC IsoId=Q15772-3; Sequence=VSP_018259, VSP_018261, VSP_018262; CC Name=3; Synonyms=APEG1; CC IsoId=Q15772-4; Sequence=VSP_018258, VSP_018261, VSP_018262; CC Name=1; Synonyms=SPEG; CC IsoId=Q15772-1; Sequence=VSP_036071; CC -!- TISSUE SPECIFICITY: Isoform 1 is preferentially expressed in striated CC muscle. Non-kinase form such as isoform 3 is predominantly expressed in CC the aorta. Isoform 3 appears to be expressed only in highly CC differentiated ASMC in normal vessel walls and down-regulated in CC dedifferentiated ASMC in vivo. In response to vascular injuries ASMC CC dedifferentiate and change from a quiescent and contractile phenotype CC to a proliferative and synthetic phenotype. This proliferation of CC vascular smooth muscle cells is one of the most prominent features of CC atherosclerosis. {ECO:0000269|PubMed:15185077, CC ECO:0000269|PubMed:8663449}. CC -!- INDUCTION: Isoform 3 is quickly down-regulated in response to vascular CC injury, when ASMC cells change from a quiescent to a proliferative CC phenotype. {ECO:0000269|PubMed:8663449}. CC -!- PTM: May be autophosphorylated. CC -!- DISEASE: Myopathy, centronuclear, 5 (CNM5) [MIM:615959]: A form of CC centronuclear myopathy, a congenital muscle disorder characterized by CC progressive muscular weakness and wasting involving mainly limb girdle, CC trunk, and neck muscles. It may also affect distal muscles. Weakness CC may be present during childhood or adolescence or may not become CC evident until the third decade of life. Ptosis is a frequent clinical CC feature. The most prominent histopathologic features include high CC frequency of centrally located nuclei in muscle fibers not secondary to CC regeneration, radial arrangement of sarcoplasmic strands around the CC central nuclei, and predominance and hypotrophy of type 1 fibers. CNM5 CC features include severe neonatal hypotonia with respiratory CC insufficiency, difficulty feeding, and delayed motor development. Some CC patients die in infancy, and some develop dilated cardiomyopathy. CC {ECO:0000269|PubMed:25087613}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: Expression is under the tight control of the locus CC control region (LCRs). CC -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative promoter usage. CC {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative splicing. CC {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr CC protein kinase family. {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAY15052.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305}; CC Sequence=ABD61734.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U57099; AAC50599.1; -; mRNA. DR EMBL; AK126500; BAC86568.1; -; mRNA. DR EMBL; AK289531; BAF82220.1; -; mRNA. DR EMBL; CR542201; CAG46998.1; -; mRNA. DR EMBL; AC053503; AAY15052.1; ALT_SEQ; Genomic_DNA. DR EMBL; CH471063; EAW70747.1; -; Genomic_DNA. DR EMBL; BC006346; AAH06346.1; -; mRNA. DR EMBL; DQ395348; ABD61734.1; ALT_FRAME; mRNA. DR EMBL; AY603755; AAT80901.1; -; mRNA. DR EMBL; AB037718; BAA92535.1; -; mRNA. DR CCDS; CCDS42824.1; -. [Q15772-5] DR CCDS; CCDS54432.1; -. [Q15772-4] DR RefSeq; NP_001166947.1; NM_001173476.2. [Q15772-4] DR RefSeq; NP_005867.3; NM_005876.4. [Q15772-5] DR RefSeq; XP_047298873.1; XM_047442917.1. [Q15772-3] DR RefSeq; XP_047298874.1; XM_047442918.1. [Q15772-3] DR RefSeq; XP_047298875.1; XM_047442919.1. [Q15772-3] DR RefSeq; XP_047298876.1; XM_047442920.1. [Q15772-3] DR RefSeq; XP_047298877.1; XM_047442921.1. [Q15772-4] DR RefSeq; XP_047298878.1; XM_047442922.1. [Q15772-4] DR RefSeq; XP_047298879.1; XM_047442923.1. [Q15772-4] DR RefSeq; XP_054196142.1; XM_054340167.1. [Q15772-3] DR RefSeq; XP_054196143.1; XM_054340168.1. [Q15772-3] DR RefSeq; XP_054196144.1; XM_054340169.1. [Q15772-3] DR RefSeq; XP_054196145.1; XM_054340170.1. [Q15772-3] DR RefSeq; XP_054196146.1; XM_054340171.1. [Q15772-4] DR RefSeq; XP_054196147.1; XM_054340172.1. [Q15772-4] DR RefSeq; XP_054196148.1; XM_054340173.1. [Q15772-4] DR PDB; 1U2H; X-ray; 0.96 A; A=864-960. DR PDBsum; 1U2H; -. DR SMR; Q15772; -. DR BioGRID; 115579; 21. DR FunCoup; Q15772; 144. DR IntAct; Q15772; 13. DR STRING; 9606.ENSP00000311684; -. DR GlyCosmos; Q15772; 1 site, 1 glycan. DR GlyGen; Q15772; 8 sites, 1 O-linked glycan (1 site). DR iPTMnet; Q15772; -. DR PhosphoSitePlus; Q15772; -. DR BioMuta; SPEG; -. DR DMDM; 218512143; -. DR jPOST; Q15772; -. DR MassIVE; Q15772; -. DR PaxDb; 9606-ENSP00000311684; -. DR PeptideAtlas; Q15772; -. DR ProteomicsDB; 60751; -. [Q15772-5] DR ProteomicsDB; 60752; -. [Q15772-1] DR ProteomicsDB; 60753; -. [Q15772-3] DR ProteomicsDB; 60754; -. [Q15772-4] DR Pumba; Q15772; -. DR Antibodypedia; 11575; 81 antibodies from 22 providers. DR DNASU; 10290; -. DR Ensembl; ENST00000312358.12; ENSP00000311684.7; ENSG00000072195.15. [Q15772-5] DR Ensembl; ENST00000396686.5; ENSP00000379917.1; ENSG00000072195.15. [Q15772-4] DR Ensembl; ENST00000396688.5; ENSP00000379919.1; ENSG00000072195.15. [Q15772-4] DR Ensembl; ENST00000396689.2; ENSP00000379920.2; ENSG00000072195.15. [Q15772-4] DR GeneID; 10290; -. DR KEGG; hsa:10290; -. DR MANE-Select; ENST00000312358.12; ENSP00000311684.7; NM_005876.5; NP_005867.3. DR UCSC; uc002vlq.4; human. [Q15772-5] DR AGR; HGNC:16901; -. DR ClinPGx; PA142672598; -. DR CTD; 10290; -. DR DisGeNET; 10290; -. DR GeneCards; SPEG; -. DR HGNC; HGNC:16901; SPEG. DR HPA; ENSG00000072195; Tissue enhanced (intestine). DR MalaCards; SPEG; -. DR MIM; 615950; gene. DR MIM; 615959; phenotype. DR OpenTargets; ENSG00000072195; -. DR Orphanet; 169186; Autosomal recessive centronuclear myopathy. DR VEuPathDB; HostDB:ENSG00000072195; -. DR eggNOG; KOG0032; Eukaryota. DR eggNOG; KOG0613; Eukaryota. DR GeneTree; ENSGT00940000161126; -. DR HOGENOM; CLU_000381_0_0_1; -. DR InParanoid; Q15772; -. DR OrthoDB; 2570713at2759; -. DR PAN-GO; Q15772; 2 GO annotations based on evolutionary models. DR PhylomeDB; Q15772; -. DR PathwayCommons; Q15772; -. DR SignaLink; Q15772; -. DR SIGNOR; Q15772; -. DR Agora; ENSG00000072195; -. DR BioGRID-ORCS; 10290; 9 hits in 1166 CRISPR screens. DR ChiTaRS; SPEG; human. DR EvolutionaryTrace; Q15772; -. DR GeneWiki; SPEG; -. DR GenomeRNAi; 10290; -. DR Pharos; Q15772; Tbio. DR PRO; PR:Q15772; -. DR Proteomes; UP000005640; Chromosome 2. DR RNAct; Q15772; protein. DR Bgee; ENSG00000072195; Expressed in popliteal artery and 171 other cell types or tissues. DR ExpressionAtlas; Q15772; baseline and differential. DR GO; GO:0005634; C:nucleus; TAS:ProtInc. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW. DR GO; GO:0042692; P:muscle cell differentiation; IBA:GO_Central. DR GO; GO:0007517; P:muscle organ development; TAS:ProtInc. DR GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:ProtInc. DR CDD; cd00063; FN3; 2. DR CDD; cd20975; IgI_APEG-1_like; 1. DR CDD; cd14108; STKc_SPEG_rpt1; 1. DR CDD; cd14111; STKc_SPEG_rpt2; 1. DR FunFam; 2.60.40.10:FF:000080; Myosin light chain kinase, smooth muscle; 1. DR FunFam; 2.60.40.10:FF:000145; Myosin light chain kinase, smooth muscle; 1. DR FunFam; 1.10.510.10:FF:000363; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000497; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000538; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000784; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:001056; Striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000428; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000513; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000539; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000541; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 2.60.40.10:FF:000601; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 3.30.200.20:FF:000302; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 3.30.200.20:FF:000312; striated muscle preferentially expressed protein kinase; 1. DR FunFam; 1.10.510.10:FF:000344; striated muscle preferentially expressed protein kinase isoform X1; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 11. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 2. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 2. DR InterPro; IPR003961; FN3_dom. DR InterPro; IPR036116; FN3_sf. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR008271; Ser/Thr_kinase_AS. DR PANTHER; PTHR47633; IMMUNOGLOBULIN; 1. DR PANTHER; PTHR47633:SF3; STRIATED MUSCLE PREFERENTIALLY EXPRESSED PROTEIN KINASE; 1. DR Pfam; PF07679; I-set; 9. DR Pfam; PF00069; Pkinase; 2. DR Pfam; PF16650; SPEG_u2; 1. DR SMART; SM00060; FN3; 2. DR SMART; SM00409; IG; 9. DR SMART; SM00408; IGc2; 9. DR SMART; SM00220; S_TKc; 2. DR SUPFAM; SSF49265; Fibronectin type III; 1. DR SUPFAM; SSF48726; Immunoglobulin; 9. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 2. DR PROSITE; PS50853; FN3; 2. DR PROSITE; PS50835; IG_LIKE; 8. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 2. DR PROSITE; PS00108; PROTEIN_KINASE_ST; 2. PE 1: Evidence at protein level; KW 3D-structure; Alternative promoter usage; Alternative splicing; KW ATP-binding; Differentiation; Disease variant; Disulfide bond; KW Immunoglobulin domain; Kinase; Methylation; Nucleotide-binding; Nucleus; KW Phosphoprotein; Proteomics identification; Reference proteome; Repeat; KW Serine/threonine-protein kinase; Transferase. FT CHAIN 1..3267 FT /note="Striated muscle preferentially expressed protein FT kinase" FT /id="PRO_0000072666" FT DOMAIN 43..124 FT /note="Ig-like 1" FT DOMAIN 722..810 FT /note="Ig-like 2" FT DOMAIN 869..958 FT /note="Ig-like 3" FT DOMAIN 963..1057 FT /note="Ig-like 4" FT DOMAIN 1064..1152 FT /note="Ig-like 5" FT DOMAIN 1188..1278 FT /note="Ig-like 6" FT DOMAIN 1285..1382 FT /note="Fibronectin type-III 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 1384..1480 FT /note="Ig-like 7" FT DOMAIN 1485..1573 FT /note="Ig-like 8" FT DOMAIN 1601..1854 FT /note="Protein kinase 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 2583..2673 FT /note="Ig-like 9" FT DOMAIN 2680..2774 FT /note="Fibronectin type-III 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00316" FT DOMAIN 2966..3218 FT /note="Protein kinase 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 1..33 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 132..227 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 276..714 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 812..872 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1157..1180 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1906..2060 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2074..2239 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2253..2325 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2339..2399 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2411..2452 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2466..2564 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2771..2896 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 2909..2966 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 156..195 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 298..314 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 400..418 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 434..443 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 505..517 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 619..633 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 658..675 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 815..825 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 850..864 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2171..2180 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2188..2201 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2214..2224 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2343..2354 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2355..2366 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2384..2395 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2466..2484 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2521..2540 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2806..2815 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2910..2924 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 2937..2954 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 1719 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT ACT_SITE 3085 FT /note="Proton acceptor" FT /evidence="ECO:0000250" FT BINDING 1607..1615 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 1630 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 2972..2980 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 2995 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT MOD_RES 139 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 364 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 371 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 375 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 378 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 381 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 419 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 449 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 453 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 488 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 506 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 526 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 549 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 1128 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 1172 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 1988 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2014 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2015 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2037 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2055 FT /note="Asymmetric dimethylarginine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2055 FT /note="Omega-N-methylarginine; alternate" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2109 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2130 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2139 FT /note="Omega-N-methylarginine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2177 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2376 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2380 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2410 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2414 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2438 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2439 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2444 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2448 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2521 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2524 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2559 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2771 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT MOD_RES 2774 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q63638" FT MOD_RES 2949 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q62407" FT DISULFID 989..1041 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT DISULFID 2605..2657 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114" FT VAR_SEQ 1..849 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:8663449, ECO:0000303|Ref.3" FT /id="VSP_018258" FT VAR_SEQ 1..792 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_018259" FT VAR_SEQ 961..962 FT /note="AH -> GE (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8663449, FT ECO:0000303|Ref.3" FT /id="VSP_018261" FT VAR_SEQ 963..3267 FT /note="Missing (in isoform 2 and isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8663449, FT ECO:0000303|Ref.3" FT /id="VSP_018262" FT VAR_SEQ 3209..3267 FT /note="LQDCLAHPWLQDAYLMKLRRQTLTFTTNRLKEFLGEQRRRRAEAATRHKVLL FT RSYPGGP -> SCLSVCHKEIKMASS (in isoform 1)" FT /evidence="ECO:0000303|PubMed:10718198, FT ECO:0000303|PubMed:15185077, ECO:0000303|PubMed:16545539" FT /id="VSP_036071" FT VARIANT 206 FT /note="R -> H (in dbSNP:rs55821435)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041101" FT VARIANT 934 FT /note="R -> C (in dbSNP:rs34398769)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041102" FT VARIANT 966 FT /note="R -> Q (in dbSNP:rs34861443)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041103" FT VARIANT 1103 FT /note="P -> L (in dbSNP:rs56334571)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041104" FT VARIANT 1135 FT /note="A -> V (in dbSNP:rs55670811)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041105" FT VARIANT 1178 FT /note="E -> D (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs757589345)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041106" FT VARIANT 1234 FT /note="R -> W (in dbSNP:rs55916864)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041107" FT VARIANT 1340 FT /note="R -> Q (in dbSNP:rs34994343)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041108" FT VARIANT 1621 FT /note="R -> C (in dbSNP:rs55646900)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041109" FT VARIANT 1903 FT /note="R -> W (in an ovarian mucinous carcinoma sample; FT somatic mutation; dbSNP:rs762000831)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041110" FT VARIANT 2189 FT /note="P -> L (in dbSNP:rs10755037)" FT /id="VAR_059769" FT VARIANT 2687 FT /note="P -> T (in dbSNP:rs13026308)" FT /evidence="ECO:0000269|PubMed:10718198, FT ECO:0000269|PubMed:15185077, ECO:0000269|PubMed:17344846" FT /id="VAR_041111" FT VARIANT 2742 FT /note="V -> M (in a gastric adenocarcinoma sample; somatic FT mutation; dbSNP:rs566841339)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041112" FT VARIANT 2757 FT /note="G -> V (in CNM5; dbSNP:rs587777676)" FT /evidence="ECO:0000269|PubMed:25087613" FT /id="VAR_071808" FT VARIANT 3079 FT /note="H -> R (in dbSNP:rs12464085)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041113" FT CONFLICT 71 FT /note="Q -> H (in Ref. 7; ABD61734)" FT /evidence="ECO:0000305" FT CONFLICT 73 FT /note="S -> I (in Ref. 7; ABD61734)" FT /evidence="ECO:0000305" FT CONFLICT 2047 FT /note="S -> G (in Ref. 8; AAT80901 and 9; BAA92535)" FT /evidence="ECO:0000305" FT CONFLICT 3005 FT /note="R -> P (in Ref. 8; AAT80901 and 9; BAA92535)" FT /evidence="ECO:0000305" FT STRAND 867..873 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 878..881 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 886..896 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 899..904 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 915..919 FT /evidence="ECO:0007829|PDB:1U2H" FT HELIX 921..923 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 924..931 FT /evidence="ECO:0007829|PDB:1U2H" FT HELIX 934..936 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 938..946 FT /evidence="ECO:0007829|PDB:1U2H" FT STRAND 949..960 FT /evidence="ECO:0007829|PDB:1U2H" SQ SEQUENCE 3267 AA; 354289 MW; E67BEB5624144233 CRC64; MQKARGTRGE DAGTRAPPSP GVPPKRAKVG AGGGAPVAVA GAPVFLRPLK NAAVCAGSDV RLRVVVSGTP QPSLRWFRDG QLLPAPAPEP SCLWLRRCGA QDAGVYSCMA QNERGRASCE AVLTVLEVGD SETAEDDISD VQGTQRLELR DDGAFSTPTG GSDTLVGTSL DTPPTSVTGT SEEQVSWWGS GQTVLEQEAG SGGGTRRLPG SPRQAQATGA GPRHLGVEPL VRASRANLVG ASWGSEDSLS VASDLYGSAF SLYRGRALSI HVSVPQSGLR REEPDLQPQL ASEAPRRPAQ PPPSKSALLP PPSPRVGKRS PPGPPAQPAA TPTSPHRRTQ EPVLPEDTTT EEKRGKKSKS SGPSLAGTAE SRPQTPLSEA SGRLSALGRS PRLVRAGSRI LDKLQFFEER RRSLERSDSP PAPLRPWVPL RKARSLEQPK SERGAPWGTP GASQEELRAP GSVAERRRLF QQKAASLDER TRQRSPASDL ELRFAQELGR IRRSTSREEL VRSHESLRAT LQRAPSPREP GEPPLFSRPS TPKTSRAVSP AAAQPPSPSS AEKPGDEPGR PRSRGPAGRT EPGEGPQQEV RRRDQFPLTR SRAIQECRSP VPPPAADPPE ARTKAPPGRK REPPAQAVRF LPWATPGLEG AAVPQTLEKN RAGPEAEKRL RRGPEEDGPW GPWDRRGARS QGKGRRARPT SPELESSDDS YVSAGEEPLE APVFEIPLQN VVVAPGADVL LKCIITANPP PQVSWHKDGS ALRSEGRLLL RAEGERHTLL LREARAADAG SYMATATNEL GQATCAASLT VRPGGSTSPF SSPITSDEEY LSPPEEFPEP GETWPRTPTM KPSPSQNRRS SDTGSKAPPT FKVSLMDQSV REGQDVIMSI RVQGEPKPVV SWLRNRQPVR PDQRRFAEEA EGGLCRLRIL AAERGDAGFY TCKAVNEYGA RQCEARLEVR AHPESRSLAV LAPLQDVDVG AGEMALFECL VAGPTDVEVD WLCRGRLLQP ALLKCKMHFD GRKCKLLLTS VHEDDSGVYT CKLSTAKDEL TCSARLTVRP SLAPLFTRLL EDVEVLEGRA ARFDCKISGT PPPVVTWTHF GCPMEESENL RLRQDGGLHS LHIAHVGSED EGLYAVSAVN THGQAHCSAQ LYVEEPRTAA SGPSSKLEKM PSIPEEPEQG ELERLSIPDF LRPLQDLEVG LAKEAMLECQ VTGLPYPTIS WFHNGHRIQS SDDRRMTQYR DVHRLVFPAV GPQHAGVYKS VIANKLGKAA CYAHLYVTDV VPGPPDGAPQ VVAVTGRMVT LTWNPPRSLD MAIDPDSLTY TVQHQVLGSD QWTALVTGLR EPGWAATGLR KGVQHIFRVL STTVKSSSKP SPPSEPVQLL EHGPTLEEAP AMLDKPDIVY VVEGQPASVT VTFNHVEAQV VWRSCRGALL EARAGVYELS QPDDDQYCLR ICRVSRRDMG ALTCTARNRH GTQTCSVTLE LAEAPRFESI MEDVEVGAGE TARFAVVVEG KPLPDIMWYK DEVLLTESSH VSFVYEENEC SLVVLSTGAQ DGGVYTCTAQ NLAGEVSCKA ELAVHSAQTA MEVEGVGEDE DHRGRRLSDF YDIHQEIGRG AFSYLRRIVE RSSGLEFAAK FIPSQAKPKA SARREARLLA RLQHDCVLYF HEAFERRRGL VIVTELCTEE LLERIARKPT VCESEIRAYM RQVLEGIHYL HQSHVLHLDV KPENLLVWDG AAGEQQVRIC DFGNAQELTP GEPQYCQYGT PEFVAPEIVN QSPVSGVTDI WPVGVVAFLC LTGISPFVGE NDRTTLMNIR NYNVAFEETT FLSLSREARG FLIKVLVQDR LRPTAEETLE HPWFKTQAKG AEVSTDHLKL FLSRRRWQRS QISYKCHLVL RPIPELLRAP PERVWVTMPR RPPPSGGLSS SSDSEEEELE ELPSVPRPLQ PEFSGSRVSL TDIPTEDEAL GTPETGAATP MDWQEQGRAP SQDQEAPSPE ALPSPGQEPA AGASPRRGEL RRGSSAESAL PRAGPRELGR GLHKAASVEL PQRRSPSPGA TRLARGGLGE GEYAQRLQAL RQRLLRGGPE DGKVSGLRGP LLESLGGRAR DPRMARAASS EAAPHHQPPL ENRGLQKSSS FSQGEAEPRG RHRRAGAPLE IPVARLGARR LQESPSLSAL SEAQPSSPAR PSAPKPSTPK SAEPSATTPS DAPQPPAPQP AQDKAPEPRP EPVRASKPAP PPQALQTLAL PLTPYAQIIQ SLQLSGHAQG PSQGPAAPPS EPKPHAAVFA RVASPPPGAP EKRVPSAGGP PVLAEKARVP TVPPRPGSSL SSSIENLESE AVFEAKFKRS RESPLSLGLR LLSRSRSEER GPFRGAEEED GIYRPSPAGT PLELVRRPER SRSVQDLRAV GEPGLVRRLS LSLSQRLRRT PPAQRHPAWE ARGGDGESSE GGSSARGSPV LAMRRRLSFT LERLSSRLQR SGSSEDSGGA SGRSTPLFGR LRRATSEGES LRRLGLPHNQ LAAQAGATTP SAESLGSEAS ATSGSSAPGE SRSRLRWGFS RPRKDKGLSP PNLSASVQEE LGHQYVRSES DFPPVFHIKL KDQVLLEGEA ATLLCLPAAC PAPHISWMKD KKSLRSEPSV IIVSCKDGRQ LLSIPRAGKR HAGLYECSAT NVLGSITSSC TVAVARVPGK LAPPEVPQTY QDTALVLWKP GDSRAPCTYT LERRVDGESV WHPVSSGIPD CYYNVTHLPV GVTVRFRVAC ANRAGQGPFS NSSEKVFVRG TQDSSAVPSA AHQEAPVTSR PARARPPDSP TSLAPPLAPA APTPPSVTVS PSSPPTPPSQ ALSSLKAVGP PPQTPPRRHR GLQAARPAEP TLPSTHVTPS EPKPFVLDTG TPIPASTPQG VKPVSSSTPV YVVTSFVSAP PAPEPPAPEP PPEPTKVTVQ SLSPAKEVVS SPGSSPRSSP RPEGTTLRQG PPQKPYTFLE EKARGRFGVV RACRENATGR TFVAKIVPYA AEGKRRVLQE YEVLRTLHHE RIMSLHEAYI TPRYLVLIAE SCGNRELLCG LSDRFRYSED DVATYMVQLL QGLDYLHGHH VLHLDIKPDN LLLAPDNALK IVDFGSAQPY NPQALRPLGH RTGTLEFMAP EMVKGEPIGS ATDIWGAGVL TYIMLSGRSP FYEPDPQETE ARIVGGRFDA FQLYPNTSQS ATLFLRKVLS VHPWSRPSLQ DCLAHPWLQD AYLMKLRRQT LTFTTNRLKE FLGEQRRRRA EAATRHKVLL RSYPGGP //